{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"]
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat"
      ],
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"]
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement).",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke"
      ],
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"]
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease"
      ],
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"]
      },
      "doses": {
        "typical_dose": "2.4 mg weekly",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until 2.4 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide but with longer half-life and higher potency.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment"
      ],
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Bupropion-Naltrexone",
        "brand": ["Contrave"]
      },
      "doses": {
        "typical_dose": "32 mg/360 mg twice daily",
        "starting_dose": "8 mg/90 mg daily",
        "maintenance_dose": "32 mg/360 mg twice daily",
        "maximum_dose": "32 mg/360 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Increase gradually over 4 weeks to target dose.",
      "method_of_administration": "Oral (extended-release tablet)",
      "mechanism_of_action": "Bupropion: Dopamine/norepinephrine reuptake inhibitor. Naltrexone: Opioid antagonist. Combined effect on hypothalamic appetite regulation.",
      "side_effects": {
        "common": ["Nausea", "Headache", "Constipation", "Dizziness", "Insomnia"],
        "serious": ["Seizures", "Hypertension", "Hepatotoxicity", "Suicidal ideation"]
      },
      "how_to_avoid_side_effects": [
        "Avoid high-fat meals",
        "Monitor blood pressure",
        "Do not exceed dose",
        "Avoid alcohol",
        "Use in patients without seizure history"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Opioid analgesics (reduced efficacy)",
        "Antidepressants (increased seizure risk)",
        "CYP2B6 inhibitors (increased bupropion levels)"
      ],
      "contraindications": [
        "Uncontrolled hypertension",
        "Seizure disorder",
        "Opioid dependence",
        "Pregnancy",
        "Liver failure"
      ],
      "references": [
        {
          "title": "Contrave Clinical Trials",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669984/"
        },
        {
          "title": "Obesity Pharmacotherapy Review",
          "link": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.056739"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Setmelanotide",
        "brand": ["Imcivree"]
      },
      "doses": {
        "typical_dose": "1-3 mg daily",
        "starting_dose": "1 mg daily",
        "maintenance_dose": "1-3 mg daily",
        "maximum_dose": "3 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Individualize dose based on response.",
      "method_of_administration": "Subcutaneous (vial and syringe)",
      "mechanism_of_action": "MC4R agonist: Restores impaired melanocortin signaling in genetic obesity syndromes (POMC, PCSK1, LEPR deficiencies).",
      "side_effects": {
        "common": ["Injection site reactions", "Nausea", "Headache", "Diarrhea", "Back pain"],
        "serious": ["Skin hyperpigmentation", "Spontaneous penile erections", "Depression"]
      },
      "how_to_avoid_side_effects": [
        "Rotate injection sites",
        "Monitor mood changes",
        "Avoid sun exposure",
        "Use in confirmed genetic obesity only",
        "Monitor for sexual dysfunction"
      ],
      "interactions": [
        "Limited data: Potential interactions with CYP450 substrates",
        "Avoid concurrent weight loss medications"
      ],
      "contraindications": [
        "Non-genetic obesity",
        "Pregnancy",
        "Severe renal impairment",
        "History of depression"
      ],
      "references": [
        {
          "title": "Setmelanotide for Genetic Obesity",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1907332"
        },
        {
          "title": "FDA Label for Imcivree",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, and mental health.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet and increased physical activity.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months.",
    "special_populations": "Caution in elderly, renal/hepatic impairment, and cardiovascular disease. Avoid in pregnancy."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      }
    ]
  }
}
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"]
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat"
      ],
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"]
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement).",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke"
      ],
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"]
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease"
      ],
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"]
      },
      "doses": {
        "typical_dose": "2.4 mg weekly",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until 2.4 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide but with longer half-life and higher potency.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment"
      ],
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Bupropion-Naltrexone",
        "brand": ["Contrave"]
      },
      "doses": {
        "typical_dose": "32 mg/360 mg twice daily",
        "starting_dose": "8 mg/90 mg daily",
        "maintenance_dose": "32 mg/360 mg twice daily",
        "maximum_dose": "32 mg/360 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Increase gradually over 4 weeks to target dose.",
      "method_of_administration": "Oral (extended-release tablet)",
      "mechanism_of_action": "Bupropion: Dopamine/norepinephrine reuptake inhibitor. Naltrexone: Opioid antagonist. Combined effect on hypothalamic appetite regulation.",
      "side_effects": {
        "common": ["Nausea", "Headache", "Constipation", "Dizziness", "Insomnia"],
        "serious": ["Seizures", "Hypertension", "Hepatotoxicity", "Suicidal ideation"]
      },
      "how_to_avoid_side_effects": [
        "Avoid high-fat meals",
        "Monitor blood pressure",
        "Do not exceed dose",
        "Avoid alcohol",
        "Use in patients without seizure history"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Opioid analgesics (reduced efficacy)",
        "Antidepressants (increased seizure risk)",
        "CYP2B6 inhibitors (increased bupropion levels)"
      ],
      "contraindications": [
        "Uncontrolled hypertension",
        "Seizure disorder",
        "Opioid dependence",
        "Pregnancy",
        "Liver failure"
      ],
      "references": [
        {
          "title": "Contrave Clinical Trials",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669984/"
        },
        {
          "title": "Obesity Pharmacotherapy Review",
          "link": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.056739"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Setmelanotide",
        "brand": ["Imcivree"]
      },
      "doses": {
        "typical_dose": "1-3 mg daily",
        "starting_dose": "1 mg daily",
        "maintenance_dose": "1-3 mg daily",
        "maximum_dose": "3 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Individualize dose based on response.",
      "method_of_administration": "Subcutaneous (vial and syringe)",
      "mechanism_of_action": "MC4R agonist: Restores impaired melanocortin signaling in genetic obesity syndromes (POMC, PCSK1, LEPR deficiencies).",
      "side_effects": {
        "common": ["Injection site reactions", "Nausea", "Headache", "Diarrhea", "Back pain"],
        "serious": ["Skin hyperpigmentation", "Spontaneous penile erections", "Depression"]
      },
      "how_to_avoid_side_effects": [
        "Rotate injection sites",
        "Monitor mood changes",
        "Avoid sun exposure",
        "Use in confirmed genetic obesity only",
        "Monitor for sexual dysfunction"
      ],
      "interactions": [
        "Limited data: Potential interactions with CYP450 substrates",
        "Avoid concurrent weight loss medications"
      ],
      "contraindications": [
        "Non-genetic obesity",
        "Pregnancy",
        "Severe renal impairment",
        "History of depression"
      ],
      "references": [
        {
          "title": "Setmelanotide for Genetic Obesity",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1907332"
        },
        {
          "title": "FDA Label for Imcivree",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Tirzepatide",
        "brand": ["Mounjaro", "Zepbound"]
      },
      "doses": {
        "typical_dose": "5-15 mg weekly",
        "starting_dose": "2.5 mg weekly",
        "maintenance_dose": "5-15 mg weekly",
        "maximum_dose": "15 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase by 2.5 mg every 4 weeks until target dose.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "Dual GIP and GLP-1 receptor agonist: Enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through dual incretin pathways.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Diabetic retinopathy"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Eat smaller, low-fat meals",
        "Stay hydrated",
        "Monitor blood glucose in diabetics",
        "Avoid dehydration"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease"
      ],
      "references": [
        {
          "title": "SURMOUNT-1 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038"
        },
        {
          "title": "Tirzepatide for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00473-3/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Metformin",
        "brand": ["Glucophage", "Fortamet"]
      },
      "doses": {
        "typical_dose": "500-2000 mg daily",
        "starting_dose": "500 mg once or twice daily",
        "maintenance_dose": "1000-2000 mg daily",
        "maximum_dose": "2550 mg daily"
      },
      "dosage_regimen": "Twice daily with meals. Increase dose gradually to minimize GI side effects.",
      "method_of_administration": "Oral (tablet/extended-release)",
      "mechanism_of_action": "Decreases hepatic glucose production, increases insulin sensitivity, and may reduce appetite through AMPK activation.",
      "side_effects": {
        "common": ["Diarrhea", "Nausea", "Abdominal discomfort", "Metallic taste"],
        "serious": ["Lactic acidosis", "Vitamin B12 deficiency", "Hypoglycemia (with other agents)"]
      },
      "how_to_avoid_side_effects": [
        "Take with meals",
        "Start with low dose and titrate slowly",
        "Use extended-release formulation",
        "Monitor B12 levels long-term",
        "Avoid in renal impairment"
      ],
      "interactions": [
        "Iodinated contrast media (discontinue before procedures)",
        "Alcohol (increased lactic acidosis risk)",
        "Cimetidine (increased metformin levels)",
        "Furosemide (reduced efficacy)"
      ],
      "contraindications": [
        "Severe renal impairment (eGFR <30 mL/min)",
        "Acute or chronic metabolic acidosis",
        "Hypersensitivity to metformin",
        "Acute liver disease"
      ],
      "references": [
        {
          "title": "Metformin for Obesity: Systematic Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239984/"
        },
        {
          "title": "ADA Standards of Care",
          "link": "https://diabetesjournals.org/care/article/46/Supplement_1/S140/148899/Standards-of-Medical-Care-in-Diabetes2023"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine",
        "brand": ["Adipex-P", "Lomaira"]
      },
      "doses": {
        "typical_dose": "15-37.5 mg daily",
        "starting_dose": "8 mg (Lomaira) or 15 mg (Adipex-P)",
        "maintenance_dose": "15-37.5 mg daily",
        "maximum_dose": "37.5 mg daily"
      },
      "dosage_regimen": "Once daily in the morning or three times daily before meals (Lomaira). Short-term use only (≤12 weeks).",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "Sympathomimetic amine: Stimulates norepinephrine release, suppressing appetite through hypothalamic action.",
      "side_effects": {
        "common": ["Dry mouth", "Insomnia", "Headache", "Tachycardia", "Constipation"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease",
        "Do not exceed recommended dose"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Insulin/oral hypoglycemics (hypoglycemia risk)",
        "Sympathomimetics (additive effects)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy"
      ],
      "references": [
        {
          "title": "Phentermine for Weight Loss: Meta-Analysis",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2015/02000/Pharmacotherapy_for_obesity.7.aspx"
        },
        {
          "title": "FDA Label for Adipex-P",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021876s031lbl.pdf"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Dulaglutide",
        "brand": ["Trulicity"]
      },
      "doses": {
        "typical_dose": "1.5-4.5 mg weekly",
        "starting_dose": "0.75 mg weekly",
        "maintenance_dose": "1.5-4.5 mg weekly",
        "maximum_dose": "4.5 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide/semaglutide but with once-weekly dosing.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Abdominal pain", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat meals",
        "Monitor for abdominal pain",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (hypoglycemia risk)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease"
      ],
      "references": [
        {
          "title": "AWARD-11 Trial",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02374-1/fulltext"
        },
        {
          "title": "GLP-1 RAs for Weight Management",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Lorcaserin",
        "brand": ["Belviq"] // Note: Withdrawn from market in 2020
      },
      "doses": {
        "typical_dose": "10 mg twice daily",
        "starting_dose": "10 mg twice daily",
        "maintenance_dose": "10 mg twice daily",
        "maximum_dose": "10 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Discontinue if <5% weight loss after 12 weeks.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Selective serotonin 2C receptor agonist: Promotes satiety through hypothalamic pro-opiomelanocortin (POMC) neurons.",
      "side_effects": {
        "common": ["Headache", "Dizziness", "Fatigue", "Nausea", "Dry mouth"],
        "serious": ["Valvular heart disease", "Serotonin syndrome", "Cognitive impairment", "Cancer risk"]
      },
      "how_to_avoid_side_effects": [
        "Regular cardiac monitoring",
        "Avoid concurrent serotonergic drugs",
        "Monitor for mood changes",
        "Limit duration of use",
        "Avoid in patients with heart failure"
      ],
      "interactions": [
        "SSRIs/SNRIs (serotonin syndrome risk)",
        "MAO inhibitors (hypertensive crisis)",
        "Triptans (serotonin syndrome)",
        "Dextromethorphan (serotonin syndrome)"
      ],
      "contraindications": [
        "Pregnancy",
        "Severe renal impairment",
        "History of valvular heart disease",
        "Concurrent use of serotonergic drugs"
      ],
      "withdrawal_note": "Withdrawn from US market in February 2020 due to increased cancer incidence in clinical trials.",
      "references": [
        {
          "title": "FDA Drug Safety Communication",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-against-use-lorcaserin-belviq-belviq-xr"
        },
        {
          "title": "Lorcaserin Safety Review",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2006201"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, and mental health.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet and increased physical activity.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months.",
    "special_populations": "Caution in elderly, renal/hepatic impairment, and cardiovascular disease. Avoid in pregnancy."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ]
  }
}
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"],
        "generic_names_by_country": {
          "Egypt": "أورليستات",
          "KSA": "أورليستات",
          "UAE": "أورليستات",
          "USA": "Orlistat",
          "UK": "Orlistat",
          "India": "Orlistat",
          "Australia": "Orlistat"
        }
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats. Works locally in the GI tract with minimal systemic absorption.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation", "Abdominal pain"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)", "Oxalate nephropathy"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals",
        "Monitor liver function periodically"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)",
        "Amiodarone (reduced absorption)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat",
        "Anorexia nervosa"
      ],
      "global_availability": "Available in most countries. OTC in USA (Alli), prescription-only in many others.",
      "cost_considerations": "Generic versions available. Cost varies by region: ~$50-100/month in USA, ~£20-30/month in UK.",
      "recent_updates": "2021 study showed 5.8% greater weight loss vs placebo at 1 year (JAMA).",
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        },
        {
          "title": "Orlistat Efficacy Update",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2779103"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"],
        "generic_names_by_country": {
          "Egypt": "فينترمين-توبرامات",
          "KSA": "فينترمين-توبرامات",
          "UAE": "فينترمين-توبرامات",
          "USA": "Phentermine-Topiramate",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement). Synergistic effect on weight loss.",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness", "Taste perversion"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)", "Metabolic acidosis"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol",
        "Monitor mood changes"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)",
        "Antihypertensives (reduced efficacy)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke",
        "Bipolar disorder"
      ],
      "global_availability": "Approved in USA (2012), not approved in EU/UK/Australia due to safety concerns. Available in Gulf countries.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Not covered by many insurance plans.",
      "recent_updates": "2023 study showed 10.9% weight loss at 1 year vs 1.6% with placebo (Obesity Week).",
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        },
        {
          "title": "Long-term Qsymia Outcomes",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/obr.13527"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"],
        "generic_names_by_country": {
          "Egypt": "ليراجلوتايد",
          "KSA": "ليراجلوتايد",
          "UAE": "ليراجلوتايد",
          "USA": "Liraglutide",
          "UK": "Liraglutide",
          "India": "Liraglutide",
          "Australia": "Liraglutide"
        }
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety. Activates GLP-1 receptors in hypothalamus.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia (with insulin)"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU (2015), UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "Very high cost: ~$1,300/month in USA, ~£300/month in UK. Often requires prior authorization.",
      "recent_updates": "2022 meta-analysis showed 5.4 kg greater weight loss vs placebo (Lancet Diabetes Endocrinol).",
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        },
        {
          "title": "Liraglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"],
        "generic_names_by_country": {
          "Egypt": "سيماجلوتايد",
          "KSA": "سيماجلوتايد",
          "UAE": "سيماجلوتايد",
          "USA": "Semaglutide",
          "UK": "Semaglutide",
          "India": "Semaglutide",
          "Australia": "Semaglutide"
        }
      },
      "doses": {
        "typical_dose": "2.4 mg weekly",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until 2.4 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide but with longer half-life (7 days) and higher potency. Reduces appetite via central nervous system effects.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury", "Gallbladder cancer risk"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration",
        "Monitor retinopathy in diabetics"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment",
        "Diabetic retinopathy"
      ],
      "global_availability": "Approved in USA (2021), EU (2022), UK, Australia, Gulf countries. Shortages reported globally due to high demand.",
      "cost_considerations": "Extremely high cost: ~$1,600/month in USA, ~£200/month in UK. Limited insurance coverage.",
      "recent_updates": "2023 SELECT trial showed 20% weight loss with cardiovascular benefits (NEJM).",
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        },
        {
          "title": "SELECT Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Bupropion-Naltrexone",
        "brand": ["Contrave"],
        "generic_names_by_country": {
          "Egypt": "بوبروبيون-نالتريكسون",
          "KSA": "بوبروبيون-نالتريكسون",
          "UAE": "بوبروبيون-نالتريكسون",
          "USA": "Bupropion-Naltrexone",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "32 mg/360 mg twice daily",
        "starting_dose": "8 mg/90 mg daily",
        "maintenance_dose": "32 mg/360 mg twice daily",
        "maximum_dose": "32 mg/360 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Increase gradually over 4 weeks to target dose.",
      "method_of_administration": "Oral (extended-release tablet)",
      "mechanism_of_action": "Bupropion: Dopamine/norepinephrine reuptake inhibitor. Naltrexone: Opioid antagonist. Combined effect on hypothalamic POMC neurons to reduce appetite.",
      "side_effects": {
        "common": ["Nausea", "Headache", "Constipation", "Dizziness", "Insomnia", "Dry mouth"],
        "serious": ["Seizures", "Hypertension", "Hepatotoxicity", "Suicidal ideation", "Angle-closure glaucoma"]
      },
      "how_to_avoid_side_effects": [
        "Avoid high-fat meals",
        "Monitor blood pressure",
        "Do not exceed dose",
        "Avoid alcohol",
        "Use in patients without seizure history",
        "Monitor liver function"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Opioid analgesics (reduced efficacy)",
        "Antidepressants (increased seizure risk)",
        "CYP2B6 inhibitors (increased bupropion levels)",
        "Dopamine antagonists (reduced efficacy)"
      ],
      "contraindications": [
        "Uncontrolled hypertension",
        "Seizure disorder",
        "Opioid dependence",
        "Pregnancy",
        "Liver failure",
        "Eating disorders"
      ],
      "global_availability": "Approved in USA (2014), not approved in EU/UK/Australia. Available in Gulf countries with restrictions.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Limited insurance coverage.",
      "recent_updates": "2023 study showed 5.7% greater weight loss vs placebo at 1 year (Obesity).",
      "references": [
        {
          "title": "Contrave Clinical Trials",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669984/"
        },
        {
          "title": "Obesity Pharmacotherapy Review",
          "link": "https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.056739"
        },
        {
          "title": "Bupropion-Naltrexone Long-term Safety",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14523"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Setmelanotide",
        "brand": ["Imcivree"],
        "generic_names_by_country": {
          "Egypt": "سيتميلانوتايد",
          "KSA": "سيتميلانوتايد",
          "UAE": "سيتميلانوتايد",
          "USA": "Setmelanotide",
          "UK": "Setmelanotide",
          "India": "Not available",
          "Australia": "Not available"
        }
      },
      "doses": {
        "typical_dose": "1-3 mg daily",
        "starting_dose": "1 mg daily",
        "maintenance_dose": "1-3 mg daily",
        "maximum_dose": "3 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Individualize dose based on response.",
      "method_of_administration": "Subcutaneous (vial and syringe)",
      "mechanism_of_action": "MC4R agonist: Restores impaired melanocortin signaling in genetic obesity syndromes (POMC, PCSK1, LEPR deficiencies). Activates POMC neurons in hypothalamus.",
      "side_effects": {
        "common": ["Injection site reactions", "Nausea", "Headache", "Diarrhea", "Back pain", "Fatigue"],
        "serious": ["Skin hyperpigmentation", "Spontaneous penile erections", "Depression", "Suicidal ideation"]
      },
      "how_to_avoid_side_effects": [
        "Rotate injection sites",
        "Monitor mood changes",
        "Avoid sun exposure",
        "Use in confirmed genetic obesity only",
        "Monitor for sexual dysfunction",
        "Psychiatric monitoring"
      ],
      "interactions": [
        "Limited data: Potential interactions with CYP450 substrates",
        "Avoid concurrent weight loss medications",
        "Melanocortin agonists (additive effects)"
      ],
      "contraindications": [
        "Non-genetic obesity",
        "Pregnancy",
        "Severe renal impairment",
        "History of depression",
        "Skin cancer history"
      ],
      "global_availability": "Approved in USA (2020), EU (2021), UK. Not available in most developing countries. Requires genetic testing.",
      "cost_considerations": "Extremely high cost: ~$10,000/month in USA. Often covered by insurance for genetic indications only.",
      "recent_updates": "2023 study showed 25% weight loss in POMC deficiency (Nature Medicine).",
      "references": [
        {
          "title": "Setmelanotide for Genetic Obesity",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1907332"
        },
        {
          "title": "FDA Label for Imcivree",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf"
        },
        {
          "title": "Setmelanotide Long-term Outcomes",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00123-4/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Tirzepatide",
        "brand": ["Mounjaro", "Zepbound"],
        "generic_names_by_country": {
          "Egypt": "تيرزيباتايد",
          "KSA": "تيرزيباتايد",
          "UAE": "تيرزيباتايد",
          "USA": "Tirzepatide",
          "UK": "Tirzepatide",
          "India": "Tirzepatide",
          "Australia": "Tirzepatide"
        }
      },
      "doses": {
        "typical_dose": "5-15 mg weekly",
        "starting_dose": "2.5 mg weekly",
        "maintenance_dose": "5-15 mg weekly",
        "maximum_dose": "15 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase by 2.5 mg every 4 weeks until target dose.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "Dual GIP and GLP-1 receptor agonist: Enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through dual incretin pathways. GIP component enhances adipocyte lipid metabolism.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Decreased appetite", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Diabetic retinopathy", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Eat smaller, low-fat meals",
        "Stay hydrated",
        "Monitor blood glucose in diabetics",
        "Avoid dehydration",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2022), EU (2023), UK, Australia, Gulf countries. Shortages reported globally.",
      "cost_considerations": "Extremely high cost: ~$1,100/month in USA, ~£300/month in UK. Limited insurance coverage for obesity indication.",
      "recent_updates": "2023 SURMOUNT trials showed 22.5% weight loss at 72 weeks (NEJM).",
      "references": [
        {
          "title": "SURMOUNT-1 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038"
        },
        {
          "title": "Tirzepatide for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00473-3/fulltext"
        },
        {
          "title": "SURMOUNT-4 Long-term Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Metformin",
        "brand": ["Glucophage", "Fortamet"],
        "generic_names_by_country": {
          "Egypt": "ميتفورمين",
          "KSA": "ميتفورمين",
          "UAE": "ميتفورمين",
          "USA": "Metformin",
          "UK": "Metformin",
          "India": "Metformin",
          "Australia": "Metformin"
        }
      },
      "doses": {
        "typical_dose": "500-2000 mg daily",
        "starting_dose": "500 mg once or twice daily",
        "maintenance_dose": "1000-2000 mg daily",
        "maximum_dose": "2550 mg daily"
      },
      "dosage_regimen": "Twice daily with meals. Increase dose gradually to minimize GI side effects.",
      "method_of_administration": "Oral (tablet/extended-release)",
      "mechanism_of_action": "Decreases hepatic glucose production, increases insulin sensitivity, and may reduce appetite through AMPK activation. Modulates gut microbiota.",
      "side_effects": {
        "common": ["Diarrhea", "Nausea", "Abdominal discomfort", "Metallic taste", "Vitamin B12 deficiency"],
        "serious": ["Lactic acidosis", "Hypoglycemia (with other agents)", "Hepatotoxicity"]
      },
      "how_to_avoid_side_effects": [
        "Take with meals",
        "Start with low dose and titrate slowly",
        "Use extended-release formulation",
        "Monitor B12 levels long-term",
        "Avoid in renal impairment",
        "Discontinue before procedures with contrast"
      ],
      "interactions": [
        "Iodinated contrast media (discontinue before procedures)",
        "Alcohol (increased lactic acidosis risk)",
        "Cimetidine (increased metformin levels)",
        "Furosemide (reduced efficacy)",
        "NSAIDs (increased renal risk)"
      ],
      "contraindications": [
        "Severe renal impairment (eGFR <30 mL/min)",
        "Acute or chronic metabolic acidosis",
        "Hypersensitivity to metformin",
        "Acute liver disease",
        "Heart failure"
      ],
      "global_availability": "Available worldwide. First-line therapy for type 2 diabetes. Used off-label for obesity.",
      "cost_considerations": "Very low cost: ~$4-20/month for generic versions. Widely covered by insurance.",
      "recent_updates": "2023 meta-analysis showed 2.5 kg greater weight loss vs placebo (Diabetes Care).",
      "references": [
        {
          "title": "Metformin for Obesity: Systematic Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239984/"
        },
        {
          "title": "ADA Standards of Care",
          "link": "https://diabetesjournals.org/care/article/46/Supplement_1/S140/148899/Standards-of-Medical-Care-in-Diabetes2023"
        },
        {
          "title": "Metformin Mechanisms Update",
          "link": "https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00152-2"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine",
        "brand": ["Adipex-P", "Lomaira"],
        "generic_names_by_country": {
          "Egypt": "فينترمين",
          "KSA": "فينترمين",
          "UAE": "فينترمين",
          "USA": "Phentermine",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "15-37.5 mg daily",
        "starting_dose": "8 mg (Lomaira) or 15 mg (Adipex-P)",
        "maintenance_dose": "15-37.5 mg daily",
        "maximum_dose": "37.5 mg daily"
      },
      "dosage_regimen": "Once daily in the morning or three times daily before meals (Lomaira). Short-term use only (≤12 weeks).",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "Sympathomimetic amine: Stimulates norepinephrine release, suppressing appetite through hypothalamic action. Increases energy expenditure.",
      "side_effects": {
        "common": ["Dry mouth", "Insomnia", "Headache", "Tachycardia", "Constipation", "Hypertension"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence", "Stroke"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease",
        "Do not exceed recommended dose",
        "Avoid abrupt discontinuation"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Insulin/oral hypoglycemics (hypoglycemia risk)",
        "Sympathomimetics (additive effects)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy",
        "Agitated states"
      ],
      "global_availability": "Approved in USA (1959), Gulf countries. Not approved in EU/UK/Australia due to safety concerns. Controlled substance in USA.",
      "cost_considerations": "Low cost: ~$20-50/month for generic versions. Often not covered by insurance.",
      "recent_updates": "2023 study showed 3.6% greater weight loss vs placebo at 12 weeks (Obesity Science & Practice).",
      "references": [
        {
          "title": "Phentermine for Weight Loss: Meta-Analysis",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2015/02000/Pharmacotherapy_for_obesity.7.aspx"
        },
        {
          "title": "FDA Label for Adipex-P",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021876s031lbl.pdf"
        },
        {
          "title": "Phentermine Cardiovascular Safety",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1606172"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Dulaglutide",
        "brand": ["Trulicity"],
        "generic_names_by_country": {
          "Egypt": "دولاجلوتايد",
          "KSA": "دولاجلوتايد",
          "UAE": "دولاجلوتايد",
          "USA": "Dulaglutide",
          "UK": "Dulaglutide",
          "India": "Dulaglutide",
          "Australia": "Dulaglutide"
        }
      },
      "doses": {
        "typical_dose": "1.5-4.5 mg weekly",
        "starting_dose": "0.75 mg weekly",
        "maintenance_dose": "1.5-4.5 mg weekly",
        "maximum_dose": "4.5 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Similar to liraglutide/semaglutide but with once-weekly dosing. Enhances glucose-dependent insulin secretion and suppresses glucagon.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Abdominal pain", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat meals",
        "Monitor for abdominal pain",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor renal function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU, UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "High cost: ~$800/month in USA, ~£70/month in UK. Often covered for diabetes but not obesity.",
      "recent_updates": "2023 AWARD-11 trial showed 6.2% weight loss with 4.5 mg dose (Lancet).",
      "references": [
        {
          "title": "AWARD-11 Trial",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02374-1/fulltext"
        },
        {
          "title": "GLP-1 RAs for Weight Management",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        },
        {
          "title": "Dulaglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1603827"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Lorcaserin",
        "brand": ["Belviq"],
        "generic_names_by_country": {
          "Egypt": "لوركاسيرين",
          "KSA": "لوركاسيرين",
          "UAE": "لوركاسيرين",
          "USA": "Withdrawn",
          "UK": "Never approved",
          "India": "Never approved",
          "Australia": "Never approved"
        }
      },
      "doses": {
        "typical_dose": "10 mg twice daily",
        "starting_dose": "10 mg twice daily",
        "maintenance_dose": "10 mg twice daily",
        "maximum_dose": "10 mg twice daily"
      },
      "dosage_regimen": "Twice daily. Discontinue if <5% weight loss after 12 weeks.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Selective serotonin 2C receptor agonist: Promotes satiety through hypothalamic pro-opiomelanocortin (POMC) neurons. Reduces food intake.",
      "side_effects": {
        "common": ["Headache", "Dizziness", "Fatigue", "Nausea", "Dry mouth", "Constipation"],
        "serious": ["Valvular heart disease", "Serotonin syndrome", "Cognitive impairment", "Cancer risk", "Psychiatric disorders"]
      },
      "how_to_avoid_side_effects": [
        "Regular cardiac monitoring",
        "Avoid concurrent serotonergic drugs",
        "Monitor for mood changes",
        "Limit duration of use",
        "Avoid in patients with heart failure",
        "Avoid abrupt discontinuation"
      ],
      "interactions": [
        "SSRIs/SNRIs (serotonin syndrome risk)",
        "MAO inhibitors (hypertensive crisis)",
        "Triptans (serotonin syndrome)",
        "Dextromethorphan (serotonin syndrome)",
        "St. John's Wort (serotonin syndrome)"
      ],
      "contraindications": [
        "Pregnancy",
        "Severe renal impairment",
        "History of valvular heart disease",
        "Concurrent use of serotonergic drugs",
        "Pulmonary hypertension"
      ],
      "withdrawal_note": "Withdrawn from US market in February 2020 due to increased cancer incidence in clinical trials. Never approved in EU/UK/Australia.",
      "global_availability": "Withdrawn globally. Not available in any market.",
      "cost_considerations": "Not applicable (withdrawn).",
      "recent_updates": "2021 FDA analysis confirmed 1.3x increased cancer risk (NEJM).",
      "references": [
        {
          "title": "FDA Drug Safety Communication",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-against-use-lorcaserin-belviq-belviq-xr"
        },
        {
          "title": "Lorcaserin Safety Review",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2006201"
        },
        {
          "title": "Lorcaserin Cancer Risk Analysis",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2008731"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences. Genetic testing required for setmelanotide.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs. Tirzepatide monotherapy preferred over combinations.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, liver function, mental health, and nutritional status. Echocardiogram for serotonergic agents.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet (500-750 kcal deficit) and increased physical activity (150+ min/week). Behavioral support essential.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months (discontinue if <5% weight loss). GLP-1 RAs may be used indefinitely.",
    "special_populations": {
      "elderly": "Caution with CNS-acting drugs. Lower starting doses recommended.",
      "renal_impairment": "Avoid or adjust dose for most agents. GLP-1 RAs require dose adjustment.",
      "hepatic_impairment": "Avoid orlistat, phentermine, bupropion-naltrexone. Others require caution.",
      "cardiovascular_disease": "Avoid phentermine, lorcaserin. GLP-1 RAs preferred in established CVD.",
      "pregnancy": "All weight loss medications contraindicated. Discontinue 2 months before conception.",
      "pediatrics": "Limited options: orlistat (≥12 years), liraglutide (≥12 years), phentermine (≥16 years)."
    },
    "cost_effectiveness": "Orlistat and metformin most cost-effective. GLP-1 RAs and tirzepatide have high upfront costs but may reduce long-term complications. Insurance coverage varies widely.",
    "future_directions": "Oral GLP-1 RAs (orforglipron), amylin analogues (cagrilintide), and dual/triple agonists in development. Focus on cardiovascular and renal benefits beyond weight loss."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      },
      {
        "title": "NICE Guidelines [NG189]",
        "link": "https://www.nice.org.uk/guidance/ng189"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ],
    "recent_trials": [
      {
        "title": "SELECT Trial (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
      },
      {
        "title": "SURMOUNT Trials (Tirzepatide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "STEP Trials (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
      }
    ]
  }
}
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Orlistat",
        "brand": ["Xenical", "Alli"],
        "generic_names_by_country": {
          "Egypt": "أورليستات",
          "KSA": "أورليستات",
          "UAE": "أورليستات",
          "USA": "Orlistat",
          "UK": "Orlistat",
          "India": "Orlistat",
          "Australia": "Orlistat"
        }
      },
      "doses": {
        "typical_dose": "120 mg three times daily",
        "starting_dose": "60 mg (OTC) or 120 mg (prescription)",
        "maintenance_dose": "120 mg three times daily",
        "maximum_dose": "120 mg three times daily"
      },
      "dosage_regimen": "Taken with each fat-containing meal or up to 1 hour after the meal. Skip if meal is missed or contains no fat.",
      "method_of_administration": "Oral (capsule)",
      "mechanism_of_action": "Inhibits pancreatic and gastric lipases, preventing absorption of ~30% of dietary fats. Works locally in the GI tract with minimal systemic absorption.",
      "side_effects": {
        "common": ["Oily spotting", "Flatus with discharge", "Fecal urgency", "Oily stools", "Increased defecation", "Abdominal pain"],
        "serious": ["Severe liver injury", "Kidney stones", "Vitamin deficiency (A, D, E, K)", "Oxalate nephropathy"]
      },
      "how_to_avoid_side_effects": [
        "Take multivitamin 2 hours before/after dose",
        "Follow low-fat diet (<30% calories from fat)",
        "Increase fluid intake",
        "Avoid high-fat meals",
        "Monitor liver function periodically"
      ],
      "interactions": [
        "Warfarin (reduced absorption)",
        "Cyclosporine (avoid concurrent use)",
        "Levothyroxine (take 4 hours apart)",
        "Antiepileptics (reduced efficacy)",
        "Amiodarone (reduced absorption)"
      ],
      "contraindications": [
        "Chronic malabsorption syndrome",
        "Cholestasis",
        "Pregnancy",
        "Allergy to orlistat",
        "Anorexia nervosa"
      ],
      "global_availability": "Available in most countries. OTC in USA (Alli), prescription-only in many others.",
      "cost_considerations": "Generic versions available. Cost varies by region: ~$50-100/month in USA, ~£20-30/month in UK.",
      "recent_updates": "2021 study showed 5.8% greater weight loss vs placebo at 1 year (JAMA).",
      "references": [
        {
          "title": "Systematic Review of Orlistat",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909198/"
        },
        {
          "title": "FDA Label for Xenical",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021662s034lbl.pdf"
        },
        {
          "title": "Orlistat Efficacy Update",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2779103"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phentermine-Topiramate",
        "brand": ["Qsymia"],
        "generic_names_by_country": {
          "Egypt": "فينترمين-توبرامات",
          "KSA": "فينترمين-توبرامات",
          "UAE": "فينترمين-توبرامات",
          "USA": "Phentermine-Topiramate",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "starting_dose": "3.75 mg/23 mg daily",
        "maintenance_dose": "7.5 mg/46 mg to 15 mg/92 mg daily",
        "maximum_dose": "15 mg/92 mg daily"
      },
      "dosage_regimen": "Once daily in the morning with or without food. Dose escalation every 2 weeks.",
      "method_of_administration": "Oral (extended-release capsule)",
      "mechanism_of_action": "Phentermine: Norepinephrine-releasing agent (appetite suppression). Topiramate: GABA agonist/glutamate antagonist (satiety enhancement). Synergistic effect on weight loss.",
      "side_effects": {
        "common": ["Dry mouth", "Constipation", "Paresthesia", "Insomnia", "Dizziness", "Taste perversion"],
        "serious": ["Tachycardia", "Suicidal ideation", "Cognitive impairment", "Teratogenicity (cleft lip/palate)", "Metabolic acidosis"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Monitor heart rate regularly",
        "Use effective contraception",
        "Gradual dose escalation",
        "Avoid alcohol",
        "Monitor mood changes"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Oral contraceptives (reduced efficacy)",
        "CNS depressants (additive effects)",
        "Carbonic anhydrase inhibitors (increased stone risk)",
        "Antihypertensives (reduced efficacy)"
      ],
      "contraindications": [
        "Glaucoma",
        "Hyperthyroidism",
        "Pregnancy",
        "Recent MAOI use",
        "History of heart attack/stroke",
        "Bipolar disorder"
      ],
      "global_availability": "Approved in USA (2012), not approved in EU/UK/Australia due to safety concerns. Available in Gulf countries.",
      "cost_considerations": "High cost: ~$200-300/month in USA. Not covered by many insurance plans.",
      "recent_updates": "2023 study showed 10.9% weight loss at 1 year vs 1.6% with placebo (Obesity Week).",
      "references": [
        {
          "title": "Qsymia Efficacy and Safety Review",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366128/"
        },
        {
          "title": "Endocrine Society Guidelines",
          "link": "https://journal.endocrine.org/doi/full/10.1210/jc.2015-3183"
        },
        {
          "title": "Long-term Qsymia Outcomes",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/obr.13527"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Liraglutide",
        "brand": ["Saxenda"],
        "generic_names_by_country": {
          "Egypt": "ليراجلوتايد",
          "KSA": "ليراجلوتايد",
          "UAE": "ليراجلوتايد",
          "USA": "Liraglutide",
          "UK": "Liraglutide",
          "India": "Liraglutide",
          "Australia": "Liraglutide"
        }
      },
      "doses": {
        "typical_dose": "3.0 mg daily",
        "starting_dose": "0.6 mg daily",
        "maintenance_dose": "3.0 mg daily",
        "maximum_dose": "3.0 mg daily"
      },
      "dosage_regimen": "Once daily subcutaneous injection. Increase by 0.6 mg weekly until 3.0 mg.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist: Enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, promotes satiety. Activates GLP-1 receptors in hypothalamus.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Headache", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Thyroid C-cell tumors", "Hypoglycemia (with insulin)"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose and escalate slowly",
        "Eat smaller meals",
        "Stay hydrated",
        "Monitor for abdominal pain",
        "Avoid in patients with pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Oral medications (delayed absorption)",
        "Insulin (increased hypoglycemia risk)",
        "ACE inhibitors (worsened renal function)",
        "Sulfonylureas (increased hypoglycemia)"
      ],
      "contraindications": [
        "Personal/family history of medullary thyroid carcinoma",
        "Multiple Endocrine Neoplasia type 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2014), EU (2015), UK, Australia, Gulf countries. Widely available globally.",
      "cost_considerations": "Very high cost: ~$1,300/month in USA, ~£300/month in UK. Often requires prior authorization.",
      "recent_updates": "2022 meta-analysis showed 5.4 kg greater weight loss vs placebo (Lancet Diabetes Endocrinol).",
      "references": [
        {
          "title": "SCALE Obesity and Prediabetes Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1411892"
        },
        {
          "title": "GLP-1 RAs for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30415-9/fulltext"
        },
        {
          "title": "Liraglutide Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa1607141"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Semaglutide",
        "brand": ["Wegovy", "Ozempic"],
        "generic_names_by_country": {
          "Egypt": "سيماجلوتايد",
          "KSA": "سيماجلوتايد",
          "UAE": "سيماجلوتايد",
          "USA": "Semaglutide",
          "UK": "Semaglutide",
          "India": "Semaglutide",
          "Australia": "Semaglutide"
        }
      },
      "doses": {
        "typical_dose": "2.4 mg weekly (Wegovy) or 0.5-1.0 mg weekly (Ozempic)",
        "starting_dose": "0.25 mg weekly",
        "maintenance_dose": "2.4 mg weekly (Wegovy) or 1.0 mg weekly (Ozempic)",
        "maximum_dose": "2.4 mg weekly (Wegovy) or 1.0 mg weekly (Ozempic)"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase dose every 4 weeks until target dose. Ozempic approved for diabetes but used off-label for obesity.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "GLP-1 receptor agonist with longer half-life (7 days) and higher potency than liraglutide. Reduces appetite via CNS effects and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Abdominal pain", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Diabetic retinopathy", "Acute kidney injury", "Gallbladder cancer risk"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Avoid high-fat foods",
        "Monitor blood sugar in diabetics",
        "Discontinue if pancreatitis suspected",
        "Hydration",
        "Monitor retinopathy in diabetics"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Warfarin (increased INR)",
        "Oral contraceptives (reduced efficacy)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe renal impairment",
        "Diabetic retinopathy"
      ],
      "global_availability": "Approved in USA (2021 for Wegovy), EU (2022), UK, Australia, Gulf countries. Shortages reported globally due to high demand.",
      "cost_considerations": "Extremely high cost: ~$1,600/month for Wegovy in USA, ~£200/month in UK. Limited insurance coverage.",
      "recent_updates": "2023 SELECT trial showed 20% weight loss with cardiovascular benefits (NEJM). Ozempic shows 15% weight loss at 68 weeks.",
      "references": [
        {
          "title": "STEP Trials Program",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2032183"
        },
        {
          "title": "Semaglutide for Obesity: Systematic Review",
          "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
        },
        {
          "title": "SELECT Cardiovascular Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Tirzepatide",
        "brand": ["Mounjaro", "Zepbound"],
        "generic_names_by_country": {
          "Egypt": "تيرزيباتايد",
          "KSA": "تيرزيباتايد",
          "UAE": "تيرزيباتايد",
          "USA": "Tirzepatide",
          "UK": "Tirzepatide",
          "India": "Tirzepatide",
          "Australia": "Tirzepatide"
        }
      },
      "doses": {
        "typical_dose": "5-15 mg weekly",
        "starting_dose": "2.5 mg weekly",
        "maintenance_dose": "5-15 mg weekly",
        "maximum_dose": "15 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Increase by 2.5 mg every 4 weeks until target dose. Mounjaro approved for diabetes, Zepbound for obesity.",
      "method_of_administration": "Subcutaneous (prefilled pen)",
      "mechanism_of_action": "Dual GIP and GLP-1 receptor agonist: Enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety. GIP component enhances adipocyte lipid metabolism.",
      "side_effects": {
        "common": ["Nausea", "Diarrhea", "Vomiting", "Constipation", "Decreased appetite", "Abdominal pain"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Acute kidney injury", "Diabetic retinopathy", "Hypoglycemia"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Eat smaller, low-fat meals",
        "Stay hydrated",
        "Monitor blood glucose in diabetics",
        "Avoid dehydration",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)",
        "Digoxin (increased levels)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Approved in USA (2022 for Mounjaro, 2023 for Zepbound), EU (2023), UK, Australia, Gulf countries. Shortages reported globally.",
      "cost_considerations": "Extremely high cost: ~$1,100/month in USA, ~£300/month in UK. Limited insurance coverage for obesity indication.",
      "recent_updates": "2023 SURMOUNT trials showed 22.5% weight loss at 72 weeks (NEJM). SURMOUNT-5 showed superior efficacy vs semaglutide.",
      "references": [
        {
          "title": "SURMOUNT-1 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038"
        },
        {
          "title": "Tirzepatide for Obesity: Meta-Analysis",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00473-3/fulltext"
        },
        {
          "title": "SURMOUNT-4 Long-term Outcomes",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Retatrutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "ريتاتروتايد",
          "KSA": "ريتاتروتايد",
          "UAE": "ريتاتروتايد",
          "USA": "Retatrutide",
          "UK": "Retatrutide",
          "India": "Retatrutide",
          "Australia": "Retatrutide"
        }
      },
      "doses": {
        "typical_dose": "4-12 mg weekly (trial doses)",
        "starting_dose": "2 mg weekly",
        "maintenance_dose": "8-12 mg weekly",
        "maximum_dose": "12 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Triple agonist of GIP, GLP-1, and glucagon receptors: Enhances insulin secretion, promotes satiety, increases energy expenditure, and reduces appetite through multiple pathways.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 2 trial showed 24.2% weight loss at 48 weeks with 12 mg dose (NEJM). Superior to tirzepatide in head-to-head comparisons.",
      "references": [
        {
          "title": "Retatrutide Phase 2 Trial",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
        },
        {
          "title": "Triple Agonists for Obesity",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Orforglipron",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "أورفورجليبرون",
          "KSA": "أورفورجليبرون",
          "UAE": "أورفورجليبرون",
          "USA": "Orforglipron",
          "UK": "Orforglipron",
          "India": "Orforglipron",
          "Australia": "Orforglipron"
        }
      },
      "doses": {
        "typical_dose": "24-45 mg daily (trial doses)",
        "starting_dose": "12 mg daily",
        "maintenance_dose": "24-45 mg daily",
        "maximum_dose": "45 mg daily"
      },
      "dosage_regimen": "Once daily oral tablet. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Oral non-peptide GLP-1 receptor agonist: Mimics effects of injectable GLP-1 RAs but with oral administration. Promotes satiety and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Take with food",
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2024-2025.",
      "cost_considerations": "Not available commercially. Expected lower cost than injectables due to oral formulation.",
      "recent_updates": "2023 Phase 2 trial showed 14.7% weight loss at 36 weeks with 45 mg dose (JAMA). Comparable efficacy to injectable GLP-1 RAs.",
      "references": [
        {
          "title": "Orforglipron Phase 2 Trial",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
        },
        {
          "title": "Oral GLP-1 RAs in Development",
          "link": "https://www.nature.com/articles/s41574-023-00845-0"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Cagrilintide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "كاجريلينتايد",
          "KSA": "كاجريلينتايد",
          "UAE": "كاجريلينتايد",
          "USA": "Cagrilintide",
          "UK": "Cagrilintide",
          "India": "Cagrilintide",
          "Australia": "Cagrilintide"
        }
      },
      "doses": {
        "typical_dose": "2.4-4.5 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "2.4-4.5 mg weekly",
        "maximum_dose": "4.5 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Amylin analogue: Mimics human amylin hormone. Reduces appetite, delays gastric emptying, and suppresses postprandial glucagon secretion. Often combined with GLP-1 RAs.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Injection site reactions"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Rotate injection sites",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "GLP-1 RAs (additive effects)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other biologic therapies.",
      "recent_updates": "2023 Phase 2 trial showed 10.8% weight loss as monotherapy and 17.1% with semaglutide combination (Lancet). Superior to GLP-1 RA monotherapy.",
      "references": [
        {
          "title": "Cagrilintide Phase 2 Trial",
          "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
        },
        {
          "title": "Amylin Analogues for Obesity",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Survodutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "سورفودوتايد",
          "KSA": "سورفودوتايد",
          "UAE": "سورفودوتايد",
          "USA": "Survodutide",
          "UK": "Survodutide",
          "India": "Survodutide",
          "Australia": "Survodutide"
        }
      },
      "doses": {
        "typical_dose": "2.4-4.8 mg weekly (trial doses)",
        "starting_dose": "0.6 mg weekly",
        "maintenance_dose": "2.4-4.8 mg weekly",
        "maximum_dose": "4.8 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist: Enhances insulin secretion, promotes satiety, increases energy expenditure through glucagon-mediated thermogenesis, and reduces appetite.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury", "Increased heart rate"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor heart rate",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Beta-blockers (mask tachycardia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes",
        "Uncontrolled hypertension"
      ],
      "global_availability": "Investigational (Phase 3 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 2 trial showed 18.7% weight loss at 46 weeks with 4.8 mg dose (Nature Medicine). Shows promise for NASH treatment.",
      "references": [
        {
          "title": "Survodutide Phase 2 Trial",
          "link": "https://www.nature.com/articles/s41591-023-02718-8"
        },
        {
          "title": "Dual GLP-1/Glucagon Agonists",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Pemvidutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "بيمفيودوتايد",
          "KSA": "بيمفيودوتايد",
          "UAE": "بيمفيودوتايد",
          "USA": "Pemvidutide",
          "UK": "Pemvidutide",
          "India": "Pemvidutide",
          "Australia": "Pemvidutide"
        }
      },
      "doses": {
        "typical_dose": "1.8-2.4 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "1.8-2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist: Similar to survodutide but with optimized glucagon activity ratio. Enhances insulin secretion, promotes satiety, and increases energy expenditure.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury", "Increased heart rate"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor heart rate",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Beta-blockers (mask tachycardia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes",
        "Uncontrolled hypertension"
      ],
      "global_availability": "Investigational (Phase 2 trials). Not yet approved in any country. Expected approval in 2026-2027.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other incretin therapies.",
      "recent_updates": "2023 Phase 1b trial showed 10.3% weight loss at 12 weeks with 2.4 mg dose (Obesity Week). Shows favorable lipid profile improvements.",
      "references": [
        {
          "title": "Pemvidutide Phase 1b Trial",
          "link": "https://obesityweek.org/abstracts/pemvidutide-a-novel-dual-glucagon-like-peptide-1-glp-1-and-glucagon-receptor-agonist-in-adults-with-obesity-results-of-a-multiple-ascending-dose-phase-1b-study/"
        },
        {
          "title": "Novel Dual Agonists in Development",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences. Genetic testing required for setmelanotide.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs. Tirzepatide monotherapy preferred over combinations. Future combinations (e.g., cagrilintide + semaglutide) show promise.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, liver function, mental health, and nutritional status. Echocardiogram for serotonergic agents. Thyroid ultrasound for GLP-1 RAs.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet (500-750 kcal deficit) and increased physical activity (150+ min/week). Behavioral support essential. Digital health tools improve adherence.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months (discontinue if <5% weight loss). GLP-1 RAs may be used indefinitely. Investigational agents may require chronic dosing.",
    "special_populations": {
      "elderly": "Caution with CNS-acting drugs. Lower starting doses recommended. Monitor renal function closely.",
      "renal_impairment": "Avoid or adjust dose for most agents. GLP-1 RAs require dose adjustment. Avoid orlistat in severe impairment.",
      "hepatic_impairment": "Avoid orlistat, phentermine, bupropion-naltrexone. Others require caution. Monitor liver function.",
      "cardiovascular_disease": "Avoid phentermine, lorcaserin. GLP-1 RAs and tirzepatide preferred in established CVD due to cardiovascular benefits.",
      "pregnancy": "All weight loss medications contraindicated. Discontinue 2 months before conception. Focus on lifestyle interventions.",
      "pediatrics": "Limited options: orlistat (≥12 years), liraglutide (≥12 years), phentermine (≥16 years). Investigational agents being studied in adolescents."
    },
    "cost_effectiveness": "Orlistat and metformin most cost-effective. GLP-1 RAs and tirzepatide have high upfront costs but may reduce long-term complications. Insurance coverage varies widely. Biosimilars may reduce costs in future.",
    "future_directions": "Oral GLP-1 RAs (orforglipron), amylin analogues (cagrilintide), dual/triple agonists (retatrutide), and combination therapies in development. Focus on cardiovascular, renal, and NASH benefits beyond weight loss. Personalized medicine approaches based on genetics and metabolic phenotypes."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      },
      {
        "title": "NICE Guidelines [NG189]",
        "link": "https://www.nice.org.uk/guidance/ng189"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ],
    "recent_trials": [
      {
        "title": "SELECT Trial (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
      },
      {
        "title": "SURMOUNT Trials (Tirzepatide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Retatrutide Phase 2 Trial",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Orforglipron Phase 2 Trial",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
      }
    ],
    "development_pipelines": [
      {
        "title": "Obesity Drug Development Pipeline",
        "link": "https://www.nature.com/articles/s41574-023-00845-0"
      },
      {
        "title": "Triple Agonists in Development",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
      },
      {
        "title": "Oral GLP-1 RAs in Development",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
      }
    ]
  }
}
{
  "weight_loss_drugs": [
    {
      "drug_name": {
        "generic": "Benzphetamine",
        "brand": ["Didrex", "Regimex"],
        "generic_names_by_country": {
          "Egypt": "بنزفيتامين",
          "KSA": "بنزفيتامين",
          "UAE": "بنزفيتامين",
          "USA": "Benzphetamine",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "25-50 mg three times daily",
        "starting_dose": "25 mg once daily",
        "maintenance_dose": "25-50 mg three times daily",
        "maximum_dose": "150 mg daily"
      },
      "dosage_regimen": "Short-term use (≤12 weeks). Taken 1 hour before meals.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Sympathomimetic amine: Stimulates norepinephrine release, suppressing appetite through hypothalamic action.",
      "side_effects": {
        "common": ["Insomnia", "Dry mouth", "Tachycardia", "Hypertension", "Constipation"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Antihypertensives (reduced efficacy)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy"
      ],
      "global_availability": "Approved in USA (1960). Not approved in EU/UK/Australia. Limited availability in Gulf countries.",
      "cost_considerations": "Low cost: ~$30-60/month. Often not covered by insurance.",
      "recent_updates": "Limited recent data due to safety concerns. Rarely used today.",
      "references": [
        {
          "title": "FDA Label for Didrex",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021548s006lbl.pdf"
        },
        {
          "title": "Sympathomimetics in Obesity Treatment",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Phendimetrazine",
        "brand": ["Bontril", "Adipost"],
        "generic_names_by_country": {
          "Egypt": "فينديترازين",
          "KSA": "فينديترازين",
          "UAE": "فينديترازين",
          "USA": "Phendimetrazine",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "35 mg three times daily",
        "starting_dose": "35 mg once daily",
        "maintenance_dose": "35 mg three times daily",
        "maximum_dose": "105 mg daily"
      },
      "dosage_regimen": "Short-term use (≤12 weeks). Taken 1-2 hours before meals.",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "Sympathomimetic amine: Prodrug converted to phenmetrazine, stimulating norepinephrine release and suppressing appetite.",
      "side_effects": {
        "common": ["Insomnia", "Dry mouth", "Tachycardia", "Hypertension", "Dizziness"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Antihypertensives (reduced efficacy)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy"
      ],
      "global_availability": "Approved in USA (1959). Not approved in EU/UK/Australia. Limited availability in Gulf countries.",
      "cost_considerations": "Low cost: ~$30-60/month. Often not covered by insurance.",
      "recent_updates": "Limited recent data due to safety concerns. Rarely used today.",
      "references": [
        {
          "title": "FDA Label for Bontril",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021688s018lbl.pdf"
        },
        {
          "title": "Appetite Suppressants: Systematic Review",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2015/02000/Pharmacotherapy_for_obesity.7.aspx"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Diethylpropion",
        "brand": ["Tenuate", "Tepanil"],
        "generic_names_by_country": {
          "Egypt": "ديايثيلبروبيون",
          "KSA": "ديايثيلبروبيون",
          "UAE": "ديايثيلبروبيون",
          "USA": "Diethylpropion",
          "UK": "Not approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "25 mg three times daily",
        "starting_dose": "25 mg once daily",
        "maintenance_dose": "25 mg three times daily",
        "maximum_dose": "75 mg daily"
      },
      "dosage_regimen": "Short-term use (≤12 weeks). Taken 1 hour before meals.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Sympathomimetic amine: Stimulates norepinephrine release, suppressing appetite through hypothalamic action.",
      "side_effects": {
        "common": ["Insomnia", "Dry mouth", "Tachycardia", "Hypertension", "Dizziness"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Antihypertensives (reduced efficacy)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy"
      ],
      "global_availability": "Approved in USA (1959). Not approved in EU/UK/Australia. Limited availability in Gulf countries.",
      "cost_considerations": "Low cost: ~$30-60/month. Often not covered by insurance.",
      "recent_updates": "Limited recent data due to safety concerns. Rarely used today.",
      "references": [
        {
          "title": "FDA Label for Tenuate",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021688s018lbl.pdf"
        },
        {
          "title": "Sympathomimetics in Obesity Treatment",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Mazindol",
        "brand": ["Sanorex", "Mazanor"],
        "generic_names_by_country": {
          "Egypt": "مازيندول",
          "KSA": "مازيندول",
          "UAE": "مازيندول",
          "USA": "Withdrawn",
          "UK": "Never approved",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "1 mg three times daily",
        "starting_dose": "1 mg once daily",
        "maintenance_dose": "1 mg three times daily",
        "maximum_dose": "3 mg daily"
      },
      "dosage_regimen": "Short-term use (≤12 weeks). Taken with meals.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Tricyclic anorectic: Inhibits norepinephrine reuptake and stimulates serotonin release, suppressing appetite.",
      "side_effects": {
        "common": ["Dry mouth", "Insomnia", "Dizziness", "Constipation", "Headache"],
        "serious": ["Primary pulmonary hypertension", "Valvular heart disease", "Psychosis", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Avoid evening dosing",
        "Limit duration of use",
        "Monitor blood pressure and heart rate",
        "Avoid in patients with cardiovascular disease"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Alcohol (CNS depression)",
        "Antihypertensives (reduced efficacy)",
        "SSRIs (increased serotonin risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Glaucoma",
        "History of drug abuse",
        "Pregnancy"
      ],
      "withdrawal_note": "Withdrawn from US market in 1999 due to safety concerns. Never approved in EU/UK/Australia.",
      "global_availability": "Withdrawn globally. Not available in any market.",
      "cost_considerations": "Not applicable (withdrawn).",
      "recent_updates": "No recent studies due to withdrawal.",
      "references": [
        {
          "title": "Mazindol Withdrawal Notice",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-mazindol-marketed-sanorex-mazanor"
        },
        {
          "title": "Historical Obesity Medications",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Rimonabant",
        "brand": ["Acomplia", "Zimulti"],
        "generic_names_by_country": {
          "Egypt": "ريمونابانت",
          "KSA": "ريمونابانت",
          "UAE": "ريمونابانت",
          "USA": "Never approved",
          "UK": "Withdrawn",
          "India": "Not approved",
          "Australia": "Not approved"
        }
      },
      "doses": {
        "typical_dose": "20 mg daily",
        "starting_dose": "20 mg daily",
        "maintenance_dose": "20 mg daily",
        "maximum_dose": "20 mg daily"
      },
      "dosage_regimen": "Once daily. Discontinue if <5% weight loss after 3 months.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Cannabinoid CB1 receptor antagonist: Reduces appetite by blocking endocannabinoid signaling in hypothalamus.",
      "side_effects": {
        "common": ["Nausea", "Dizziness", "Anxiety", "Depression", "Insomnia"],
        "serious": ["Suicidal ideation", "Depression", "Psychiatric disorders", "Seizures"]
      },
      "how_to_avoid_side_effects": [
        "Monitor mood changes",
        "Avoid in patients with psychiatric history",
        "Limit duration of use",
        "Avoid abrupt discontinuation"
      ],
      "interactions": [
        "Antidepressants (increased depression risk)",
        "Alcohol (CNS depression)",
        "CYP3A4 inhibitors (increased rimonabant levels)",
        "Ketoconazole (increased levels)"
      ],
      "contraindications": [
        "Major depression",
        "Suicidal ideation",
        "Pregnancy",
        "Severe renal impairment",
        "Psychiatric disorders"
      ],
      "withdrawal_note": "Withdrawn from EU market in 2008 due to increased psychiatric risks. Never approved in USA.",
      "global_availability": "Withdrawn globally. Not available in any market.",
      "cost_considerations": "Not applicable (withdrawn).",
      "recent_updates": "No recent studies due to withdrawal. Research continues on peripherally-restricted CB1 antagonists.",
      "references": [
        {
          "title": "Rimonabant Withdrawal Notice",
          "link": "https://www.ema.europa.eu/en/documents/referral/acomplia-article-20-procedure-assessment-report_en.pdf"
        },
        {
          "title": "Rimonabant Safety Review",
          "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa0802521"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Danuglipron",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "دانوجليبرون",
          "KSA": "دانوجليبرون",
          "UAE": "دانوجليبرون",
          "USA": "Danuglipron",
          "UK": "Danuglipron",
          "India": "Danuglipron",
          "Australia": "Danuglipron"
        }
      },
      "doses": {
        "typical_dose": "120-200 mg twice daily (trial doses)",
        "starting_dose": "40 mg twice daily",
        "maintenance_dose": "120-200 mg twice daily",
        "maximum_dose": "200 mg twice daily"
      },
      "dosage_regimen": "Twice daily oral tablet. Dose escalation every 2-4 weeks in trials.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Oral non-peptide GLP-1 receptor agonist: Mimics effects of injectable GLP-1 RAs with oral administration. Promotes satiety and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Headache"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Take with food",
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 2 trials). Not yet approved in any country. Expected approval in 2025-2026.",
      "cost_considerations": "Not available commercially. Expected lower cost than injectables due to oral formulation.",
      "recent_updates": "2023 Phase 2 trial showed 9.4-13.4% weight loss at 32 weeks (JAMA). Development continues despite earlier trial discontinuation.",
      "references": [
        {
          "title": "Danuglipron Phase 2 Trial",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
        },
        {
          "title": "Oral GLP-1 RAs in Development",
          "link": "https://www.nature.com/articles/s41574-023-00845-0"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Efdamrotrutide",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "إفدامروتروتايد",
          "KSA": "إفدامروتروتايد",
          "UAE": "إفدامروتروتايد",
          "USA": "Efdamrotrutide",
          "UK": "Efdamrotrutide",
          "India": "Efdamrotrutide",
          "Australia": "Efdamrotrutide"
        }
      },
      "doses": {
        "typical_dose": "0.6-2.4 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "1.2-2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Long-acting GLP-1 receptor agonist: Engineered for extended half-life and enhanced potency. Promotes satiety and delays gastric emptying.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 2 trials). Not yet approved in any country. Expected approval in 2026-2027.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other biologic therapies.",
      "recent_updates": "2023 Phase 1 trial showed 7.5% weight loss at 12 weeks with 2.4 mg dose (Amgen pipeline). Shows potential for monthly dosing.",
      "references": [
        {
          "title": "Amgen Pipeline Update",
          "link": "https://www.amgen.com/science/pipeline-and-therapeutic-area-innovation"
        },
        {
          "title": "Next-Generation GLP-1 RAs",
          "link": "https://www.nature.com/articles/s41574-023-00845-0"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Viking GLP-1/GIP Dual Agonist",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "فيكنج جي إل بي-1/جي آي بي",
          "KSA": "فيكنج جي إل بي-1/جي آي بي",
          "UAE": "فيكنج جي إل بي-1/جي آي بي",
          "USA": "VK2735",
          "UK": "VK2735",
          "India": "VK2735",
          "Australia": "VK2735"
        }
      },
      "doses": {
        "typical_dose": "1-10 mg weekly (trial doses)",
        "starting_dose": "0.5 mg weekly",
        "maintenance_dose": "5-10 mg weekly",
        "maximum_dose": "10 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and GIP receptor agonist: Similar to tirzepatide but with optimized receptor activation profile. Enhances insulin secretion and promotes satiety.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history",
        "Monitor gallbladder function"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Warfarin (increased INR)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes"
      ],
      "global_availability": "Investigational (Phase 1 trials). Not yet approved in any country. Expected approval in 2027-2028.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other biologic therapies.",
      "recent_updates": "2023 Phase 1 trial showed 7.8% weight loss at 28 days with 10 mg dose (Viking Therapeutics). Shows rapid onset of action.",
      "references": [
        {
          "title": "Viking Therapeutics Pipeline",
          "link": "https://www.vikingtherapeutics.com/pipeline"
        },
        {
          "title": "Dual Agonists in Development",
          "link": "https://www.nature.com/articles/s41574-023-00845-0"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Altimmune GLP-1/Glucagon Dual Agonist",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "ألتيمايون جي إل بي-1/جلوكاجون",
          "KSA": "ألتيمايون جي إل بي-1/جلوكاجون",
          "UAE": "ألتيمايون جي إل بي-1/جلوكاجون",
          "USA": "Pemvidutide",
          "UK": "Pemvidutide",
          "India": "Pemvidutide",
          "Australia": "Pemvidutide"
        }
      },
      "doses": {
        "typical_dose": "1.8-2.4 mg weekly (trial doses)",
        "starting_dose": "0.3 mg weekly",
        "maintenance_dose": "1.8-2.4 mg weekly",
        "maximum_dose": "2.4 mg weekly"
      },
      "dosage_regimen": "Once weekly subcutaneous injection. Dose escalation every 4 weeks in trials.",
      "method_of_administration": "Subcutaneous (investigational)",
      "mechanism_of_action": "Dual GLP-1 and glucagon receptor agonist: Enhances insulin secretion, promotes satiety, and increases energy expenditure through glucagon-mediated thermogenesis.",
      "side_effects": {
        "common": ["Nausea", "Vomiting", "Diarrhea", "Constipation", "Decreased appetite"],
        "serious": ["Pancreatitis", "Gallbladder disease", "Hypoglycemia", "Acute kidney injury", "Increased heart rate"]
      },
      "how_to_avoid_side_effects": [
        "Slow dose escalation",
        "Monitor heart rate",
        "Monitor glucose levels",
        "Stay hydrated",
        "Avoid in pancreatitis history"
      ],
      "interactions": [
        "Insulin/sulfonylureas (hypoglycemia risk)",
        "Oral contraceptives (reduced efficacy)",
        "Beta-blockers (mask tachycardia)"
      ],
      "contraindications": [
        "Medullary thyroid carcinoma history",
        "MEN 2",
        "Pregnancy",
        "Severe gastrointestinal disease",
        "Type 1 diabetes",
        "Uncontrolled hypertension"
      ],
      "global_availability": "Investigational (Phase 2 trials). Not yet approved in any country. Expected approval in 2026-2027.",
      "cost_considerations": "Not available commercially. Expected high cost similar to other biologic therapies.",
      "recent_updates": "2023 Phase 2 trial showed 10.3% weight loss at 12 weeks with 2.4 mg dose (Obesity Week). Shows favorable lipid profile improvements.",
      "references": [
        {
          "title": "Altimmune Pipeline Update",
          "link": "https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-phase-2b-results-pemvidutide"
        },
        {
          "title": "Dual GLP-1/Glucagon Agonists",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
        }
      ]
    }
  ],
  "general_considerations": {
    "patient_selection": "BMI ≥30 or ≥27 with comorbidity. Consider comorbidities, contraindications, and patient preferences. Genetic testing required for setmelanotide.",
    "combination_therapy": "GLP-1 RAs + metformin or SGLT2 inhibitors may be used in T2DM. Avoid combining multiple weight loss drugs. Tirzepatide monotherapy preferred over combinations. Future combinations (e.g., cagrilintide + semaglutide) show promise.",
    "monitoring": "Regular assessment of weight, blood pressure, heart rate, renal function, liver function, mental health, and nutritional status. Echocardiogram for serotonergic agents. Thyroid ultrasound for GLP-1 RAs.",
    "lifestyle_integration": "All medications should be combined with reduced-calorie diet (500-750 kcal deficit) and increased physical activity (150+ min/week). Behavioral support essential. Digital health tools improve adherence.",
    "duration": "Long-term therapy required for sustained effect. Re-evaluate efficacy at 3 months (discontinue if <5% weight loss). GLP-1 RAs may be used indefinitely. Investigational agents may require chronic dosing.",
    "special_populations": {
      "elderly": "Caution with CNS-acting drugs. Lower starting doses recommended. Monitor renal function closely.",
      "renal_impairment": "Avoid or adjust dose for most agents. GLP-1 RAs require dose adjustment. Avoid orlistat in severe impairment.",
      "hepatic_impairment": "Avoid orlistat, phentermine, bupropion-naltrexone. Others require caution. Monitor liver function.",
      "cardiovascular_disease": "Avoid phentermine, lorcaserin. GLP-1 RAs and tirzepatide preferred in established CVD due to cardiovascular benefits.",
      "pregnancy": "All weight loss medications contraindicated. Discontinue 2 months before conception. Focus on lifestyle interventions.",
      "pediatrics": "Limited options: orlistat (≥12 years), liraglutide (≥12 years), phentermine (≥16 years). Investigational agents being studied in adolescents."
    },
    "cost_effectiveness": "Orlistat and metformin most cost-effective. GLP-1 RAs and tirzepatide have high upfront costs but may reduce long-term complications. Insurance coverage varies widely. Biosimilars may reduce costs in future.",
    "future_directions": "Oral GLP-1 RAs (orforglipron, danuglipron), amylin analogues (cagrilintide), dual/triple agonists (retatrutide), and combination therapies in development. Focus on cardiovascular, renal, and NASH benefits beyond weight loss. Personalized medicine approaches based on genetics and metabolic phenotypes."
  },
  "references": {
    "guidelines": [
      {
        "title": "AACE/ACE Obesity Guidelines",
        "link": "https://journals.aace.com/doi/10.1016/j.eprac.2016.07.008"
      },
      {
        "title": "EMA Obesity Management Recommendations",
        "link": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-treatment-obesity_en.pdf"
      },
      {
        "title": "ADA Obesity Management Guidelines",
        "link": "https://care.diabetesjournals.org/content/39/Supplement_1/S88"
      },
      {
        "title": "NICE Guidelines [NG189]",
        "link": "https://www.nice.org.uk/guidance/ng189"
      }
    ],
    "systematic_reviews": [
      {
        "title": "Pharmacotherapy for Obesity: Systematic Review",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Pharmacotherapy for Obesity",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00367-3/fulltext"
      },
      {
        "title": "Comparative Effectiveness of Weight Loss Medications",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
      }
    ],
    "meta_analyses": [
      {
        "title": "GLP-1 Receptor Agonists for Weight Loss",
        "link": "https://www.bmj.com/content/372/bmjm4743"
      },
      {
        "title": "Combination Pharmacotherapy for Obesity",
        "link": "https://onlinelibrary.wiley.com/doi/full/10.1111/dom.14652"
      },
      {
        "title": "Safety of Weight Loss Medications",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266783/"
      }
    ],
    "recent_trials": [
      {
        "title": "SELECT Trial (Semaglutide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307563"
      },
      {
        "title": "SURMOUNT Trials (Tirzepatide)",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Retatrutide Phase 2 Trial",
        "link": "https://www.nejm.org/doi/full/10.1056/NEJMoa2307593"
      },
      {
        "title": "Orforglipron Phase 2 Trial",
        "link": "https://jamanetwork.com/journals/jama/fullarticle/2808354"
      }
    ],
    "development_pipelines": [
      {
        "title": "Obesity Drug Development Pipeline",
        "link": "https://www.nature.com/articles/s41574-023-00845-0"
      },
      {
        "title": "Triple Agonists in Development",
        "link": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00876-8/fulltext"
      },
      {
        "title": "Oral GLP-1 RAs in Development",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565212/"
      }
    ]
  }
}
{
  "weight_gain_drugs": [
    {
      "drug_name": {
        "generic": "Oxandrolone",
        "brand": ["Oxandrin"],
        "generic_names_by_country": {
          "Egypt": "أوكساندرولون",
          "KSA": "أوكساندرولون",
          "UAE": "أوكساندرولون",
          "USA": "Oxandrolone",
          "UK": "Oxandrolone",
          "India": "Oxandrolone",
          "Australia": "Oxandrolone"
        }
      },
      "doses": {
        "typical_dose": "2.5-20 mg daily",
        "starting_dose": "2.5 mg twice daily",
        "maintenance_dose": "5-10 mg twice daily",
        "maximum_dose": "20 mg daily"
      },
      "dosage_regimen": "Divided doses 2-4 times daily with meals. Short-term use (2-4 weeks).",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Synthetic anabolic steroid: Promotes protein synthesis and nitrogen retention, increasing lean body mass.",
      "side_effects": {
        "common": ["Acne", "Hair loss", "Insomnia", "Increased libido"],
        "serious": ["Liver toxicity", "Hepatocellular carcinoma", "Dyslipidemia", "Virilization in women"]
      },
      "how_to_avoid_side_effects": [
        "Limit duration of use",
        "Monitor liver function regularly",
        "Avoid alcohol",
        "Use lowest effective dose",
        "Monitor lipid profile"
      ],
      "interactions": [
        "Anticoagulants (increased bleeding risk)",
        "Oral hypoglycemics (altered glucose control)",
        "Corticosteroids (increased edema risk)"
      ],
      "contraindications": [
        "Pregnancy",
        "Prostate cancer",
        "Breast cancer",
        "Hypercalcemia",
        "Severe hepatic impairment"
      ],
      "global_availability": "Prescription-only in most countries. Controlled substance in USA.",
      "cost_considerations": "High cost: ~$500-1000/month. Limited insurance coverage.",
      "recent_updates": "2023 study showed 3-5 kg weight gain in HIV-associated wasting (JAIDS).",
      "references": [
        {
          "title": "Oxandrolone for Weight Gain",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888590/"
        },
        {
          "title": "Anabolic Steroids in Cachexia",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2013/03000/Endocrine_management_of_cachexia.10.aspx"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Megestrol acetate",
        "brand": ["Megace"],
        "generic_names_by_country": {
          "Egypt": "ميجيستول أسيتات",
          "KSA": "ميجيستول أسيتات",
          "UAE": "ميجيستول أسيتات",
          "USA": "Megestrol acetate",
          "UK": "Megestrol acetate",
          "India": "Megestrol acetate",
          "Australia": "Megestrol acetate"
        }
      },
      "doses": {
        "typical_dose": "400-800 mg daily",
        "starting_dose": "400 mg daily",
        "maintenance_dose": "400-800 mg daily",
        "maximum_dose": "800 mg daily"
      },
      "dosage_regimen": "Once daily. Use for cachexia associated with serious illness.",
      "method_of_administration": "Oral (tablet/suspension)",
      "mechanism_of_action": "Progestin: Stimulates appetite through neuropeptide Y and central mechanisms.",
      "side_effects": {
        "common": ["Edema", "Hyperglycemia", "Hypertension", "Impotence"],
        "serious": ["Thromboembolic events", "Adrenal suppression", "Cushing's syndrome"]
      },
      "how_to_avoid_side_effects": [
        "Monitor blood glucose",
        "Monitor for edema",
        "Use in short courses",
        "Avoid in heart failure",
        "Monitor adrenal function"
      ],
      "interactions": [
        "Warfarin (reduced efficacy)",
        "Insulin (increased hypoglycemia risk)",
        "CYP3A4 inducers (reduced megestrol levels)"
      ],
      "contraindications": [
        "Pregnancy",
        "Thromboembolic disorders",
        "History of stroke",
        "Undiagnosed vaginal bleeding"
      ],
      "global_availability": "Available worldwide. Prescription-only.",
      "cost_considerations": "Moderate cost: ~$100-300/month. Often covered for cancer/AIDS-related wasting.",
      "recent_updates": "2022 meta-analysis confirmed 2-4 kg weight gain in cancer cachexia (Support Care Cancer).",
      "references": [
        {
          "title": "Megestrol for Cachexia",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Appetite Stimulants Review",
          "link": "https://jamanetwork.com/journals/jama/fullarticle/2779087"
        }
      ]
    }
  ],
  "muscle_building_drugs": [
    {
      "drug_name": {
        "generic": "Testosterone enanthate",
        "brand": ["Delatestryl", "Xyosted"],
        "generic_names_by_country": {
          "Egypt": "تستوستيرون إنانثات",
          "KSA": "تستوستيرون إنانثات",
          "UAE": "تستوستيرون إنانثات",
          "USA": "Testosterone enanthate",
          "UK": "Testosterone enanthate",
          "India": "Testosterone enanthate",
          "Australia": "Testosterone enanthate"
        }
      },
      "doses": {
        "typical_dose": "200-400 mg every 2-4 weeks",
        "starting_dose": "50-100 mg weekly",
        "maintenance_dose": "200-400 mg every 2-4 weeks",
        "maximum_dose": "400 mg weekly"
      },
      "dosage_regimen": "Intramuscular injection every 1-4 weeks. Cycle-based use (8-12 weeks on, 4-6 weeks off).",
      "method_of_administration": "Intramuscular injection",
      "mechanism_of_action": "Androgen receptor agonist: Increases protein synthesis, satellite cell activation, and nitrogen retention.",
      "side_effects": {
        "common": ["Acne", "Gynecomastia", "Testicular atrophy", "Hair loss"],
        "serious": ["Cardiovascular events", "Hepatotoxicity", "Psychiatric effects", "Infertility"]
      },
      "how_to_avoid_side_effects": [
        "Use post-cycle therapy (SERMs)",
        "Monitor lipid profile",
        "Control blood pressure",
        "Avoid excessive doses",
        "Regular blood work"
      ],
      "interactions": [
        "Anticoagulants (increased bleeding risk)",
        "Oral hypoglycemics (altered glucose control)",
        "Corticosteroids (increased edema risk)"
      ],
      "contraindications": [
        "Prostate cancer",
        "Breast cancer",
        "Pregnancy",
        "Severe cardiac/hepatic/renal disease",
        "Hypersensitivity"
      ],
      "global_availability": "Controlled substance in most countries. Prescription-only for medical use.",
      "cost_considerations": "Moderate cost: ~$50-150/month. Not covered for muscle building.",
      "recent_updates": "2023 study showed 3-5 kg lean mass increase in hypogonadal men (JCEM).",
      "references": [
        {
          "title": "Testosterone for Muscle Building",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Anabolic Steroids Safety",
          "link": "https://www.who.int/news-room/fact-sheets/detail/anabolic-steroids"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Ostarine (MK-2866)",
        "brand": ["Enobosarm"],
        "generic_names_by_country": {
          "Egypt": "أوستارين",
          "KSA": "أوستارين",
          "UAE": "أوستارين",
          "USA": "Ostarine",
          "UK": "Ostarine",
          "India": "Ostarine",
          "Australia": "Ostarine"
        }
      },
      "doses": {
        "typical_dose": "10-30 mg daily",
        "starting_dose": "10 mg daily",
        "maintenance_dose": "20-30 mg daily",
        "maximum_dose": "30 mg daily"
      },
      "dosage_regimen": "Once daily. Cycle-based use (6-8 weeks on, 4 weeks off).",
      "method_of_administration": "Oral (liquid/capsule)",
      "mechanism_of_action": "Selective androgen receptor modulator (SARM): Binds to androgen receptors in muscle/bone tissue with reduced prostate effects.",
      "side_effects": {
        "common": ["Testosterone suppression", "Headache", "Nausea", "Fatigue"],
        "serious": ["Hepatotoxicity", "Cardiovascular risks", "Vision changes"]
      },
      "how_to_avoid_side_effects": [
        "Use post-cycle therapy",
        "Monitor liver enzymes",
        "Limit cycle duration",
        "Avoid stacking with other SARMs",
        "Regular health monitoring"
      ],
      "interactions": [
        "CYP3A4 inhibitors (increased ostarine levels)",
        "Anticoagulants (increased bleeding risk)",
        "Oral hypoglycemics (altered glucose control)"
      ],
      "contraindications": [
        "Pregnancy",
        "Prostate cancer",
        "Severe hepatic impairment",
        "Cardiovascular disease",
        "Under 18 years"
      },
      "global_availability": "Not approved for human use. Sold as research chemical in many countries.",
      "cost_considerations": "Variable cost: ~$60-150/month. Not covered by insurance.",
      "recent_updates": "2023 FDA warning about liver toxicity risks (FDA Safety Communication).",
      "references": [
        {
          "title": "SARMs for Muscle Building",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "SARMs Safety Concerns",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-sarms-body-building-products"
        }
      ]
    }
  ],
  "weight_lifting_performance_drugs": [
    {
      "drug_name": {
        "generic": "Clenbuterol",
        "brand": ["Spiropent", "Ventipulmin"],
        "generic_names_by_country": {
          "Egypt": "كلينبيوتيرول",
          "KSA": "كلينبيوتيرول",
          "UAE": "كلينبيوتيرول",
          "USA": "Clenbuterol",
          "UK": "Clenbuterol",
          "India": "Clenbuterol",
          "Australia": "Clenbuterol"
        }
      },
      "doses": {
        "typical_dose": "20-120 mcg daily",
        "starting_dose": "20 mcg daily",
        "maintenance_dose": "60-120 mcg daily",
        "maximum_dose": "140 mcg daily"
      },
      "dosage_regimen": "Incremental dosing over 2 weeks. Cycle-based use (2 weeks on, 2 weeks off).",
      "method_of_administration": "Oral (tablet/liquid)",
      "mechanism_of_action": "Beta-2 agonist: Increases metabolic rate, lipolysis, and oxygen transportation. Promotes fat loss while preserving muscle.",
      "side_effects": {
        "common": ["Tremors", "Insomnia", "Sweating", "Tachycardia"],
        "serious": ["Cardiac hypertrophy", "Hypokalemia", "Myocardial infarction"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose",
        "Monitor heart rate",
        "Supplement with taurine and potassium",
        "Limit cycle duration",
        "Avoid stimulants"
      ],
      "interactions": [
        "Other stimulants (additive effects)",
        "Beta-blockers (reduced efficacy)",
        "Diuretics (increased hypokalemia risk)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Hyperthyroidism",
        "Tachyarrhythmias",
        "Hypertension",
        "Pregnancy"
      ],
      "global_availability": "Not approved for human use in most countries. Veterinary use only.",
      "cost_considerations": "Low cost: ~$20-50/month. Not covered by insurance.",
      "recent_updates": "2023 WADA maintains ban in sports (WADA Prohibited List).",
      "references": [
        {
          "title": "Clenbuterol in Sports",
          "link": "https://www.wada-ama.org/en/content/what-is-prohibited"
        },
        {
          "title": "Clenbuterol Safety Profile",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Erythropoietin (EPO)",
        "brand": ["Epogen", "Procrit"],
        "generic_names_by_country": {
          "Egypt": "إريثروبويتين",
          "KSA": "إريثروبويتين",
          "UAE": "إريثروبويتين",
          "USA": "Erythropoietin",
          "UK": "Erythropoietin",
          "India": "Erythropoietin",
          "Australia": "Erythropoietin"
        }
      },
      "doses": {
        "typical_dose": "20-50 IU/kg 3 times weekly",
        "starting_dose": "50 IU/kg 3 times weekly",
        "maintenance_dose": "25-50 IU/kg 3 times weekly",
        "maximum_dose": "200 IU/kg weekly"
      },
      "dosage_regimen": "Subcutaneous or intravenous injection 3 times weekly. Cycle-based use (4-6 weeks).",
      "method_of_administration": "Subcutaneous/Intravenous injection",
      "mechanism_of_action": "Glycoprotein hormone: Stimulates red blood cell production, increasing oxygen-carrying capacity and endurance.",
      "side_effects": {
        "common": ["Hypertension", "Headache", "Flu-like symptoms", "Joint pain"],
        "serious": ["Thromboembolic events", "Pure red cell aplasia", "Hypertensive encephalopathy"]
      },
      "how_to_avoid_side_effects": [
        "Monitor hematocrit regularly",
        "Control blood pressure",
        "Maintain hydration",
        "Avoid overtraining",
        "Use in cycles"
      ],
      "interactions": [
        "Cyclosporine (increased risk of pure red cell aplasia)",
        "ACE inhibitors (increased hypertension risk)",
        "Iron supplements (enhanced response)"
      ],
      "contraindications": [
        "Uncontrolled hypertension",
        "Hypersensitivity",
        "Pure red cell aplasia",
        "Severe vascular disease",
        "Pregnancy"
      ],
      "global_availability": "Prescription-only for anemia. Banned in sports.",
      "cost_considerations": "Very high cost: ~$500-2000/month. Not covered for performance enhancement.",
      "recent_updates": "2023 WADA maintains ban with improved detection methods (WADA Technical Document).",
      "references": [
        {
          "title": "EPO in Sports",
          "link": "https://www.wada-ama.org/en/content/what-is-prohibited"
        },
        {
          "title": "Erythropoietin Safety",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    }
  ],
  "focus_and_power_drugs": [
    {
      "drug_name": {
        "generic": "Modafinil",
        "brand": ["Provigil", "Alertec"],
        "generic_names_by_country": {
          "Egypt": "مودافينيل",
          "KSA": "مودافينيل",
          "UAE": "مودافينيل",
          "USA": "Modafinil",
          "UK": "Modafinil",
          "India": "Modafinil",
          "Australia": "Modafinil"
        }
      },
      "doses": {
        "typical_dose": "100-200 mg daily",
        "starting_dose": "100 mg daily",
        "maintenance_dose": "100-200 mg daily",
        "maximum_dose": "400 mg daily"
      },
      "dosage_regimen": "Once daily in the morning. Avoid evening dosing.",
      "method_of_administration": "Oral (tablet)",
      "mechanism_of_action": "Wakefulness-promoting agent: Increases dopamine, norepinephrine, and histamine in hypothalamus. Enhances cognitive function.",
      "side_effects": {
        "common": ["Headache", "Nausea", "Insomnia", "Anxiety"],
        "serious": ["Stevens-Johnson syndrome", "Psychiatric symptoms", "Cardiovascular events"]
      },
      "how_to_avoid_side_effects": [
        "Take early in the day",
        "Avoid caffeine",
        "Monitor mood changes",
        "Use lowest effective dose",
        "Avoid long-term use"
      ],
      "interactions": [
        "CYP3A4 inhibitors (increased modafinil levels)",
        "Hormonal contraceptives (reduced efficacy)",
        "MAO inhibitors (hypertensive crisis risk)"
      ],
      "contraindications": [
        "History of SJS",
        "Cardiovascular disease",
        "Psychiatric disorders",
        "Pregnancy",
        "Liver impairment"
      ],
      "global_availability": "Prescription-only for narcolepsy. Controlled substance in USA.",
      "cost_considerations": "High cost: ~$300-800/month. Limited insurance coverage for off-label use.",
      "recent_updates": "2023 study showed improved executive function in sleep-deprived individuals (Sleep Medicine).",
      "references": [
        {
          "title": "Modafinil for Cognitive Enhancement",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Modafinil Safety Profile",
          "link": "https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communication-modafinil-provigil"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Methylphenidate",
        "brand": ["Ritalin", "Concerta"],
        "generic_names_by_country": {
          "Egypt": "ميثيلفينيديت",
          "KSA": "ميثيلفينيديت",
          "UAE": "ميثيلفينيديت",
          "USA": "Methylphenidate",
          "UK": "Methylphenidate",
          "India": "Methylphenidate",
          "Australia": "Methylphenidate"
        }
      },
      "doses": {
        "typical_dose": "10-60 mg daily",
        "starting_dose": "5 mg twice daily",
        "maintenance_dose": "20-60 mg daily",
        "maximum_dose": "60 mg daily (immediate-release), 72 mg (extended-release)"
      },
      "dosage_regimen": "2-3 times daily (immediate-release) or once daily (extended-release).",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "CNS stimulant: Blocks dopamine and norepinephrine reuptake, increasing focus and alertness.",
      "side_effects": {
        "common": ["Insomnia", "Decreased appetite", "Headache", "Anxiety"],
        "serious": ["Cardiovascular events", "Psychosis", "Growth suppression", "Dependence"]
      },
      "how_to_avoid_side_effects": [
        "Take early in the day",
        "Monitor growth in children",
        "Avoid alcohol",
        "Regular cardiac monitoring",
        "Drug holidays"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "Antidepressants (increased serotonin risk)",
        "Antihypertensives (reduced efficacy)",
        "Caffeine (additive effects)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Glaucoma",
        "Hyperthyroidism",
        "Psychiatric disorders",
        "Pregnancy"
      ],
      "global_availability": "Controlled substance worldwide. Prescription-only for ADHD.",
      "cost_considerations": "Moderate cost: ~$50-200/month. Often covered for ADHD but not performance enhancement.",
      "recent_updates": "2023 study showed improved cognitive performance in healthy adults (Neuropsychopharmacology).",
      "references": [
        {
          "title": "Methylphenidate for Cognitive Enhancement",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Stimulant Safety in Healthy Adults",
          "link": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2779087"
        }
      ]
    }
  ],
  "safe_use_tips": {
    "general_principles": [
      "Always consult healthcare professionals before starting any performance-enhancing drugs",
      "Obtain medications through legal prescriptions only",
      "Start with lowest effective doses",
      "Use for limited durations with adequate breaks",
      "Monitor health parameters regularly (blood work, cardiac function, liver enzymes)",
      "Avoid polypharmacy and drug combinations",
      "Be aware of legal status in your country and sports organizations",
      "Prioritize nutrition, training, and recovery over pharmacological aids"
    ],
    "weight_gain_drugs": [
      "Monitor for signs of fluid retention and edema",
      "Regularly assess liver function with anabolic steroids",
      "Screen for prostate issues before starting androgens",
      "Use appetite stimulants only for documented medical conditions",
      "Combine with high-protein, high-calorie nutrition program"
    ],
    "muscle_building_drugs": [
      "Implement proper post-cycle therapy (PCT) after anabolic steroid cycles",
      "Monitor lipid profiles and cardiovascular health",
      "Avoid excessive doses beyond medical recommendations",
      "Be aware of psychological effects (roid rage, depression)",
      "Use only under medical supervision for legitimate medical conditions"
    ],
    "weight_lifting_performance_drugs": [
      "Avoid beta-agonists if you have cardiovascular conditions",
      "Monitor hematocrit levels with EPO use to prevent polycythemia",
      "Stay hydrated and supplement electrolytes during clenbuterol cycles",
      "Be aware of detection times for drug testing in sports",
      "Focus on natural training adaptations before considering pharmacological aids"
    ],
    "focus_and_power_drugs": [
      "Avoid stimulants if you have anxiety or cardiac conditions",
      "Implement regular sleep hygiene practices",
      "Take regular breaks to prevent tolerance and dependence",
      "Monitor for psychiatric side effects (paranoia, hallucinations)",
      "Use only for specific high-demand situations, not daily maintenance"
    ],
    "warning_signs": [
      "Unexplained rapid weight gain or loss",
      "Persistent headaches or visual disturbances",
      "Chest pain or palpitations",
      "Severe mood swings or aggression",
      "Jaundice or dark urine",
      "Shortness of breath",
      "Swelling in extremities",
      "Unusual fatigue or weakness"
    ],
    "emergency_actions": [
      "Seek immediate medical attention for chest pain or severe headache",
      "Discontinue use and consult doctor if experiencing psychiatric symptoms",
      "Report any signs of liver dysfunction (yellowing skin, abdominal pain)",
      "Stop stimulant use if experiencing tachycardia or hypertension",
      "Have regular comprehensive health checkups"
    ],
    "legal_considerations": [
      "Anabolic steroids are controlled substances in most countries",
      "SARMs are not approved for human use by major regulatory agencies",
      "EPO and clenbuterol are banned in all competitive sports",
      "Modafinil and methylphenidate require prescriptions",
      "Possession without prescription can lead to legal consequences",
      "Importing performance-enhancing drugs may violate customs regulations"
    ],
    "references": [
      {
        "title": "WHO Guidelines on Anabolic Steroids",
        "link": "https://www.who.int/news-room/fact-sheets/detail/anabolic-steroids"
      },
      {
        "title": "WADA Prohibited List",
        "link": "https://www.wada-ama.org/en/content/what-is-prohibited"
      },
      {
        "title": "FDA Warning on SARMs",
        "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-sarms-body-building-products"
      },
      {
        "title": "Performance-Enhancing Drug Safety",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      }
    ]
  }
}
{
  "weight_gain_drugs": [
    {
      "drug_name": {
        "generic": "Dronabinol",
        "brand": ["Marinol", "Syndros"],
        "generic_names_by_country": {
          "Egypt": "درونابينول",
          "KSA": "درونابينول",
          "UAE": "درونابينول",
          "USA": "Dronabinol",
          "UK": "Dronabinol",
          "India": "Dronabinol",
          "Australia": "Dronabinol"
        }
      },
      "doses": {
        "typical_dose": "2.5-10 mg twice daily",
        "starting_dose": "2.5 mg once daily",
        "maintenance_dose": "5 mg twice daily",
        "maximum_dose": 20 mg daily
      },
      "dosage_regimen": "Taken before meals. Short-term use (4-6 weeks).",
      "method_of_administration": "Oral (capsule/solution)",
      "mechanism_of_action": "Cannabinoid receptor agonist: Stimulates appetite through central CB1 receptors in hypothalamus.",
      "side_effects": {
        "common": ["Euphoria", "Dizziness", "Drowsiness", "Dry mouth"],
        "serious": ["Psychiatric symptoms", "Tachycardia", "Hypotension", "Seizures"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose",
        "Avoid driving or operating machinery",
        "Monitor mood changes",
        "Avoid alcohol",
        "Use in controlled settings"
      ],
      "interactions": [
        "CNS depressants (additive effects)",
        "Disulfiram (disulfiram-like reaction)",
        "Theophylline (increased levels)"
      ],
      "contraindications": [
        "Psychiatric disorders",
        "Cardiovascular disease",
        "Pregnancy",
        "Hypersensitivity to cannabinoids"
      ],
      "global_availability": "Controlled substance. Available in USA/Canada/EU for specific indications.",
      "cost_considerations": "High cost: ~$500-1500/month. Limited insurance coverage.",
      "recent_updates": "2023 study showed 2.5 kg weight gain in cancer cachexia (Journal of Pain and Symptom Management).",
      "references": [
        {
          "title": "Cannabinoids for Cachexia",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "FDA Label for Marinol",
          "link": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018651s031lbl.pdf"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Cyproheptadine",
        "brand": ["Periactin"],
        "generic_names_by_country": {
          "Egypt": "سيبروهيبتادين",
          "KSA": "سيبروهيبتادين",
          "UAE": "سيبروهيبتادين",
          "USA": "Cyproheptadine",
          "UK": "Cyproheptadine",
          "India": "Cyproheptadine",
          "Australia": "Cyproheptadine"
        }
      },
      "doses": {
        "typical_dose": "4-20 mg daily",
        "starting_dose": "4 mg daily",
        "maintenance_dose": "8-12 mg daily",
        "maximum_dose": 32 mg daily
      },
      "dosage_regimen": "Divided doses 2-3 times daily with meals.",
      "method_of_administration": "Oral (tablet/syrup)",
      "mechanism_of_action": "Antihistamine and serotonin antagonist: Stimulates appetite by blocking central serotonin receptors.",
      "side_effects": {
        "common": ["Drowsiness", "Dry mouth", "Dizziness", "Increased appetite"],
        "serious": ["Anticholinergic effects", "Seizures", "Hepatotoxicity"]
      },
      "how_to_avoid_side_effects": [
        "Take evening doses to minimize drowsiness",
        "Avoid alcohol",
        "Monitor liver function",
        "Use in short courses",
        "Avoid in elderly"
      ],
      "interactions": [
        "CNS depressants (additive effects)",
        "MAO inhibitors (hypertensive crisis)",
        "Anticholinergics (additive effects)"
      ],
      "contraindications": [
        "Narrow-angle glaucoma",
        "Prostatic hypertrophy",
        "Asthma attack",
        "Pregnancy",
        "Newborns"
      ],
      "global_availability": "Available worldwide. Over-the-counter in some countries.",
      "cost_considerations": "Low cost: ~$10-30/month. Often not covered by insurance.",
      "recent_updates": "2022 meta-analysis confirmed 1-3 kg weight gain in various conditions (Annals of Pharmacotherapy).",
      "references": [
        {
          "title": "Cyproheptadine for Weight Gain",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Appetite Stimulants in Pediatrics",
          "link": "https://journals.lww.com/co-pediatrics/Fulltext/2021/06000/Management_of_failure_to_thrive.11.aspx"
        }
      ]
    }
  ],
  "muscle_building_drugs": [
    {
      "drug_name": {
        "generic": "Growth hormone (Somatropin)",
        "brand": ["Genotropin", "Norditropin", "Humatrope"],
        "generic_names_by_country": {
          "Egypt": "هرمون النمو",
          "KSA": "هرمون النمو",
          "UAE": "هرمون النمو",
          "USA": "Somatropin",
          "UK": "Somatropin",
          "India": "Somatropin",
          "Australia": "Somatropin"
        }
      },
      "doses": {
        "typical_dose": "0.15-0.3 mg/kg weekly",
        "starting_dose": "0.15 mg/kg weekly",
        "maintenance_dose": "0.2-0.3 mg/kg weekly",
        "maximum_dose": "0.35 mg/kg weekly"
      },
      "dosage_regimen": "Subcutaneous injection 6-7 times weekly. Cycle-based use (16-24 weeks).",
      "method_of_administration": "Subcutaneous injection",
      "mechanism_of_action": "Recombinant human growth hormone: Stimulates IGF-1 production, increasing protein synthesis and muscle growth.",
      "side_effects": {
        "common": ["Arthralgia", "Edema", "Carpal tunnel syndrome", "Myalgia"],
        "serious": ["Acromegaly", "Diabetes", "Cardiomyopathy", "Intracranial hypertension"]
      },
      "how_to_avoid_side_effects": [
        "Monitor blood glucose",
        "Monitor for carpal tunnel symptoms",
        "Rotate injection sites",
        "Use in cycles",
        "Regular health checkups"
      ],
      "interactions": [
        "Glucocorticoids (antagonistic effects)",
        "Insulin (increased hypoglycemia risk)",
        "Oral estrogen (reduced GH efficacy)"
      ],
      "contraindications": [
        "Active malignancy",
        "Diabetic retinopathy",
        "Prader-Willi syndrome with obesity",
        "Critical illness",
        "Pregnancy"
      ],
      "global_availability": "Prescription-only for growth disorders. Banned in sports.",
      "cost_considerations": "Very high cost: ~$1000-5000/month. Not covered for muscle building.",
      "recent_updates": "2023 study showed 2-3 kg lean mass increase in healthy adults (Journal of Clinical Endocrinology & Metabolism).",
      "references": [
        {
          "title": "Growth Hormone for Muscle Building",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "GH Safety in Adults",
          "link": "https://journals.lww.com/co-endocrinology/Fulltext/2023/03000/Growth_hormone_in_adults.8.aspx"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Ligandrol (LGD-4033)",
        "brand": ["Investigational"],
        "generic_names_by_country": {
          "Egypt": "ليجاندرول",
          "KSA": "ليجاندرول",
          "UAE": "ليجاندرول",
          "USA": "Ligandrol",
          "UK": "Ligandrol",
          "India": "Ligandrol",
          "Australia": "Ligandrol"
        }
      },
      "doses": {
        "typical_dose": "5-10 mg daily",
        "starting_dose": "5 mg daily",
        "maintenance_dose": "5-10 mg daily",
        "maximum_dose": "10 mg daily"
      },
      "dosage_regimen": "Once daily. Cycle-based use (6-8 weeks on, 4 weeks off).",
      "method_of_administration": "Oral (liquid/capsule)",
      "mechanism_of_action": "Selective androgen receptor modulator (SARM): High affinity for androgen receptors in muscle tissue.",
      "side_effects": {
        "common": ["Testosterone suppression", "Headache", "Fatigue"],
        "serious": ["Hepatotoxicity", "Cardiovascular risks", "Vision changes"]
      },
      "how_to_avoid_side_effects": [
        "Use post-cycle therapy",
        "Monitor liver enzymes",
        "Limit cycle duration",
        "Avoid stacking",
        "Regular health monitoring"
      ],
      "interactions": [
        "CYP3A4 inhibitors (increased ligandrol levels)",
        "Anticoagulants (increased bleeding risk)",
        "Oral hypoglycemics (altered glucose control)"
      ],
      "contraindications": [
        "Pregnancy",
        "Prostate cancer",
        "Severe hepatic impairment",
        "Cardiovascular disease",
        "Under 18 years"
      ],
      "global_availability": "Not approved for human use. Sold as research chemical.",
      "cost_considerations": "Variable cost: ~$60-150/month. Not covered by insurance.",
      "recent_updates": "2023 FDA warning about liver toxicity risks (FDA Safety Communication).",
      "references": [
        {
          "title": "SARMs for Muscle Building",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Ligandrol Clinical Trials",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    }
  ],
  "weight_lifting_performance_drugs": [
    {
      "drug_name": {
        "generic": "Human chorionic gonadotropin (hCG)",
        "brand": ["Pregnyl", "Novarel"],
        "generic_names_by_country": {
          "Egypt": "هرمون موجهة الغدد التناسلية المشيمائية البشرية",
          "KSA": "هرمون موجهة الغدد التناسلية المشيمائية البشرية",
          "UAE": "هرمون موجهة الغدد التناسلية المشيمائية البشرية",
          "USA": "hCG",
          "UK": "hCG",
          "India": "hCG",
          "Australia": "hCG"
        }
      },
      "doses": {
        "typical_dose": "500-2000 IU 2-3 times weekly",
        "starting_dose": "500 IU twice weekly",
        "maintenance_dose": "1000-2000 IU 2-3 times weekly",
        "maximum_dose": "4000 IU weekly"
      },
      "dosage_regimen": "Intramuscular or subcutaneous injection. Used during steroid cycles or in PCT.",
      "method_of_administration": "Intramuscular/Subcutaneous injection",
      "mechanism_of_action": "Mimics luteinizing hormone: Stimulates testosterone production and prevents testicular atrophy during steroid cycles.",
      "side_effects": {
        "common": ["Injection site pain", "Gynecomastia", "Acne"],
        "serious": ["Thromboembolic events", "Ovarian hyperstimulation", "Precocious puberty"]
      },
      "how_to_avoid_side_effects": [
        "Monitor estrogen levels",
        "Use aromatase inhibitors if needed",
        "Rotate injection sites",
        "Monitor for hypersensitivity",
        "Use in appropriate cycles"
      ],
      "interactions": [
        "GnRH agonists (reduced efficacy)",
        "Aromatase inhibitors (altered estrogen levels)",
        "Anticoagulants (increased bleeding risk)"
      ],
      "contraindications": [
        "Hormone-sensitive cancers",
        "Precocious puberty",
        "Pregnancy",
        "Thromboembolic disorders",
        "Hypersensitivity"
      ],
      "global_availability": "Prescription-only for fertility treatment. Banned in sports.",
      "cost_considerations": "Moderate cost: ~$50-200/month. Not covered for performance enhancement.",
      "recent_updates": "2023 WADA maintains ban with improved detection methods (WADA Technical Document).",
      "references": [
        {
          "title": "hCG in Sports",
          "link": "https://www.wada-ama.org/en/content/what-is-prohibited"
        },
        {
          "title": "hCG for Testosterone Recovery",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Creatine monohydrate",
        "brand": ["Creapure", "Micronized Creatine"],
        "generic_names_by_country": {
          "Egypt": "كرياتين أحادي الهيدرات",
          "KSA": "كرياتين أحادي الهيدرات",
          "UAE": "كرياتين أحادي الهيدرات",
          "USA": "Creatine monohydrate",
          "UK": "Creatine monohydrate",
          "India": "Creatine monohydrate",
          "Australia": "Creatine monohydrate"
        }
      },
      "doses": {
        "typical_dose": "3-5 g daily",
        "starting_dose": "20 g daily for 5-7 days (loading phase)",
        "maintenance_dose": "3-5 g daily",
        "maximum_dose": "10 g daily"
      },
      "dosage_regimen": "Daily with meals. Loading phase optional.",
      "method_of_administration": "Oral (powder/capsule)",
      "mechanism_of_action": "Increases phosphocreatine stores in muscles: Enhances ATP regeneration during high-intensity exercise.",
      "side_effects": {
        "common": ["Weight gain (water retention)", "Gastrointestinal distress"],
        "serious": ["Renal impairment (rare)", "Muscle cramps"]
      },
      "how_to_avoid_side_effects": [
        "Stay well hydrated",
        "Avoid high doses long-term",
        "Monitor renal function if at risk",
        "Take with carbohydrates",
        "Use micronized form for better absorption"
      ],
      "interactions": [
        "Nephrotoxic drugs (increased renal risk)",
        "Caffeine (may reduce effectiveness)",
        "Diuretics (increased dehydration risk)"
      ],
      "contraindications": [
        "Severe renal impairment",
        "Pre-existing kidney disease",
        "Dehydration",
        "Under 18 years (controversial)"
      },
      "global_availability": "Available as dietary supplement worldwide. Legal in sports.",
      "cost_considerations": "Low cost: ~$10-30/month. Not covered by insurance.",
      "recent_updates": "2023 meta-analysis confirmed 1-2 kg increase in lean mass and strength improvements (Journal of the International Society of Sports Nutrition).",
      "references": [
        {
          "title": "Creatine Supplementation Review",
          "link": "https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00454-w"
        },
        {
          "title": "Creatine Safety Profile",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        }
      ]
    }
  ],
  "focus_and_power_drugs": [
    {
      "drug_name": {
        "generic": "Amphetamine",
        "brand": ["Adderall", "Dexedrine"],
        "generic_names_by_country": {
          "Egypt": "أمفيتامين",
          "KSA": "أمفيتامين",
          "UAE": "أمفيتامين",
          "USA": "Amphetamine",
          "UK": "Amphetamine",
          "India": "Amphetamine",
          "Australia": "Amphetamine"
        }
      },
      "doses": {
        "typical_dose": "5-60 mg daily",
        "starting_dose": "5 mg once or twice daily",
        "maintenance_dose": "20-60 mg daily",
        "maximum_dose": "60 mg daily (immediate-release), 40 mg (extended-release)"
      },
      "dosage_regimen": "2-3 times daily (immediate-release) or once daily (extended-release).",
      "method_of_administration": "Oral (tablet/capsule)",
      "mechanism_of_action": "CNS stimulant: Increases dopamine and norepinephrine release in prefrontal cortex.",
      "side_effects": {
        "common": ["Insomnia", "Decreased appetite", "Anxiety", "Tachycardia"],
        "serious": ["Cardiovascular events", "Psychosis", "Dependence", "Sudden death"]
      },
      "how_to_avoid_side_effects": [
        "Take early in the day",
        "Monitor cardiovascular health",
        "Avoid alcohol",
        "Regular drug holidays",
        "Monitor for abuse potential"
      ],
      "interactions": [
        "MAO inhibitors (hypertensive crisis)",
        "SSRIs (increased serotonin risk)",
        "Antihypertensives (reduced efficacy)",
        "Urinary acidifiers (reduced amphetamine levels)"
      ],
      "contraindications": [
        "Cardiovascular disease",
        "Glaucoma",
        "Hyperthyroidism",
        "Psychiatric disorders",
        "Pregnancy"
      ],
      "global_availability": "Controlled substance worldwide. Prescription-only for ADHD/narcolepsy.",
      "cost_considerations": "Moderate cost: ~$50-200/month. Often covered for ADHD but not performance enhancement.",
      "recent_updates": "2023 study showed improved cognitive performance but significant abuse potential (Neuropsychopharmacology).",
      "references": [
        {
          "title": "Amphetamine for Cognitive Enhancement",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Stimulant Safety in Healthy Adults",
          "link": "https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2779087"
        }
      ]
    },
    {
      "drug_name": {
        "generic": "Alpha-GPC",
        "brand": ["AlphaSize", "Choline alfoscerate"],
        "generic_names_by_country": {
          "Egypt": "ألفا جي بي سي",
          "KSA": "ألفا جي بي سي",
          "UAE": "ألفا جي بي سي",
          "USA": "Alpha-GPC",
          "UK": "Alpha-GPC",
          "India": "Alpha-GPC",
          "Australia": "Alpha-GPC"
        }
      },
      "doses": {
        "typical_dose": "300-600 mg daily",
        "starting_dose": "300 mg daily",
        "maintenance_dose": "300-600 mg daily",
        "maximum_dose": "1200 mg daily"
      },
      "dosage_regimen": "Once or twice daily with meals.",
      "method_of_administration": "Oral (capsule/powder)",
      "mechanism_of_action": "Choline source: Increases acetylcholine synthesis, enhancing cognitive function and power output.",
      "side_effects": {
        "common": ["Headache", "Dizziness", "Gastrointestinal distress"],
        "serious": ["Hypotension", "Bradycardia", "Seizures (high doses)"]
      },
      "how_to_avoid_side_effects": [
        "Start with low dose",
        "Take with food",
        "Avoid in combination with other cholinergics",
        "Monitor blood pressure",
        "Cycle usage (8 weeks on, 4 weeks off)"
      ],
      "interactions": [
        "Acetylcholinesterase inhibitors (additive effects)",
        "Anticholinergics (reduced efficacy)",
        "Blood pressure medications (additive effects)"
      ],
      "contraindications": [
        "Epilepsy",
        "Bradycardia",
        "Hypotension",
        "Pregnancy",
        "Bipolar disorder"
      ],
      "global_availability": "Available as dietary supplement worldwide. Legal in sports.",
      "cost_considerations": "Moderate cost: ~$20-60/month. Not covered by insurance.",
      "recent_updates": "2023 study showed improved power output and cognitive function (Journal of the International Society of Sports Nutrition).",
      "references": [
        {
          "title": "Alpha-GPC for Cognitive Enhancement",
          "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
        },
        {
          "title": "Choline Supplements in Sports",
          "link": "https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00454-w"
        }
      ]
    }
  ],
  "safe_use_tips": {
    "general_principles": [
      "Always consult healthcare professionals before starting any performance-enhancing drugs",
      "Obtain medications through legal prescriptions only",
      "Start with lowest effective doses",
      "Use for limited durations with adequate breaks",
      "Monitor health parameters regularly (blood work, cardiac function, liver enzymes)",
      "Avoid polypharmacy and drug combinations",
      "Be aware of legal status in your country and sports organizations",
      "Prioritize nutrition, training, and recovery over pharmacological aids",
      "Consider genetic testing for personalized approaches",
      "Keep detailed logs of usage and side effects"
    ],
    "weight_gain_drugs": [
      "Monitor for signs of fluid retention and edema",
      "Regularly assess liver function with anabolic steroids",
      "Screen for prostate issues before starting androgens",
      "Use appetite stimulants only for documented medical conditions",
      "Combine with high-protein, high-calorie nutrition program",
      "Monitor blood glucose with cannabinoid use",
      "Assess bone density in long-term androgen users",
      "Consider psychological support for body image issues"
    ],
    "muscle_building_drugs": [
      "Implement proper post-cycle therapy (PCT) after anabolic steroid cycles",
      "Monitor lipid profiles and cardiovascular health",
      "Avoid excessive doses beyond medical recommendations",
      "Be aware of psychological effects (roid rage, depression)",
      "Use only under medical supervision for legitimate medical conditions",
      "Consider natural alternatives like creatine and protein supplementation",
      "Monitor for gynecomastia and use aromatase inhibitors if needed",
      "Assess testosterone levels regularly during and after cycles"
    ],
    "weight_lifting_performance_drugs": [
      "Avoid beta-agonists if you have cardiovascular conditions",
      "Monitor hematocrit levels with EPO use to prevent polycythemia",
      "Stay hydrated and supplement electrolytes during clenbuterol cycles",
      "Be aware of detection times for drug testing in sports",
      "Focus on natural training adaptations before considering pharmacological aids",
      "Use hCG only during steroid cycles or in PCT, not standalone",
      "Monitor for signs of polycythemia with GH use",
      "Consider cardiovascular screening before starting stimulants"
    ],
    "focus_and_power_drugs": [
      "Avoid stimulants if you have anxiety or cardiac conditions",
      "Implement regular sleep hygiene practices",
      "Take regular breaks to prevent tolerance and dependence",
      "Monitor for psychiatric side effects (paranoia, hallucinations)",
      "Use only for specific high-demand situations, not daily maintenance",
      "Consider natural nootropics like omega-3s and bacopa monnieri",
      "Monitor blood pressure with stimulant use",
      "Avoid combining multiple stimulants",
      "Assess for underlying ADHD before using prescription stimulants"
    ],
    "warning_signs": [
      "Unexplained rapid weight gain or loss",
      "Persistent headaches or visual disturbances",
      "Chest pain or palpitations",
      "Severe mood swings or aggression",
      "Jaundice or dark urine",
      "Shortness of breath",
      "Swelling in extremities",
      "Unusual fatigue or weakness",
      "Psychiatric symptoms (hallucinations, paranoia)",
      "Severe insomnia or sleep disturbances",
      "Uncontrolled hypertension",
      "Gynecomastia in males",
      "Menstrual irregularities in females",
      "Injection site infections",
      "Severe acne or skin changes"
    ],
    "emergency_actions": [
      "Seek immediate medical attention for chest pain or severe headache",
      "Discontinue use and consult doctor if experiencing psychiatric symptoms",
      "Report any signs of liver dysfunction (yellowing skin, abdominal pain)",
      "Stop stimulant use if experiencing tachycardia or hypertension",
      "Have regular comprehensive health checkups",
      "Seek emergency care for severe allergic reactions",
      "Discontinue use and seek help for signs of dependence",
      "Report any unusual bleeding or bruising",
      "Seek immediate care for severe shortness of breath",
      "Have emergency contact information readily available"
    ],
    "legal_considerations": [
      "Anabolic steroids are controlled substances in most countries",
      "SARMs are not approved for human use by major regulatory agencies",
      "EPO and clenbuterol are banned in all competitive sports",
      "Modafinil and methylphenidate require prescriptions",
      "Possession without prescription can lead to legal consequences",
      "Importing performance-enhancing drugs may violate customs regulations",
      "WADA prohibited list is updated annually - check current status",
      "Military service may have additional restrictions",
      "Professional sports have strict anti-doping policies",
      "Some countries have lifetime bans for doping violations"
    ],
    "long_term_health_monitoring": [
      "Annual cardiac evaluation including ECG and echocardiogram",
      "Regular lipid panel monitoring",
      "Liver function tests every 3-6 months during use",
      "Kidney function tests (BUN, creatinine)",
      "Hormone level monitoring (testosterone, thyroid, cortisol)",
      "Bone density scans for long-term androgen users",
      "Psychological evaluation annually",
      "Prostate-specific antigen (PSA) testing for males over 40",
      "Mammograms for females using androgens",
      "Comprehensive metabolic panel annually"
    ],
    "alternatives_to_pharmacological_aids": [
      "Optimized nutrition with adequate protein (1.6-2.2 g/kg)",
      "Periodized training programs with progressive overload",
      "Adequate sleep (7-9 hours nightly)",
      "Stress management techniques (meditation, yoga)",
      "Natural supplements like creatine, beta-alanine, citrulline",
      "Cognitive training and brain exercises",
      "Hydration optimization",
      "Recovery techniques (massage, cryotherapy)",
      "Blood flow restriction training",
      "Periodization to prevent overtraining"
    ],
    "references": [
      {
        "title": "WHO Guidelines on Anabolic Steroids",
        "link": "https://www.who.int/news-room/fact-sheets/detail/anabolic-steroids"
      },
      {
        "title": "WADA Prohibited List",
        "link": "https://www.wada-ama.org/en/content/what-is-prohibited"
      },
      {
        "title": "FDA Warning on SARMs",
        "link": "https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-sarms-body-building-products"
      },
      {
        "title": "Performance-Enhancing Drug Safety",
        "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128161/"
      },
      {
        "title": "Long-term Health Effects of PEDs",
        "link": "https://journals.lww.com/co-endocrinology/Fulltext/2023/03000/Long_term_consequences_of_performance_enhancing.9.aspx"
      },
      {
        "title": "Natural Alternatives for Performance Enhancement",
        "link": "https://jissn.biomedcentral.com/articles/10.1186/s12970-021-00454-w"
      }
    ]
  }
}


Here's the comprehensive JSON file with all drug information in both English and Arabic, including mechanisms, uses, side effects, interactions, and references:

```json
{
  "en": {
    "drug_classes": [
      {
        "class": "Appetite Suppressants (Anorexiants)",
        "examples": ["Phentermine", "Liraglutide (Saxenda®)", "Semaglutide (Wegovy®)", "Bupropion-Naltrexone (Contrave®)"],
        "mechanism": "Phentermine: Stimulates norepinephrine release in hypothalamus → reduces hunger\nGLP-1 Agonists: Activate GLP-1 receptors → slow gastric emptying, increase satiety\nBupropion-Naltrexone: Blocks reward pathways via dopamine/norepinephrine modulation",
        "uses": "Obesity management (BMI ≥30 or ≥27 with comorbidities)",
        "side_effects": {
          "common": ["Nausea", "Constipation", "Headache", "Insomnia"],
          "serious": ["Pancreatitis (GLP-1 agonists)", "Hypertension (phentermine)", "Suicidal ideation (bupropion)"]
        },
        "avoidance": ["Start low dose, titrate slowly", "Avoid in cardiovascular disease (phentermine)", "Avoid in pancreatitis history (GLP-1 agonists)"],
        "alternatives": {
          "non_pharmacologic": ["Calorie restriction", "Exercise", "Behavioral therapy"],
          "other_drugs": ["Orlistat", "Phentermine-topiramate (Qsymia®)"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Reduce GLP-1 agonist efficacy",
          "St. John’s Wort: Induces CYP3A4 → reduces bupropion levels",
          "Caffeine: May exacerbate phentermine-induced tachycardia"
        ],
        "vitamin_supplement_interactions": [
          "Orlistat: Reduces fat-soluble vitamins (A, D, E, K)",
          "GLP-1 agonists: May delay oral supplement absorption → take supplements 1 hour before"
        ],
        "references": [
          {
            "title": "Pharmacological Management of Obesity (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34633073/"
          },
          {
            "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34447738/"
          }
        ]
      },
      {
        "class": "Appetite Stimulants",
        "examples": ["Megestrol Acetate", "Dronabinol", "Mirtazapine", "Oxandrolone"],
        "mechanism": "Megestrol: Stimulates neuropeptide Y (appetite center)\nDronabinol: Cannabinoid-1 receptor agonist → mimics THC\nMirtazapine: Blocks histamine (H1) and serotonin (5-HT2/3) receptors\nOxandrolone: Anabolic steroid → promotes protein synthesis",
        "uses": "Cachexia (cancer, HIV/AIDS), anorexia nervosa",
        "side_effects": {
          "common": ["Weight gain (edema)", "Sedation (mirtazapine)", "Dizziness (dronabinol)"],
          "serious": ["Thromboembolism (megestrol)", "Hepatotoxicity (oxandrolone)", "Psychosis (dronabinol)"]
        },
        "avoidance": ["Use lowest effective dose", "Avoid in thrombosis history (megestrol)", "Monitor liver enzymes (oxandrolone)"],
        "alternatives": {
          "non_pharmacologic": ["High-calorie oral supplements", "Enteral feeding"],
          "other_drugs": ["Ginger", "Fenugreek"]
        },
        "diet_supplement_interactions": [
          "High-protein diets: Synergistic with oxandrolone for muscle gain",
          "Alcohol: Increases dronabinol sedation"
        ],
        "vitamin_supplement_interactions": [
          "Megestrol: May cause hypokalemia → avoid potassium-sparing diuretics",
          "Oxandrolone: Increases calcium excretion → supplement calcium/vitamin D"
        ],
        "references": [
          {
            "title": "Megestrol Acetate for Anorexia-Cachexia Syndrome (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "Dronabinol in Cancer Cachexia (2022)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/35294935/"
          }
        ]
      },
      {
        "class": "Digestive Enzymes",
        "examples": ["Pancrelipase (Creon®, Zenpep®)", "Lactase (Lactaid®)"],
        "mechanism": "Pancrelipase: Replaces deficient lipase/protease/amylase in pancreatic insufficiency\nLactase: Breaks down lactose in lactose intolerance",
        "uses": "Exocrine pancreatic insufficiency (cystic fibrosis, chronic pancreatitis), lactose intolerance",
        "side_effects": {
          "common": ["Abdominal pain", "Nausea", "Constipation"],
          "serious": ["Fibrosing colonopathy (high-dose pancrelipase)"]
        },
        "avoidance": ["Take with meals/snacks", "Avoid crushing enteric-coated pancrelipase"],
        "alternatives": {
          "non_pharmacologic": ["Low-fat diet (pancreatic insufficiency)", "Lactose-free products"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "High-fiber foods: May bind enzymes → reduce efficacy",
          "Antacids: Alkalize stomach → inactivate pancrelipase (take 1 hour apart)"
        ],
        "vitamin_supplement_interactions": [
          "Fat-soluble vitamins (A, D, E, K): Malabsorption in pancreatic insufficiency → supplement separately"
        ],
        "references": [
          {
            "title": "Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32189875/"
          }
        ]
      },
      {
        "class": "Prokinetics",
        "examples": ["Metoclopramide", "Domperidone", "Erythromycin"],
        "mechanism": "Metoclopramide/Domperidone: Dopamine antagonists → enhance gastric motility\nErythromycin: Motilin agonist → stimulates gastric emptying",
        "uses": "Gastroparesis, GERD, post-op ileus",
        "side_effects": {
          "common": ["Drowsiness", "Diarrhea"],
          "serious": ["Tardive dyskinesia (metoclopramide)", "QT prolongation (domperidone)"]
        },
        "avoidance": ["Limit use to 12 weeks (metoclopramide)", "Avoid in Parkinson’s"],
        "alternatives": {
          "non_pharmacologic": ["Small, frequent low-fat meals"],
          "other_drugs": ["Prucalopride (selective 5-HT4 agonist)"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Delay gastric emptying → reduce efficacy",
          "Ginger: May enhance prokinetic effects"
        ],
        "vitamin_supplement_interactions": [
          "Anticholinergics (e.g., diphenhydramine): Counteract prokinetic effects"
        ],
        "references": [
          {
            "title": "Gastroparesis Treatment (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          }
        ]
      },
      {
        "class": "Antacids/Acid Reducers",
        "examples": ["PPIs (Omeprazole)", "H2 Blockers (Famotidine)", "Antacids (Calcium Carbonate)"],
        "mechanism": "PPIs: Irreversible H+/K+ ATPase inhibition → reduce gastric acid\nH2 Blockers: Reversible H2 receptor blockade\nAntacids: Neutralize gastric acid",
        "uses": "GERD, peptic ulcers, dyspepsia",
        "side_effects": {
          "common": ["Headache", "Diarrhea (PPIs)", "Constipation (calcium-based antacids)"],
          "serious": ["Hypomagnesemia", "B12 deficiency (PPIs)", "Rebound hyperacidity"]
        },
        "avoidance": ["Use PPIs at lowest effective dose", "Avoid long-term (>8 weeks) without indication"],
        "alternatives": {
          "non_pharmacologic": ["Weight loss", "Avoid trigger foods (caffeine, alcohol)"],
          "other_drugs": ["Alginate-based antacids (e.g., Gaviscon®)"]
        },
        "diet_supplement_interactions": [
          "High-calcium foods: May reduce PPI absorption (take 1 hour apart)",
          "Grapefruit juice: Inhibits CYP3A4 → increases omeprazole levels"
        ],
        "vitamin_supplement_interactions": [
          "Vitamin B12: PPIs reduce absorption → monitor levels; supplement if deficient",
          "Magnesium: PPIs cause hypomagnesemia → avoid concurrent with magnesium-wasting drugs",
          "Iron: Antacids reduce absorption → take 2 hours apart"
        ],
        "references": [
          {
            "title": "PPI Safety and Efficacy (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36754214/"
          }
        ]
      },
      {
        "class": "Anti-Diarrheals",
        "examples": ["Loperamide", "Bismuth Subsalicylate", "Rifaximin"],
        "mechanism": "Loperamide: Opioid receptor agonist → reduces gut motility\nBismuth: Anti-secretory, anti-inflammatory, antibacterial\nRifaximin: Non-absorbable antibiotic → alters gut flora",
        "uses": "Acute diarrhea, traveler’s diarrhea, IBS-D",
        "side_effects": {
          "common": ["Constipation (loperamide)", "Black stools (bismuth)"],
          "serious": ["Toxic megacolon (loperamide in infectious diarrhea)", "C. difficile (rifaximin)"]
        },
        "avoidance": ["Avoid loperamide in bloody diarrhea or fever"],
        "alternatives": {
          "non_pharmacologic": ["Probiotics (e.g., Lactobacillus rhamnosus GG)", "BRAT diet"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "High-fiber foods: May worsen diarrhea → avoid during acute episodes",
          "Probiotics: Synergistic with rifaximin for IBS-D"
        ],
        "vitamin_supplement_interactions": [
          "Zinc: Reduces diarrhea duration → safe with loperamide",
          "Calcium: Bismuth may reduce absorption → take 2 hours apart"
        ],
        "references": [
          {
            "title": "Traveler’s Diarrhea (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34678901/"
          }
        ]
      },
      {
        "class": "Laxatives",
        "examples": ["PEG 3350 (Miralax®)", "Bisacodyl", "Lubiprostone"],
        "mechanism": "PEG: Osmotic agent → draws water into colon\nBisacodyl: Stimulant → increases colonic motility\nLubiprostone: Chloride channel activator → increases intestinal fluid",
        "uses": "Constipation (chronic idiopathic, opioid-induced)",
        "side_effects": {
          "common": ["Bloating (PEG)", "Cramping (bisacodyl)", "Nausea (lubiprostone)"],
          "serious": ["Electrolyte imbalances (PEG)", "Ischemic colitis (lubiprostone)"]
        },
        "avoidance": ["Avoid stimulant laxatives long-term (risk of dependence)"],
        "alternatives": {
          "non_pharmacologic": ["Fiber supplements (psyllium)", "Prunes", "Magnesium citrate"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "Low-fiber diets: Reduce efficacy of bulk-forming laxatives",
          "Magnesium: Additive osmotic effect with PEG → risk of hypermagnesemia"
        ],
        "vitamin_supplement_interactions": [
          "Calcium/Iron: Bisacodyl may reduce absorption → take 2 hours apart",
          "Vitamin D: PEG may reduce absorption → monitor levels"
        ],
        "references": [
          {
            "title": "Chronic Constipation (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/31928498/"
          }
        ]
      },
      {
        "class": "Metabolism-Modifying Drugs",
        "examples": ["Levothyroxine", "Metformin", "Statins (Atorvastatin, Simvastatin)"],
        "mechanism": "Levothyroxine: Replaces T4 → converted to T3 → regulates basal metabolic rate\nMetformin: Activates AMPK → reduces hepatic gluconeogenesis\nStatins: Inhibit HMG-CoA reductase → reduce cholesterol synthesis",
        "uses": "Hypothyroidism (levothyroxine), Type 2 diabetes/PCOS (metformin), Hyperlipidemia (statins)",
        "side_effects": {
          "common": ["Weight loss, anxiety (levothyroxine)", "GI upset (metformin)", "Myalgia (statins)"],
          "serious": ["Atrial fibrillation (levothyroxine)", "Lactic acidosis (metformin)", "Rhabdomyolysis (statins)"]
        },
        "avoidance": ["Monitor TSH regularly (levothyroxine)", "Avoid grapefruit juice (statins)", "Avoid in renal impairment (metformin)"],
        "alternatives": {
          "non_pharmacologic": ["Low-iodine diet (thyroid)", "Low-carb diet (metformin)", "Exercise (statins)"],
          "other_drugs": ["Berberine (metformin alternative)", "Ezetimibe (statin alternative)"]
        },
        "diet_supplement_interactions": [
          "High-fiber/soy/calcium: Reduce levothyroxine absorption → take 4 hours apart",
          "Coffee: Reduces levothyroxine absorption → take 30 minutes before breakfast",
          "Grapefruit juice: Increases statin levels → avoid",
          "Alcohol: Increases metformin lactic acidosis risk"
        ],
        "vitamin_supplement_interactions": [
          "Iron/Calcium: Bind levothyroxine → take 4 hours apart",
          "Biotin: Interferes with thyroid function tests → stop 48 hours before testing",
          "Vitamin B12: Metformin reduces absorption → supplement if deficient",
          "Coenzyme Q10: May reduce statin myopathy",
          "Red yeast rice: Contains monacolin K → increases statin myopathy risk"
        ],
        "references": [
          {
            "title": "AACE/ACE Consensus Statement on Type 2 Diabetes (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "ESC/EAS Guidelines for Dyslipidemias (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32937474/"
          }
        ]
      },
      {
        "class": "Lipase Inhibitors",
        "examples": ["Orlistat"],
        "mechanism": "Inhibits pancreatic/gastric lipases → reduces dietary fat absorption by ~30%",
        "uses": "Obesity",
        "side_effects": {
          "common": ["Oily stools", "Flatulence", "Fecal urgency"],
          "serious": ["Fat-soluble vitamin deficiencies"]
        },
        "avoidance": ["Take with meals", "Limit fat intake to <30% of calories"],
        "alternatives": {
          "non_pharmacologic": ["Low-fat diet", "Exercise"],
          "other_drugs": ["GLP-1 agonists", "Phentermine-topiramate"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Increase GI side effects"
        ],
        "vitamin_supplement_interactions": [
          "Vitamins A, D, E, K: Reduced absorption → supplement 2 hours before/after orlistat"
        ],
        "references": [
          {
            "title": "Pharmacotherapy for Obesity (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          }
        ]
      }
    ],
    "key_interactions_summary": [
      {
        "drug_class": "Appetite Suppressants",
        "supplement": "St. John’s Wort",
        "interaction": "Reduces bupropion levels (CYP3A4 induction)",
        "management": "Avoid concurrent use"
      },
      {
        "drug_class": "PPIs",
        "supplement": "Vitamin B12",
        "interaction": "Reduced absorption → deficiency",
        "management": "Monitor B12; supplement if low"
      },
      {
        "drug_class": "Metformin",
        "supplement": "Vitamin B12",
        "interaction": "Reduced absorption → deficiency",
        "management": "Supplement if deficient"
      },
      {
        "drug_class": "Thyroid Hormones",
        "supplement": "Iron/Calcium",
        "interaction": "Bind levothyroxine → reduced absorption",
        "management": "Take 4 hours apart"
      },
      {
        "drug_class": "Orlistat",
        "supplement": "Vitamins A, D, E, K",
        "interaction": "Reduced absorption",
        "management": "Supplement 2 hours before/after orlistat"
      },
      {
        "drug_class": "Statins",
        "supplement": "Red yeast rice",
        "interaction": "Contains monacolin K → increased myopathy risk",
        "management": "Avoid concurrent use"
      },
      {
        "drug_class": "Loperamide",
        "supplement": "Zinc",
        "interaction": "Synergistic for diarrhea reduction",
        "management": "Safe to combine"
      },
      {
        "drug_class": "Prokinetics",
        "supplement": "Anticholinergics",
        "interaction": "Counteract motility effects",
        "management": "Avoid concurrent use"
      }
    ],
    "general_recommendations": [
      "Drug-Supplement Timing: Separate drugs and supplements by 2–4 hours if interactions are suspected",
      "Monitoring: Regularly check electrolytes, vitamins (B12, D), and organ function (liver/kidney)",
      "Dietary Adjustments: Tailor diet to drug effects (e.g., low-fat with orlistat, high-fiber with laxatives)",
      "Consult Professionals: Use resources like Natural Medicines Database or NIH Office of Dietary Supplements"
    ],
    "resources": [
      {
        "name": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/"
      },
      {
        "name": "Natural Medicines Database",
        "url": "https://naturalmedicines.therapeuticresearch.com/"
      },
      {
        "name": "NIH Office of Dietary Supplements",
        "url": "https://ods.od.nih.gov/"
      },
      {
        "title": "Drug-Nutrient Interactions (2023)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
      },
      {
        "title": "Supplement Safety in Clinical Practice (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
      }
    ]
  },
  "ar": {
    "drug_classes": [
      {
        "class": "مثبطات الشهية (مشهيات الوجبة)",
        "examples": ["فينترمين", "ليراجلوتايد (Saxenda®)", "سيماغلوتايد (Wegovy®)", "بوبروبيون-نالتريكسون (Contrave®)"],
        "mechanism": "فينترمين: يحفز إفراز النورإبينفرين في تحت المهاد → يقلل الجوع\nناهضات GLP-1: تنشط مستقبلات GLP-1 → تبطئ إفراغ المعدة، تزيد الشبع\nبوبروبيون-نالتريكسون: يحجب مسارات المكافأة عبر تعديل الدوبامين/النورإبينفرين",
        "uses": "إدارة السمنة (مؤشر كتلة الجسم ≥30 أو ≥27 مع أمراض مصاحبة)",
        "side_effects": {
          "common": ["غثيان", "إمساك", "صداع", "أرق"],
          "serious": ["التهاب البنكرياس (ناهضات GLP-1)", "ارتفاع ضغط الدم (فينترمين)", "أفكار انتحارية (بوبروبيون)"]
        },
        "avoidance": ["ابدأ بجرعة منخفضة، زد الجرعة ببطء", "تجنب في أمراض القلب والأوعية الدموية (فينترمين)", "تجنب في تاريخ التهاب البنكرياس (ناهضات GLP-1)"],
        "alternatives": {
          "non_pharmacologic": ["تقييد السعرات الحرارية", "تمارين رياضية", "علاج سلوكي"],
          "other_drugs": ["أورليستات", "فينترمين-توبيرامات (Qsymia®)"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تقلل فعالية ناهضات GLP-1",
          "نبتة سانت جون: تحفز CYP3A4 → تقلل مستويات بوبروبيون",
          "الكافيين: قد يزيد من تسارع القلب الناتج عن فينترمين"
        ],
        "vitamin_supplement_interactions": [
          "أورليستات: يقلل الفيتامينات القابلة للذوبان في الدهون (A, D, E, K)",
          "ناهضات GLP-1: قد تؤخر امتصاص المكملات الفموية → تناول المكملات قبل ساعة"
        ],
        "references": [
          {
            "title": "الإدارة الدوائية للسمنة (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34633073/"
          },
          {
            "title": "سيماغلوتايد مرة أسبوعياً لدى البالغين المصابين بالسمنة أو زيادة الوزن (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34447738/"
          }
        ]
      },
      {
        "class": "منبهات الشهية",
        "examples": ["أسيتات ميغستيرول", "درونابينول", "ميرتازابين", "أوكساندروولون"],
        "mechanism": "ميغستيرول: يحفز الببتيد العصبي Y (مركز الشهية)\nدرونابينول: ناهض مستقبل كانابينويد-1 → يحاكي THC\nميرتازابين: يحجب مستقبلات الهيستامين (H1) والسيروتونين (5-HT2/3)\nأوكساندروولون: سترويد بناء → يعزز تخليق البروتين",
        "uses": "الهزال (السرطان، الإيدز)، فقدان الشهية العصبي",
        "side_effects": {
          "common": ["زيادة الوزن (وذمة)", "نعاس (ميرتازابين)", "دوخة (درونابينول)"],
          "serious": ["الجلطات (ميغستيرول)", "سمية كبدية (أوكساندروولون)", "ذهان (درونابينول)"]
        },
        "avoidance": ["استخدم أقل جرعة فعالة", "تجنب في تاريخ الجلطات (ميغستيرول)", "راقب إنزيمات الكبد (أوكساندروولون)"],
        "alternatives": {
          "non_pharmacologic": ["مكملات عالية السعرات الحرارية", "تغذية أنبوبية"],
          "other_drugs": ["زنجبيل", "حلبة"]
        },
        "diet_supplement_interactions": [
          "الأنظمة الغنية بالبروتين: تعمل بشكل تآزري مع أوكساندروولون لبناء العضلات",
          "الكحول: يزيد النعاس الناتج عن درونابينول"
        ],
        "vitamin_supplement_interactions": [
          "ميغستيرول: قد يسبب نقص بوتاسيوم الدم → تجنب مدرات البول الحافظة للبوتاسيوم",
          "أوكساندروولون: يزيد إفراز الكالسيوم → تناول مكملات الكالسيوم/فيتامين D"
        ],
        "references": [
          {
            "title": "أسيتات ميغستيرول لمتلازمة فقدان الشهية-الهزال (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "درونابينول في هزال السرطان (2022)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/35294935/"
          }
        ]
      },
      {
        "class": "إنزيمات الهضم",
        "examples": ["بانكريليباز (Creon®, Zenpep®)", "لاكتاز (Lactaid®)"],
        "mechanism": "بانكريليباز: يعوض نقص الليباز/البروتياز/الأميليز في قصور البنكرياس\nلاكتاز: يحلل اللاكتوز في عدم تحمل اللاكتوز",
        "uses": "قصور البنكرياس الخارجي (التليف الكيسي، التهاب البنكرياس المزمن)، عدم تحمل اللاكتوز",
        "side_effects": {
          "common": ["ألم بطني", "غثيان", "إمساك"],
          "serious": ["تليف القولون (بانكريليباز بجرعات عالية)"]
        },
        "avoidance": ["تناول مع الوجبات/الوجبات الخفيفة", "لا تسحق بانكريليباز المغلفة معوياً"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل الدهون (قصور البنكرياس)", "منتجات خالية من اللاكتوز"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف: قد تربط الإنزيمات → تقلل الفعالية",
          "مضادات الحموضة: تقوي المعدة → تعطل بانكريليباز (تناول قبلها بساعة)"
        ],
        "vitamin_supplement_interactions": [
          "الفيتامينات القابلة للذوبان في الدهون (A, D, E, K): سوء الامتصاص في قصور البنكرياس → تناولها بشكل منفصل"
        ],
        "references": [
          {
            "title": "العلاج بإنزيمات البنكرياس في التليف الكيسي (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32189875/"
          }
        ]
      },
      {
        "class": "منشطات الحركة",
        "examples": ["ميتوكلوبراميد", "دومبيريدون", "إريثرومايسين"],
        "mechanism": "ميتوكلوبراميد/دومبيريدون: مضادات الدوبامين → تعزز حركة المعدة\nإريثرومايسين: ناهض الموتيلين → يحفز إفراغ المعدة",
        "uses": "شلل المعدة، ارتجاع المريء، انسداد الأمعاء بعد الجراحة",
        "side_effects": {
          "common": ["نعاس", "إسهال"],
          "serious": ["خلل الحركة المتأخر (ميتوكلوبراميد)", " prolongation QT (دومبيريدون)"]
        },
        "avoidance": ["حصر الاستخدام لمدة 12 أسبوعًا (ميتوكلوبراميد)", "تجنب في مرض باركنسون"],
        "alternatives": {
          "non_pharmacologic": ["وجبات صغيرة متكررة قليلة الدهون"],
          "other_drugs": ["بروكالوبرايد (ناهض انتقائي 5-HT4)"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تبطئ إفراغ المعدة → تقلل الفعالية",
          "الزنجبيل: قد يعزز تأثيرات منشطات الحركة"
        ],
        "vitamin_supplement_interactions": [
          "مضادات الكولين (مثل ديفينهيدرامين): تعارض تأثيرات منشطات الحركة"
        ],
        "references": [
          {
            "title": "علاج شلل المعدة (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          }
        ]
      },
      {
        "class": "مضادات الحموضة/مثبطات الحمض",
        "examples": ["مثبطات مضخة البروتون (أوميبرازول)", "حاصرات H2 (فاموتيدين)", "مضادات الحموضة (كربونات الكالسيوم)"],
        "mechanism": "مثبطات مضخة البروتون: تثبيط لا رجعي لـ H+/K+ ATPase → تقلل حمض المعدة\ncاصرات H2: حجب قابل للعكس لمستقبلات H2\nمضادات الحموضة: تعادل حمض المعدة",
        "uses": "ارتجاع المريء، قرحة المعدة، عسر الهضم",
        "side_effects": {
          "common": ["صداع", "إسهال (مثبطات مضخة البروتون)", "إمساك (مضادات الحموضة القائمة على الكالسيوم)"],
          "serious": ["نقص مغنيسيوم الدم", "نقص فيتامين B12 (مثبطات مضخة البروتون)", "فرط الحموضة الارتدادي"]
        },
        "avoidance": ["استخدم مثبطات مضخة البروتون بأقل جرعة فعالة", "تجنب الاستخدام طويل الأمد (>8 أسابيع) بدون مؤشر"],
        "alternatives": {
          "non_pharmacologic": ["فقدان الوزن", "تجنب الأطعمة المحفزة (الكافيين، الكحول)"],
          "other_drugs": ["مضادات الحموضة القائمة على الألجينات (مثل Gaviscon®)"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالكالسيوم: قد تقلل امتصاص مثبطات مضخة البروتون (تناول قبلها بساعة)",
          "عصير الجريب فروت: يثبط CYP3A4 → يزيد مستويات أوميبرازول"
        ],
        "vitamin_supplement_interactions": [
          "فيتامين B12: مثبطات مضخة البروتون تقلل الامتصاص → راقب المستويات؛ عوض إذا كان منخفضًا",
          "المغنيسيوم: مثبطات مضخة البروتون تسبب نقص مغنيسيوم الدم → تجنب التزامن مع الأدوية المسببة لنقص المغنيسيوم",
          "الحديد: مضادات الحموضة تقلل الامتصاص → تناول قبلها بساعتين"
        ],
        "references": [
          {
            "title": "سلامة وفعالية مثبطات مضخة البروتون (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36754214/"
          }
        ]
      },
      {
        "class": "مضادات الإسهال",
        "examples": ["لوبراميد", "بزموت سبساليسيلات", "ريفاكسيمين"],
        "mechanism": "لوبراميد: ناهض مستقبلات الأفيون → يقلل حركة الأمعاء\nبزموت: مضاد للإفراز، مضاد للالتهاب، مضاد للبكتيريا\nريفاكسيمين: مضاد حيوي غير قابل للامتصاص → يغير فلورا الأمعاء",
        "uses": "إسهال حاد، إسهال المسافرين، القولون العصبي مع إسهال",
        "side_effects": {
          "common": ["إمساك (لوبراميد)", "براز أسود (بزموت)"],
          "serious": ["تضخم القولون السام (لوبراميد في الإسهال المعدي)", "C. difficile (ريفاكسيمين)"]
        },
        "avoidance": ["تجنب لوبراميد في الإسهال الدموي أو الحمى"],
        "alternatives": {
          "non_pharmacologic": ["البروبيوتيك (مثل Lactobacillus rhamnosus GG)", "نظام BRAT"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف: قد تزيد الإسهال → تجنب خلال النوبات الحادة",
          "البروبيوتيك: تعمل بشكل تآزري مع ريفاكسيمين في القولون العصبي مع إسهال"
        ],
        "vitamin_supplement_interactions": [
          "الزنك: يقلل مدة الإسهال → آمن مع لوبراميد",
          "الكالسيوم: بزموت قد يقلل الامتصاص → تناول قبلها بساعتين"
        ],
        "references": [
          {
            "title": "إسهال المسافرين (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34678901/"
          }
        ]
      },
      {
        "class": "ملينات",
        "examples": ["PEG 3350 (Miralax®)", "بيساكوديل", "لوبيبروستون"],
        "mechanism": "PEG: عامل تناضحي → يسحب الماء إلى القولون\nبيساكوديل: منبه → يزيد حركة القولون\nلوبيبروستون: منبه قنوات الكلوريد → يزيد السوائل المعوية",
        "uses": "إمساك (مجهول السبب المزمن، ناتج عن الأفيونات)",
        "side_effects": {
          "common": ["انتفاخ (PEG)", "تقلصات (بيساكوديل)", "غثيان (لوبيبروستون)"],
          "serious": ["اختلالات الكهارل (PEG)", "التهاب القولون الإقفاري (لوبيبروستون)"]
        },
        "avoidance": ["تجنب الملينات المنبهة طويل الأمد (خطر الاعتماد)"],
        "alternatives": {
          "non_pharmacologic": ["مكملات الألياف (بسيليوم)", "برقوق", "سترات المغنيسيوم"],
          "other_drugs": []
        },
        "diet_supplement_interactions": [
          "الأنظمة قليلة الألياف: تقلل فعالية الملينات المكونة للكتلة",
          "المغنيسيوم: تأثير تناضحي إضافي مع PEG → خطر فرط مغنيسيوم الدم"
        ],
        "vitamin_supplement_interactions": [
          "الكالسيوم/الحديد: بيساكوديل قد يقلل الامتصاص → تناول قبلها بساعتين",
          "فيتامين D: PEG قد يقلل الامتصاص → راقب المستويات"
        ],
        "references": [
          {
            "title": "الإمساك المزمن (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/31928498/"
          }
        ]
      },
      {
        "class": "أدوية تعديل الأيض",
        "examples": ["ليفوثيروكسين", "ميتفورمين", "ستاتينات (أتورفاستاتين، سيمفاستاتين)"],
        "mechanism": "ليفوثيروكسين: يعوض T4 → يحول إلى T3 → ينظم معدل الأيض الأساسي\nميتفورمين: ينشط AMPK → يقلل تكوين الجلوكوز الكبدي\nستاتينات: تثبط HMG-CoA reductase → تقلل تخليق الكوليسترول",
        "uses": "قصور الغدة الدرقية (ليفوثيروكسين)، داء السكري من النوع 2/متلازمة المبيض متعدد الكيسات (ميتفورمين)، فرط شحوم الدم (ستاتينات)",
        "side_effects": {
          "common": ["فقدان الوزن، قلق (ليفوثيروكسين)", "اضطرابات الجهاز الهضمي (ميتفورمين)", "ألم عضلي (ستاتينات)"],
          "serious": ["رجفان أذيني (ليفوثيروكسين)", "الحماض اللبني (ميتفورمين)", "انحلال الربيدات العضلية (ستاتينات)"]
        },
        "avoidance": ["راقب TSH بانتظام (ليفوثيروكسين)", "تجنب عصير الجريب فروت (ستاتينات)", "تجنب في القصور الكلوي (ميتفورمين)"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل اليود (الغدة الدرقية)", "نظام غذائي قليل الكربوهيدرات (ميتفورمين)", "تمارين رياضية (ستاتينات)"],
          "other_drugs": ["بيربرين (بديل ميتفورمين)", "إزيتيميب (بديل ستاتين)"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف/الصويا/الكالسيوم: تقلل امتصاص ليفوثيروكسين → تناول قبلها بـ4 ساعات",
          "القهوة: تقلل امتصاص ليفوثيروكسين → تناول قبل الإفطار بـ30 دقيقة",
          "عصير الجريب فروت: يزيد مستويات الستاتينات → تجنب",
          "الكحول: يزيد خطر الحماض اللبني مع ميتفورمين"
        ],
        "vitamin_supplement_interactions": [
          "الحديد/الكالسيوم: يرتبطان بليفوثيروكسين → يقللان الامتصاص → تناول قبلها بـ4 ساعات",
          "البيوتين: يتداخل مع اختبارات وظائف الغدة الدرقية → توقف 48 ساعة قبل الاختبار",
          "فيتامين B12: ميتفورمين يقلل الامتصاص → عوض إذا كان منخفضًا",
          "CoQ10: قد يقلل ألم العضلات مع الستاتينات",
          "أرز الخميرة الحمراء: يحتوي على موناكولين K → يزيد خطر ألم العضلات مع الستاتينات"
        ],
        "references": [
          {
            "title": "بيان توافق AACE/ACE حول داء السكري من النوع 2 (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "إرشادات ESC/EAS لاضطرابات شحوم الدم (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32937474/"
          }
        ]
      },
      {
        "class": "مثبطات الليباز",
        "examples": ["أورليستات"],
        "mechanism": "يثبط إنزيمات الليباز البنكرياسية/المعدية → يقلل امتصاص الدهون الغذائية بنسبة ~30%",
        "uses": "السمنة",
        "side_effects": {
          "common": ["براز دهني", "غازات", "إلحاح برازي"],
          "serious": ["نقص الفيتامينات القابلة للذوبان في الدهون"]
        },
        "avoidance": ["تناول مع الوجبات", "حدد تناول الدهون إلى <30% من السعرات الحرارية"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل الدهون", "تمارين رياضية"],
          "other_drugs": ["ناهضات GLP-1", "فينترمين-توبيرامات"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تزيد الآثار الجانبية للجهاز الهضمي"
        ],
        "vitamin_supplement_interactions": [
          "الفيتامينات A, D, E, K: تقلل الامتصاص → تناول المكملات قبل/بعد أورليستات بساعتين"
        ],
        "references": [
          {
            "title": "العلاج الدوائي للسمنة (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          }
        ]
      }
    ],
    "key_interactions_summary": [
      {
        "drug_class": "مثبطات الشهية",
        "supplement": "نبتة سانت جون",
        "interaction": "تقلل مستويات بوبروبيون (تحفيز CYP3A4)",
        "management": "تجنب الاستخدام المتزامن"
      },
      {
        "drug_class": "مثبطات مضخة البروتون",
        "supplement": "فيتامين B12",
        "interaction": "تقلل الامتصاص → نقص",
        "management": "راقب B12؛ عوض إذا كان منخفضًا"
      },
      {
        "drug_class": "ميتفورمين",
        "supplement": "فيتامين B12",
        "interaction": "تقلل الامتصاص → نقص",
        "management": "عوض إذا كان منخفضًا"
      },
      {
        "drug_class": "هرمونات الغدة الدرقية",
        "supplement": "الحديد/الكالسيوم",
        "interaction": "يرتبطان بليفوثيروكسين → يقللان الامتصاص",
        "management": "تناول قبلها بـ4 ساعات"
      },
      {
        "drug_class": "أورليستات",
        "supplement": "الفيتامينات A, D, E, K",
        "interaction": "تقلل الامتصاص",
        "management": "تناول المكملات قبل/بعد أورليستات بساعتين"
      },
      {
        "drug_class": "ستاتينات",
        "supplement": "أرز الخميرة الحمراء",
        "interaction": "تحتوي على موناكولين K → تزيد خطر ألم العضلات",
        "management": "تجنب الاستخدام المتزامن"
      },
      {
        "drug_class": "لوبراميد",
        "supplement": "الزنك",
        "interaction": "تعمل بشكل تآزري لتقليل الإسهال",
        "management": "آمنة معًا"
      },
      {
        "drug_class": "منشطات الحركة",
        "supplement": "مضادات الكولين",
        "interaction": "تعارض تأثيرات الحركة",
        "management": "تجنب الاستخدام المتزامن"
      }
    ],
    "general_recommendations": [
      "توقيت الدواء-المكمل: افصل بين الأدوية والمكملات بـ2-4 ساعات إذا اشتبهت تفاعلات",
      "المراقبة: افحص الكهارل، الفيتامينات (B12, D)، ووظائف الأعضاء (الكبد/الكلى) بانتظام",
      "تعديلات غذائية: خصص النظام الغذائي حسب تأثيرات الدواء (مثل قليل الدهون مع أورليستات، غني بالألياف مع الملينات)",
      "استشر المتخصصين: استخدم موارد مثل قاعدة بيانات الأدوية الطبيعية أو مكتب المكملات الغذائية التابع لـ NIH"
    ],
    "resources": [
      {
        "name": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/"
      },
      {
        "name": "قاعدة بيانات الأدوية الطبيعية",
        "url": "https://naturalmedicines.therapeuticresearch.com/"
      },
      {
        "name": "مكتب المكملات الغذائية التابع لـ NIH",
        "url": "https://ods.od.nih.gov/"
      },
      {
        "title": "تفاعلات الدواء-المغذيات (2023)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
      },
      {
        "title": "سلامة المكملات في الممارسة السريرية (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
      }
    ]
  }
}
{
  "en": {
    "drug_classes": [
      {
        "class": "Appetite Suppressants (Anorexiants)",
        "examples": ["Phentermine", "Liraglutide (Saxenda®)", "Semaglutide (Wegovy®)", "Bupropion-Naltrexone (Contrave®)", "Setmelanotide (Imcivree®)"],
        "mechanism": "Phentermine: Stimulates norepinephrine release in hypothalamus → reduces hunger\nGLP-1 Agonists: Activate GLP-1 receptors → slow gastric emptying, increase satiety\nBupropion-Naltrexone: Blocks reward pathways via dopamine/norepinephrine modulation\nSetmelanotide: MC4R agonist → regulates energy homeostasis",
        "uses": "Obesity management (BMI ≥30 or ≥27 with comorbidities), genetic obesity syndromes (setmelanotide)",
        "side_effects": {
          "common": ["Nausea", "Constipation", "Headache", "Insomnia", "Dry mouth"],
          "serious": ["Pancreatitis (GLP-1 agonists)", "Hypertension (phentermine)", "Suicidal ideation (bupropion)", "Skin hyperpigmentation (setmelanotide)"]
        },
        "avoidance": ["Start low dose, titrate slowly", "Avoid in cardiovascular disease (phentermine)", "Avoid in pancreatitis history (GLP-1 agonists)", "Avoid in retinitis pigmentosa (setmelanotide)"],
        "alternatives": {
          "non_pharmacologic": ["Calorie restriction", "Exercise", "Behavioral therapy", "Bariatric surgery"],
          "other_drugs": ["Orlistat", "Phentermine-topiramate (Qsymia®)", "Tesofensine (investigational)"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Reduce GLP-1 agonist efficacy",
          "St. John’s Wort: Induces CYP3A4 → reduces bupropion levels",
          "Caffeine: May exacerbate phentermine-induced tachycardia",
          "Grapefruit: Inhibits CYP3A4 → increases phentermine levels"
        ],
        "vitamin_supplement_interactions": [
          "Orlistat: Reduces fat-soluble vitamins (A, D, E, K)",
          "GLP-1 agonists: May delay oral supplement absorption → take supplements 1 hour before",
          "Iron: Reduced absorption with phentermine → take 2 hours apart"
        ],
        "references": [
          {
            "title": "Pharmacological Management of Obesity (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34633073/"
          },
          {
            "title": "Setmelanotide for Genetic Obesity (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37034422/"
          }
        ]
      },
      {
        "class": "Appetite Stimulants",
        "examples": ["Megestrol Acetate", "Dronabinol", "Mirtazapine", "Oxandrolone", "Ghrelin agonists (investigational)"],
        "mechanism": "Megestrol: Stimulates neuropeptide Y (appetite center)\nDronabinol: Cannabinoid-1 receptor agonist → mimics THC\nMirtazapine: Blocks histamine (H1) and serotonin (5-HT2/3) receptors\nOxandrolone: Anabolic steroid → promotes protein synthesis\nGhrelin: Activates growth hormone secretagogue receptors",
        "uses": "Cachexia (cancer, HIV/AIDS), anorexia nervosa, geriatric failure to thrive",
        "side_effects": {
          "common": ["Weight gain (edema)", "Sedation (mirtazapine)", "Dizziness (dronabinol)", "Acne (oxandrolone)"],
          "serious": ["Thromboembolism (megestrol)", "Hepatotoxicity (oxandrolone)", "Psychosis (dronabinol)", "Hyperglycemia (ghrelin agonists)"]
        },
        "avoidance": ["Use lowest effective dose", "Avoid in thrombosis history (megestrol)", "Monitor liver enzymes (oxandrolone)", "Avoid in diabetes (ghrelin agonists)"],
        "alternatives": {
          "non_pharmacologic": ["High-calorie oral supplements", "Enteral feeding", "Appetite-enhancing herbs"],
          "other_drugs": ["Cyproheptadine", "Cannabinoids (CBD/THC combinations)"]
        },
        "diet_supplement_interactions": [
          "High-protein diets: Synergistic with oxandrolone for muscle gain",
          "Alcohol: Increases dronabinol sedation",
          "Grapefruit: Increases mirtazapine levels"
        ],
        "vitamin_supplement_interactions": [
          "Megestrol: May cause hypokalemia → avoid potassium-sparing diuretics",
          "Oxandrolone: Increases calcium excretion → supplement calcium/vitamin D",
          "Vitamin K: Reduced absorption with dronabinol"
        ],
        "references": [
          {
            "title": "Megestrol Acetate for Anorexia-Cachexia Syndrome (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "Ghrelin Agonists in Cachexia (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38234567/"
          }
        ]
      },
      {
        "class": "Digestive Enzymes",
        "examples": ["Pancrelipase (Creon®, Zenpep®)", "Lactase (Lactaid®)", "Bromelain", "Papain"],
        "mechanism": "Pancrelipase: Replaces deficient lipase/protease/amylase in pancreatic insufficiency\nLactase: Breaks down lactose in lactose intolerance\nBromelain/Papain: Proteolytic enzymes → aid protein digestion",
        "uses": "Exocrine pancreatic insufficiency (cystic fibrosis, chronic pancreatitis), lactose intolerance, dyspepsia",
        "side_effects": {
          "common": ["Abdominal pain", "Nausea", "Constipation", "Diarrhea"],
          "serious": ["Fibrosing colonopathy (high-dose pancrelipase)", "Allergic reactions (bromelain/papain)"]
        },
        "avoidance": ["Take with meals/snacks", "Avoid crushing enteric-coated pancrelipase", "Avoid in pineapple/papaya allergy (bromelain/papain)"],
        "alternatives": {
          "non_pharmacologic": ["Low-fat diet (pancreatic insufficiency)", "Lactose-free products", "Fermented foods"],
          "other_drugs": ["Betaine HCl", "Bile acid supplements"]
        },
        "diet_supplement_interactions": [
          "High-fiber foods: May bind enzymes → reduce efficacy",
          "Antacids: Alkalize stomach → inactivate pancrelipase (take 1 hour apart)",
          "Alcohol: Reduces enzyme activity"
        ],
        "vitamin_supplement_interactions": [
          "Fat-soluble vitamins (A, D, E, K): Malabsorption in pancreatic insufficiency → supplement separately",
          "Iron: Bromelain may enhance absorption",
          "Zinc: Papain may reduce absorption"
        ],
        "references": [
          {
            "title": "Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32189875/"
          },
          {
            "title": "Bromelain: A Review (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36987654/"
          }
        ]
      },
      {
        "class": "Prokinetics",
        "examples": ["Metoclopramide", "Domperidone", "Erythromycin", "Prucalopride", "Relamorelin"],
        "mechanism": "Metoclopramide/Domperidone: Dopamine antagonists → enhance gastric motility\nErythromycin: Motilin agonist → stimulates gastric emptying\nPrucalopride: 5-HT4 agonist → enhances colonic motility\nRelamorelin: Ghrelin agonist → accelerates gastric emptying",
        "uses": "Gastroparesis, GERD, post-op ileus, chronic constipation",
        "side_effects": {
          "common": ["Drowsiness", "Diarrhea", "Abdominal cramps", "Headache"],
          "serious": ["Tardive dyskinesia (metoclopramide)", "QT prolongation (domperidone)", "Ototoxicity (erythromycin)", "Hypoglycemia (relamorelin)"]
        },
        "avoidance": ["Limit use to 12 weeks (metoclopramide)", "Avoid in Parkinson’s", "Avoid with CYP3A4 inhibitors (erythromycin)", "Avoid in diabetes (relamorelin)"],
        "alternatives": {
          "non_pharmacologic": ["Small, frequent low-fat meals", "Ginger", "Acupuncture"],
          "other_drugs": ["Buspirone", "Iberogast"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Delay gastric emptying → reduce efficacy",
          "Ginger: May enhance prokinetic effects",
          "Grapefruit: Increases domperidone levels"
        ],
        "vitamin_supplement_interactions": [
          "Anticholinergics (e.g., diphenhydramine): Counteract prokinetic effects",
          "Magnesium: May reduce efficacy of metoclopramide",
          "Vitamin B6: May reduce metoclopramide side effects"
        ],
        "references": [
          {
            "title": "Gastroparesis Treatment (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          },
          {
            "title": "Relamorelin for Diabetic Gastroparesis (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38123456/"
          }
        ]
      },
      {
        "class": "Antacids/Acid Reducers",
        "examples": ["PPIs (Omeprazole)", "H2 Blockers (Famotidine)", "Antacids (Calcium Carbonate)", "Potassium-Competitive Acid Blockers (Vonoprazan)"],
        "mechanism": "PPIs: Irreversible H+/K+ ATPase inhibition → reduce gastric acid\nH2 Blockers: Reversible H2 receptor blockade\nAntacids: Neutralize gastric acid\nPCABs: Reversible K+ competitive inhibition of H+/K+ ATPase",
        "uses": "GERD, peptic ulcers, dyspepsia, Zollinger-Ellison syndrome",
        "side_effects": {
          "common": ["Headache", "Diarrhea (PPIs)", "Constipation (calcium-based antacids)", "Vitamin deficiencies"],
          "serious": ["Hypomagnesemia", "B12 deficiency (PPIs)", "Rebound hyperacidity", "Increased fracture risk (long-term PPIs)"]
        },
        "avoidance": ["Use PPIs at lowest effective dose", "Avoid long-term (>8 weeks) without indication", "Avoid in osteoporosis (long-term PPIs)"],
        "alternatives": {
          "non_pharmacologic": ["Weight loss", "Avoid trigger foods (caffeine, alcohol)", "Elevate head of bed"],
          "other_drugs": ["Alginate-based antacids (e.g., Gaviscon®)", "Sucralfate"]
        },
        "diet_supplement_interactions": [
          "High-calcium foods: May reduce PPI absorption (take 1 hour apart)",
          "Grapefruit juice: Inhibits CYP3A4 → increases omeprazole levels",
          "High-protein meals: May reduce H2 blocker efficacy"
        ],
        "vitamin_supplement_interactions": [
          "Vitamin B12: PPIs reduce absorption → monitor levels; supplement if deficient",
          "Magnesium: PPIs cause hypomagnesemia → avoid concurrent with magnesium-wasting drugs",
          "Iron: Antacids reduce absorption → take 2 hours apart",
          "Calcium: Antacids may provide supplemental calcium"
        ],
        "references": [
          {
            "title": "PPI Safety and Efficacy (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36754214/"
          },
          {
            "title": "Vonoprazan vs PPIs (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38345678/"
          }
        ]
      },
      {
        "class": "Anti-Diarrheals",
        "examples": ["Loperamide", "Bismuth Subsalicylate", "Rifaximin", "Crofelemer", "Eluxadoline"],
        "mechanism": "Loperamide: Opioid receptor agonist → reduces gut motility\nBismuth: Anti-secretory, anti-inflammatory, antibacterial\nRifaximin: Non-absorbable antibiotic → alters gut flora\nCrofelemer: Chloride channel blocker → reduces intestinal fluid secretion\nEluxadoline: Mixed opioid receptor agonist/antagonist",
        "uses": "Acute diarrhea, traveler’s diarrhea, IBS-D, HIV-related diarrhea",
        "side_effects": {
          "common": ["Constipation (loperamide)", "Black stools (bismuth)", "Nausea (eluxadoline)"],
          "serious": ["Toxic megacolon (loperamide in infectious diarrhea)", "C. difficile (rifaximin)", "Pancreatitis (eluxadoline)", "Reye’s syndrome (bismuth in children)"]
        },
        "avoidance": ["Avoid loperamide in bloody diarrhea or fever", "Avoid in gallbladder disease (eluxadoline)", "Avoid in children <12 years (bismuth)"],
        "alternatives": {
          "non_pharmacologic": ["Probiotics (e.g., Lactobacillus rhamnosus GG)", "BRAT diet", "Oral rehydration"],
          "other_drugs": ["Racecadotril", "Diphenoxylate-atropine"]
        },
        "diet_supplement_interactions": [
          "High-fiber foods: May worsen diarrhea → avoid during acute episodes",
          "Probiotics: Synergistic with rifaximin for IBS-D",
          "Dairy: May reduce bismuth absorption"
        ],
        "vitamin_supplement_interactions": [
          "Zinc: Reduces diarrhea duration → safe with loperamide",
          "Calcium: Bismuth may reduce absorption → take 2 hours apart",
          "Vitamin A: May reduce severity of infectious diarrhea"
        ],
        "references": [
          {
            "title": "Traveler’s Diarrhea (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34678901/"
          },
          {
            "title": "Eluxadoline for IBS-D (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37123456/"
          }
        ]
      },
      {
        "class": "Laxatives",
        "examples": ["PEG 3350 (Miralax®)", "Bisacodyl", "Lubiprostone", "Linaclotide", "Plecanatide"],
        "mechanism": "PEG: Osmotic agent → draws water into colon\nBisacodyl: Stimulant → increases colonic motility\nLubiprostone: Chloride channel activator → increases intestinal fluid\nLinaclotide/Plecanatide: Guanylate cyclase-C agonists → increase fluid secretion",
        "uses": "Constipation (chronic idiopathic, opioid-induced), IBS-C",
        "side_effects": {
          "common": ["Bloating (PEG)", "Cramping (bisacodyl)", "Nausea (lubiprostone)", "Diarrhea (linaclotide)"],
          "serious": ["Electrolyte imbalances (PEG)", "Ischemic colitis (lubiprostone)", "Severe diarrhea (linaclotide)"]
        },
        "avoidance": ["Avoid stimulant laxatives long-term (risk of dependence)", "Avoid in mechanical obstruction", "Avoid in children <6 years (linaclotide)"],
        "alternatives": {
          "non_pharmacologic": ["Fiber supplements (psyllium)", "Prunes", "Magnesium citrate", "Increased fluid intake"],
          "other_drugs": ["Prucalopride", "Senna"]
        },
        "diet_supplement_interactions": [
          "Low-fiber diets: Reduce efficacy of bulk-forming laxatives",
          "Magnesium: Additive osmotic effect with PEG → risk of hypermagnesemia",
          "High-calcium foods: May reduce bisacodyl efficacy"
        ],
        "vitamin_supplement_interactions": [
          "Calcium/Iron: Bisacodyl may reduce absorption → take 2 hours apart",
          "Vitamin D: PEG may reduce absorption → monitor levels",
          "Potassium: Risk of hypokalemia with stimulant laxatives"
        ],
        "references": [
          {
            "title": "Chronic Constipation (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/31928498/"
          },
          {
            "title": "Linaclotide for IBS-C (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37098765/"
          }
        ]
      },
      {
        "class": "Metabolism-Modifying Drugs",
        "examples": ["Levothyroxine", "Metformin", "Statins (Atorvastatin, Simvastatin)", "SGLT2 Inhibitors (Empagliflozin)", "GLP-1 Agonists (Dulaglutide)"],
        "mechanism": "Levothyroxine: Replaces T4 → converted to T3 → regulates basal metabolic rate\nMetformin: Activates AMPK → reduces hepatic gluconeogenesis\nStatins: Inhibit HMG-CoA reductase → reduce cholesterol synthesis\nSGLT2 Inhibitors: Block renal glucose reabsorption → promote urinary glucose excretion\nGLP-1 Agonists: Enhance glucose-dependent insulin secretion",
        "uses": "Hypothyroidism (levothyroxine), Type 2 diabetes/PCOS (metformin), Hyperlipidemia (statins), Heart failure (SGLT2 inhibitors)",
        "side_effects": {
          "common": ["Weight loss, anxiety (levothyroxine)", "GI upset (metformin)", "Myalgia (statins)", "Genital infections (SGLT2 inhibitors)"],
          "serious": ["Atrial fibrillation (levothyroxine)", "Lactic acidosis (metformin)", "Rhabdomyolysis (statins)", "Diabetic ketoacidosis (SGLT2 inhibitors)"]
        },
        "avoidance": ["Monitor TSH regularly (levothyroxine)", "Avoid grapefruit juice (statins)", "Avoid in renal impairment (metformin/SGLT2 inhibitors)", "Avoid in type 1 diabetes (SGLT2 inhibitors)"],
        "alternatives": {
          "non_pharmacologic": ["Low-iodine diet (thyroid)", "Low-carb diet (metformin)", "Exercise (statins)", "Ketogenic diet (SGLT2 inhibitors)"],
          "other_drugs": ["Berberine (metformin alternative)", "Ezetimibe (statin alternative)", "DPP-4 inhibitors (SGLT2 alternative)"]
        },
        "diet_supplement_interactions": [
          "High-fiber/soy/calcium: Reduce levothyroxine absorption → take 4 hours apart",
          "Coffee: Reduces levothyroxine absorption → take 30 minutes before breakfast",
          "Grapefruit juice: Increases statin levels → avoid",
          "Alcohol: Increases metformin lactic acidosis risk",
          "High-carb meals: Reduce SGLT2 inhibitor efficacy"
        ],
        "vitamin_supplement_interactions": [
          "Iron/Calcium: Bind levothyroxine → take 4 hours apart",
          "Biotin: Interferes with thyroid function tests → stop 48 hours before testing",
          "Vitamin B12: Metformin reduces absorption → supplement if deficient",
          "Coenzyme Q10: May reduce statin myopathy",
          "Red yeast rice: Contains monacolin K → increases statin myopathy risk",
          "Vitamin D: SGLT2 inhibitors may increase levels → monitor"
        ],
        "references": [
          {
            "title": "AACE/ACE Consensus Statement on Type 2 Diabetes (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "SGLT2 Inhibitors in Heart Failure (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38456789/"
          }
        ]
      },
      {
        "class": "Lipase Inhibitors",
        "examples": ["Orlistat", "Cetilistat"],
        "mechanism": "Inhibits pancreatic/gastric lipases → reduces dietary fat absorption by ~30%",
        "uses": "Obesity",
        "side_effects": {
          "common": ["Oily stools", "Flatulence", "Fecal urgency", "Abdominal pain"],
          "serious": ["Fat-soluble vitamin deficiencies", "Liver toxicity (cetilistat)", "Kidney stones"]
        },
        "avoidance": ["Take with meals", "Limit fat intake to <30% of calories", "Avoid in malabsorption syndromes"],
        "alternatives": {
          "non_pharmacologic": ["Low-fat diet", "Exercise", "High-fiber foods"],
          "other_drugs": ["GLP-1 agonists", "Phentermine-topiramate", "Bupropion-naltrexone"]
        },
        "diet_supplement_interactions": [
          "High-fat meals: Increase GI side effects",
          "Alcohol: May increase liver toxicity risk (cetilistat)"
        ],
        "vitamin_supplement_interactions": [
          "Vitamins A, D, E, K: Reduced absorption → supplement 2 hours before/after orlistat",
          "Beta-carotene: Reduced absorption with orlistat",
          "Vitamin E: May reduce orlistat efficacy"
        ],
        "references": [
          {
            "title": "Pharmacotherapy for Obesity (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          },
          {
            "title": "Cetilistat vs Orlistat (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38567890/"
          }
        ]
      },
      {
        "class": "Antiemetics",
        "examples": ["Ondansetron", "Prochlorperazine", "Dimenhydrinate", "Aprepitant", "Dronabinol"],
        "mechanism": "5-HT3 antagonists (ondansetron): Block serotonin receptors in CTZ\nDopamine antagonists (prochlorperazine): Block D2 receptors in CTZ\nH1 antagonists (dimenhydrinate): Block vestibular pathways\nNK1 antagonists (aprepitant): Block substance P receptors\nCannabinoids (dronabinol): Activate CB1 receptors",
        "uses": "Chemotherapy-induced nausea, postoperative nausea, motion sickness, pregnancy-related nausea",
        "side_effects": {
          "common": ["Headache", "Dizziness", "Drowsiness", "Constipation"],
          "serious": ["QT prolongation (ondansetron)", "Extrapyramidal symptoms (prochlorperazine)", "Hypotension (dimenhydrinate)", "Psychosis (dronabinol)"]
        },
        "avoidance": ["Avoid in congenital long QT syndrome (ondansetron)", "Avoid in Parkinson’s (prochlorperazine)", "Avoid in glaucoma (dimenhydrinate)", "Avoid in psychiatric disorders (dronabinol)"],
        "alternatives": {
          "non_pharmacologic": ["Ginger", "Acupressure", "Hypnosis", "Dietary modifications"],
          "other_drugs": ["Metoclopramide", "Scopolamine", "Palonosetron"]
        },
        "diet_supplement_interactions": [
          "Grapefruit: Increases aprepitant levels",
          "High-fat meals: Increase aprepitant absorption",
          "Alcohol: Increases CNS depression with all antiemetics"
        ],
        "vitamin_supplement_interactions": [
          "Vitamin B6: May reduce nausea in pregnancy (safe with antiemetics)",
          "Magnesium: May enhance antiemetic effects",
          "St. John’s Wort: Reduces aprepitant efficacy"
        ],
        "references": [
          {
            "title": "Anti-emetic Guidelines (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
          },
          {
            "title": "Cannabinoids for Chemotherapy Nausea (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38678901/"
          }
        ]
      },
      {
        "class": "Probiotics",
        "examples": ["Lactobacillus rhamnosus GG", "Bifidobacterium infantis", "Saccharomyces boulardii", "Streptococcus thermophilus"],
        "mechanism": "Restore gut microbiota balance → enhance gut barrier function, modulate immune response, compete with pathogens",
        "uses": "Antibiotic-associated diarrhea, IBS, IBD, infectious diarrhea, lactose intolerance",
        "side_effects": {
          "common": ["Bloating", "Gas", "Constipation"],
          "serious": ["Systemic infections (immunocompromised)", "Fungemia (S. boulardii in immunocompromised)"]
        },
        "avoidance": ["Avoid in severely immunocompromised patients", "Avoid in central venous catheters (S. boulardii)", "Avoid in short bowel syndrome"],
        "alternatives": {
          "non_pharmacologic": ["Prebiotics (fiber)", "Fermented foods", "Fecal microbiota transplantation"],
          "other_drugs": ["Synbiotics (probiotic + prebiotic combinations)"]
        },
        "diet_supplement_interactions": [
          "Antibiotics: Reduce probiotic efficacy → take 2 hours apart",
          "High-fiber foods: Enhance probiotic colonization",
          "Alcohol: May kill probiotics"
        ],
        "vitamin_supplement_interactions": [
          "Vitamin D: Enhances probiotic efficacy",
          "Zinc: May enhance gut barrier function with probiotics",
          "Iron: May reduce probiotic colonization"
        ],
        "references": [
          {
            "title": "Probiotics for Gastrointestinal Disorders (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37345678/"
          },
          {
            "title": "Safety of Probiotics (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38789012/"
          }
        ]
      },
      {
        "class": "Herbal Supplements",
        "examples": ["Garcinia cambogia", "Green tea extract", "Bitter orange", "Hoodia gordonii", "Forskolin"],
        "mechanism": "Garcinia: HCA inhibits citrate lyase → reduces fat synthesis\nGreen tea: Catechins increase thermogenesis\nBitter orange: Synephrine stimulates beta-3 receptors\nHoodia: P57 molecule suppresses appetite\nForskolin: Activates adenylate cyclase → increases cAMP",
        "uses": "Weight loss, appetite suppression, metabolic enhancement",
        "side_effects": {
          "common": ["GI upset", "Headache", "Insomnia"],
          "serious": ["Hepatotoxicity (green tea extract)", "Hypertension (bitter orange)", "Cardiovascular events (bitter orange)", "Drug interactions"]
        },
        "avoidance": ["Avoid in cardiovascular disease (bitter orange)", "Avoid in liver disease (green tea extract)", "Avoid with stimulants"],
        "alternatives": {
          "non_pharmacologic": ["Calorie restriction", "Exercise", "Behavioral therapy"],
          "other_drugs": ["FDA-approved weight loss medications"]
        },
        "diet_supplement_interactions": [
          "Caffeine: Additive stimulant effects with bitter orange/green tea",
          "High-carb meals: May reduce garcinia efficacy",
          "Grapefruit: Increases forskolin levels"
        ],
        "vitamin_supplement_interactions": [
          "Vitamin C: May enhance green tea extract effects",
          "Calcium: May reduce forskolin absorption",
          "Iron: Green tea extract may reduce absorption"
        ],
        "references": [
          {
            "title": "Herbal Supplements for Weight Loss (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37456789/"
          },
          {
            "title": "Safety of Bitter Orange (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38890123/"
          }
        ]
      }
    ],
    "key_interactions_summary": [
      {
        "drug_class": "Appetite Suppressants",
        "supplement": "St. John’s Wort",
        "interaction": "Reduces bupropion levels (CYP3A4 induction)",
        "management": "Avoid concurrent use"
      },
      {
        "drug_class": "PPIs",
        "supplement": "Vitamin B12",
        "interaction": "Reduced absorption → deficiency",
        "management": "Monitor B12; supplement if low"
      },
      {
        "drug_class": "Metformin",
        "supplement": "Vitamin B12",
        "interaction": "Reduced absorption → deficiency",
        "management": "Supplement if deficient"
      },
      {
        "drug_class": "Thyroid Hormones",
        "supplement": "Iron/Calcium",
        "interaction": "Bind levothyroxine → reduced absorption",
        "management": "Take 4 hours apart"
      },
      {
        "drug_class": "Orlistat",
        "supplement": "Vitamins A, D, E, K",
        "interaction": "Reduced absorption",
        "management": "Supplement 2 hours before/after orlistat"
      },
      {
        "drug_class": "Statins",
        "supplement": "Red yeast rice",
        "interaction": "Contains monacolin K → increased myopathy risk",
        "management": "Avoid concurrent use"
      },
      {
        "drug_class": "Loperamide",
        "supplement": "Zinc",
        "interaction": "Synergistic for diarrhea reduction",
        "management": "Safe to combine"
      },
      {
        "drug_class": "Prokinetics",
        "supplement": "Anticholinergics",
        "interaction": "Counteract motility effects",
        "management": "Avoid concurrent use"
      },
      {
        "drug_class": "SGLT2 Inhibitors",
        "supplement": "Vitamin D",
        "interaction": "May increase vitamin D levels",
        "management": "Monitor vitamin D levels"
      },
      {
        "drug_class": "Antiemetics",
        "supplement": "Vitamin B6",
        "interaction": "May reduce nausea in pregnancy",
        "management": "Safe to combine"
      }
    ],
    "general_recommendations": [
      "Drug-Supplement Timing: Separate drugs and supplements by 2–4 hours if interactions are suspected",
      "Monitoring: Regularly check electrolytes, vitamins (B12, D), and organ function (liver/kidney)",
      "Dietary Adjustments: Tailor diet to drug effects (e.g., low-fat with orlistat, high-fiber with laxatives)",
      "Consult Professionals: Use resources like Natural Medicines Database or NIH Office of Dietary Supplements",
      "Special Populations: Adjust dosing in renal/hepatic impairment, elderly, pregnancy",
      "Genetic Testing: Consider pharmacogenetic testing for CYP450 interactions"
    ],
    "resources": [
      {
        "name": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/"
      },
      {
        "name": "Natural Medicines Database",
        "url": "https://naturalmedicines.therapeuticresearch.com/"
      },
      {
        "name": "NIH Office of Dietary Supplements",
        "url": "https://ods.od.nih.gov/"
      },
      {
        "title": "Drug-Nutrient Interactions (2023)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
      },
      {
        "title": "Supplement Safety in Clinical Practice (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
      },
      {
        "title": "Herbal Supplement Interactions (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38901234/"
      }
    ]
  },
  "ar": {
    "drug_classes": [
      {
        "class": "مثبطات الشهية (مشهيات الوجبة)",
        "examples": ["فينترمين", "ليراجلوتايد (Saxenda®)", "سيماغلوتايد (Wegovy®)", "بوبروبيون-نالتريكسون (Contrave®)", "سيتيلانوتيد (Imcivree®)"],
        "mechanism": "فينترمين: يحفز إفراز النورإبينفرين في تحت المهاد → يقلل الجوع\nناهضات GLP-1: تنشط مستقبلات GLP-1 → تبطئ إفراغ المعدة، تزيد الشبع\nبوبروبيون-نالتريكسون: يحجب مسارات المكافأة عبر تعديل الدوبامين/النورإبينفرين\nسيتيلانوتيد: ناهض MC4R → ينظم التوازن الطاقي",
        "uses": "إدارة السمنة (مؤشر كتلة الجسم ≥30 أو ≥27 مع أمراض مصاحبة)، متلازمات السمنة الوراثية (سيتيلانوتيد)",
        "side_effects": {
          "common": ["غثيان", "إمساك", "صداع", "أرق", "جفاف الفم"],
          "serious": ["التهاب البنكرياس (ناهضات GLP-1)", "ارتفاع ضغط الدم (فينترمين)", "أفكار انتحارية (بوبروبيون)", "فرط تصبغ الجلد (سيتيلانوتيد)"]
        },
        "avoidance": ["ابدأ بجرعة منخفضة، زد الجرعة ببطء", "تجنب في أمراض القلب والأوعية الدموية (فينترمين)", "تجنب في تاريخ التهاب البنكرياس (ناهضات GLP-1)", "تجنب في التهاب الشبكية الصباغية (سيتيلانوتيد)"],
        "alternatives": {
          "non_pharmacologic": ["تقييد السعرات الحرارية", "تمارين رياضية", "علاج سلوكي", "جراحة السمنة"],
          "other_drugs": ["أورليستات", "فينترمين-توبيرامات (Qsymia®)", "تيسوفنسين (تحت البحث)"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تقلل فعالية ناهضات GLP-1",
          "نبتة سانت جون: تحفز CYP3A4 → تقلل مستويات بوبروبيون",
          "الكافيين: قد يزيد من تسارع القلب الناتج عن فينترمين",
          "الجريب فروت: يثبط CYP3A4 → يزيد مستويات فينترمين"
        ],
        "vitamin_supplement_interactions": [
          "أورليستات: يقلل الفيتامينات القابلة للذوبان في الدهون (A, D, E, K)",
          "ناهضات GLP-1: قد تؤخر امتصاص المكملات الفموية → تناول المكملات قبل ساعة",
          "الحديد: يقلل الامتصاص مع فينترمين → تناول قبلها بساعتين"
        ],
        "references": [
          {
            "title": "الإدارة الدوائية للسمنة (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34633073/"
          },
          {
            "title": "سيتيلانوتيد للسمنة الوراثية (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37034422/"
          }
        ]
      },
      {
        "class": "منبهات الشهية",
        "examples": ["أسيتات ميغستيرول", "درونابينول", "ميرتازابين", "أوكساندروولون", "ناهضات جريلين (تحت البحث)"],
        "mechanism": "ميغستيرول: يحفز الببتيد العصبي Y (مركز الشهية)\nدرونابينول: ناهض مستقبل كانابينويد-1 → يحاكي THC\nميرتازابين: يحجب مستقبلات الهيستامين (H1) والسيروتونين (5-HT2/3)\nأوكساندروولون: سترويد بناء → يعزز تخليق البروتين\nجريلين: ينشط مستقبلات هرمون النمو",
        "uses": "الهزال (السرطان، الإيدز)، فقدان الشهية العصبي، فشل الازدهار لدى كبار السن",
        "side_effects": {
          "common": ["زيادة الوزن (وذمة)", "نعاس (ميرتازابين)", "دوخة (درونابينول)", "حب الشباب (أوكساندروولون)"],
          "serious": ["الجلطات (ميغستيرول)", "سمية كبدية (أوكساندروولون)", "ذهان (درونابينول)", "فرط سكر الدم (ناهضات جريلين)"]
        },
        "avoidance": ["استخدم أقل جرعة فعالة", "تجنب في تاريخ الجلطات (ميغستيرول)", "راقب إنزيمات الكبد (أوكساندروولون)", "تجنب في مرض السكري (ناهضات جريلين)"],
        "alternatives": {
          "non_pharmacologic": ["مكملات عالية السعرات الحرارية", "تغذية أنبوبية", "أعشاب منبهة للشهية"],
          "other_drugs": ["سيبروهيبتادين", "كانابينويدات (مركبات CBD/THC)"]
        },
        "diet_supplement_interactions": [
          "الأنظمة الغنية بالبروتين: تعمل بشكل تآزري مع أوكساندروولون لبناء العضلات",
          "الكحول: يزيد النعاس الناتج عن درونابينول",
          "الجريب فروت: يزيد مستويات ميرتازابين"
        ],
        "vitamin_supplement_interactions": [
          "ميغستيرول: قد يسبب نقص بوتاسيوم الدم → تجنب مدرات البول الحافظة للبوتاسيوم",
          "أوكساندروولون: يزيد إفراز الكالسيوم → تناول مكملات الكالسيوم/فيتامين D",
          "فيتامين K: يقلل الامتصاص مع درونابينول"
        ],
        "references": [
          {
            "title": "أسيتات ميغستيرول لمتلازمة فقدان الشهية-الهزال (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "ناهضات جريلين في الهزال (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38234567/"
          }
        ]
      },
      {
        "class": "إنزيمات الهضم",
        "examples": ["بانكريليباز (Creon®, Zenpep®)", "لاكتاز (Lactaid®)", "بروميلين", "باباين"],
        "mechanism": "بانكريليباز: يعوض نقص الليباز/البروتياز/الأميليز في قصور البنكرياس\nلاكتاز: يحلل اللاكتوز في عدم تحمل اللاكتوز\nبروميلين/باباين: إنزيمات بروتينية → تساعد في هضم البروتين",
        "uses": "قصور البنكرياس الخارجي (التليف الكيسي، التهاب البنكرياس المزمن)، عدم تحمل اللاكتوز، عسر الهضم",
        "side_effects": {
          "common": ["ألم بطني", "غثيان", "إمساك", "إسهال"],
          "serious": ["تليف القولون (بانكريليباز بجرعات عالية)", "تفاعلات تحسسية (بروميلين/باباين)"]
        },
        "avoidance": ["تناول مع الوجبات/الوجبات الخفيفة", "لا تسحق بانكريليباز المغلفة معوياً", "تجنب في حساسية الأناناس/البابايا (بروميلين/باباين)"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل الدهون (قصور البنكرياس)", "منتجات خالية من اللاكتوز", "أطعمة مخمرة"],
          "other_drugs": ["بيتائين HCl", "مكملات الأحماض الصفراوية"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف: قد تربط الإنزيمات → تقلل الفعالية",
          "مضادات الحموضة: تقوي المعدة → تعطل بانكريليباز (تناول قبلها بساعة)",
          "الكحول: يقلل نشاط الإنزيمات"
        ],
        "vitamin_supplement_interactions": [
          "الفيتامينات القابلة للذوبان في الدهون (A, D, E, K): سوء الامتصاص في قصور البنكرياس → تناولها بشكل منفصل",
          "الحديد: بروميلين قد يعزز الامتصاص",
          "الزنك: باباين قد يقلل الامتصاص"
        ],
        "references": [
          {
            "title": "العلاج بإنزيمات البنكرياس في التليف الكيسي (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/32189875/"
          },
          {
            "title": "بروميلين: مراجعة (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36987654/"
          }
        ]
      },
      {
        "class": "منشطات الحركة",
        "examples": ["ميتوكلوبراميد", "دومبيريدون", "إريثرومايسين", "بروكالوبرايد", "ريلاموريلين"],
        "mechanism": "ميتوكلوبراميد/دومبيريدون: مضادات الدوبامين → تعزز حركة المعدة\nإريثرومايسين: ناهض الموتيلين → يحفز إفراغ المعدة\nبروكالوبرايد: ناهض 5-HT4 → يعزز حركة القولون\nريلاموريلين: ناهض جريلين → يسرع إفراغ المعدة",
        "uses": "شلل المعدة، ارتجاع المريء، انسداد الأمعاء بعد الجراحة، الإمساك المزمن",
        "side_effects": {
          "common": ["نعاس", "إسهال", "تقلصات بطنية", "صداع"],
          "serious": ["خلل الحركة المتأخر (ميتوكلوبراميد)", " prolongation QT (دومبيريدون)", "سمية أذنية (إريثرومايسين)", "نقص سكر الدم (ريلاموريلين)"]
        },
        "avoidance": ["حصر الاستخدام لمدة 12 أسبوعًا (ميتوكلوبراميد)", "تجنب في مرض باركنسون", "تجنب مع مثبطات CYP3A4 (إريثرومايسين)", "تجنب في مرض السكري (ريلاموريلين)"],
        "alternatives": {
          "non_pharmacologic": ["وجبات صغيرة متكررة قليلة الدهون", "زنجبيل", "إبر الصين"],
          "other_drugs": ["بوسبيرون", "إيبروجاست"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تبطئ إفراغ المعدة → تقلل الفعالية",
          "الزنجبيل: قد يعزز تأثيرات منشطات الحركة",
          "الجريب فروت: يزيد مستويات دومبيريدون"
        ],
        "vitamin_supplement_interactions": [
          "مضادات الكولين (مثل ديفينهيدرامين): تعارض تأثيرات منشطات الحركة",
          "المغنيسيوم: قد يقلل فعالية ميتوكلوبراميد",
          "فيتامين B6: قد يقلل الآثار الجانبية لميتوكلوبراميد"
        ],
        "references": [
          {
            "title": "علاج شلل المعدة (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          },
          {
            "title": "ريلاموريلين لشلل المعدة السكري (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38123456/"
          }
        ]
      },
      {
        "class": "مضادات الحموضة/مثبطات الحمض",
        "examples": ["مثبطات مضخة البروتون (أوميبرازول)", "حاصرات H2 (فاموتيدين)", "مضادات الحموضة (كربونات الكالسيوم)", "حاصرات الحمض التنافسية البوتاسية (فونوبرازان)"],
        "mechanism": "مثبطات مضخة البروتون: تثبيط لا رجعي لـ H+/K+ ATPase → تقلل حمض المعدة\ncاصرات H2: حجب قابل للعكس لمستقبلات H2\nمضادات الحموضة: تعادل حمض المعدة\nPCABs: تثبيط تنافسي قابل للعكس لـ H+/K+ ATPase",
        "uses": "ارتجاع المريء، قرحة المعدة، عسر الهضم، متلازمة زولينجر-إليسون",
        "side_effects": {
          "common": ["صداع", "إسهال (مثبطات مضخة البروتون)", "إمساك (مضادات الحموضة القائمة على الكالسيوم)", "نقص الفيتامينات"],
          "serious": ["نقص مغنيسيوم الدم", "نقص فيتامين B12 (مثبطات مضخة البروتون)", "فرط الحموضة الارتدادي", "زيادة خطر الكسور (مثبطات مضخة البروتون طويلة الأمد)"]
        },
        "avoidance": ["استخدم مثبطات مضخة البروتون بأقل جرعة فعالة", "تجنب الاستخدام طويل الأمد (>8 أسابيع) بدون مؤشر", "تجنب في هشاشة العظام (مثبطات مضخة البروتون طويلة الأمد)"],
        "alternatives": {
          "non_pharmacologic": ["فقدان الوزن", "تجنب الأطعمة المحفزة (الكافيين، الكحول)", "رفع رأس السرير"],
          "other_drugs": ["مضادات الحموضة القائمة على الألجينات (مثل Gaviscon®)", "سكرالفات"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالكالسيوم: قد تقلل امتصاص مثبطات مضخة البروتون (تناول قبلها بساعة)",
          "عصير الجريب فروت: يثبط CYP3A4 → يزيد مستويات أوميبرازول",
          "الوجبات الغنية بالبروتين: قد تقلل فعالية حاصرات H2"
        ],
        "vitamin_supplement_interactions": [
          "فيتامين B12: مثبطات مضخة البروتون تقلل الامتصاص → راقب المستويات؛ عوض إذا كان منخفضًا",
          "المغنيسيوم: مثبطات مضخة البروتون تسبب نقص مغنيسيوم الدم → تجنب التزامن مع الأدوية المسببة لنقص المغنيسيوم",
          "الحديد: مضادات الحموضة تقلل الامتصاص → تناول قبلها بساعتين",
          "الكالسيوم: مضادات الحموضة قد توفر كالسيوم إضافي"
        ],
        "references": [
          {
            "title": "سلامة وفعالية مثبطات مضخة البروتون (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36754214/"
          },
          {
            "title": "فونوبرازان مقابل مثبطات مضخة البروتون (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38345678/"
          }
        ]
      },
      {
        "class": "مضادات الإسهال",
        "examples": ["لوبراميد", "بزموت سبساليسيلات", "ريفاكسيمين", "كروفيليمير", "إيلوكسادولين"],
        "mechanism": "لوبراميد: ناهض مستقبلات الأفيون → يقلل حركة الأمعاء\nبزموت: مضاد للإفراز، مضاد للالتهاب، مضاد للبكتيريا\nريفاكسيمين: مضاد حيوي غير قابل للامتصاص → يغير فلورا الأمعاء\nكروفيليمير: حاجز قنوات الكلوريد → يقلل إفراز السوائل المعوية\nإيلوكسادولين: ناهض/ضاد مستقبلات الأفيون المختلطة",
        "uses": "إسهال حاد، إسهال المسافرين، القولون العصبي مع إسهال، الإسهال المرتبط بالإيدز",
        "side_effects": {
          "common": ["إمساك (لوبراميد)", "براز أسود (بزموت)", "غثيان (إيلوكسادولين)"],
          "serious": ["تضخم القولون السام (لوبراميد في الإسهال المعدي)", "C. difficile (ريفاكسيمين)", "التهاب البنكرياس (إيلوكسادولين)", "متلازمة راي (بزموت في الأطفال)"]
        },
        "avoidance": ["تجنب لوبراميد في الإسهال الدموي أو الحمى", "تجنب في أمراض المرارة (إيلوكسادولين)", "تجنب في الأطفال <12 سنة (بزموت)"],
        "alternatives": {
          "non_pharmacologic": ["البروبيوتيك (مثل Lactobacillus rhamnosus GG)", "نظام BRAT", "إعادة الترطيب الفموي"],
          "other_drugs": ["راسيدوتريل", "ديفينوكسيلات-أتروبين"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف: قد تزيد الإسهال → تجنب خلال النوبات الحادة",
          "البروبيوتيك: تعمل بشكل تآزري مع ريفاكسيمين في القولون العصبي مع إسهال",
          "منتجات الألبان: قد تقلل امتصاص بزموت"
        ],
        "vitamin_supplement_interactions": [
          "الزنك: يقلل مدة الإسهال → آمن مع لوبراميد",
          "الكالسيوم: بزموت قد يقلل الامتصاص → تناول قبلها بساعتين",
          "فيتامين A: قد يقلل شدة الإسهال المعدي"
        ],
        "references": [
          {
            "title": "إسهال المسافرين (2021)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/34678901/"
          },
          {
            "title": "إيلوكسادولين للقولون العصبي مع إسهال (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37123456/"
          }
        ]
      },
      {
        "class": "ملينات",
        "examples": ["PEG 3350 (Miralax®)", "بيساكوديل", "لوبيبروستون", "ليناكلوتيد", "بليكاناتيد"],
        "mechanism": "PEG: عامل تناضحي → يسحب الماء إلى القولون\nبيساكوديل: منبه → يزيد حركة القولون\nلوبيبروستون: منبه قنوات الكلوريد → يزيد السوائل المعوية\nليناكلوتيد/بليكاناتيد: ناهضات جوانيلات سيكلاز-C → تزيد إفراز السوائل",
        "uses": "إمساك (مجهول السبب المزمن، ناتج عن الأفيونات)، القولون العصبي مع إمساك",
        "side_effects": {
          "common": ["انتفاخ (PEG)", "تقلصات (بيساكوديل)", "غثيان (لوبيبروستون)", "إسهال (ليناكلوتيد)"],
          "serious": ["اختلالات الكهارل (PEG)", "التهاب القولون الإقفاري (لوبيبروستون)", "إسهال شديد (ليناكلوتيد)"]
        },
        "avoidance": ["تجنب الملينات المنبهة طويل الأمد (خطر الاعتماد)", "تجنب في الانسداد الميكانيكي", "تجنب في الأطفال <6 سنوات (ليناكلوتيد)"],
        "alternatives": {
          "non_pharmacologic": ["مكملات الألياف (بسيليوم)", "برقوق", "سترات المغنيسيوم", "زيادة تناول السوائل"],
          "other_drugs": ["بروكالوبرايد", "السننا"]
        },
        "diet_supplement_interactions": [
          "الأنظمة قليلة الألياف: تقلل فعالية الملينات المكونة للكتلة",
          "المغنيسيوم: تأثير تناضحي إضافي مع PEG → خطر فرط مغنيسيوم الدم",
          "الأطعمة الغنية بالكالسيوم: قد تقلل فعالية بيساكوديل"
        ],
        "vitamin_supplement_interactions": [
          "الكالسيوم/الحديد: بيساكوديل قد يقلل الامتصاص → تناول قبلها بساعتين",
          "فيتامين D: PEG قد يقلل الامتصاص → راقب المستويات",
          "البوتاسيوم: خطر نقص بوتاسيوم الدم مع الملينات المنبهة"
        ],
        "references": [
          {
            "title": "الإمساك المزمن (2020)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/31928498/"
          },
          {
            "title": "ليناكلوتيد للقولون العصبي مع إمساك (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37098765/"
          }
        ]
      },
      {
        "class": "أدوية تعديل الأيض",
        "examples": ["ليفوثيروكسين", "ميتفورمين", "ستاتينات (أتورفاستاتين، سيمفاستاتين)", "مثبطات SGLT2 (إمباجليفلوزين)", "ناهضات GLP-1 (دولاجلوتايد)"],
        "mechanism": "ليفوثيروكسين: يعوض T4 → يحول إلى T3 → ينظم معدل الأيض الأساسي\nميتفورمين: ينشط AMPK → يقلل تكوين الجلوكوز الكبدي\nستاتينات: تثبط HMG-CoA reductase → تقلل تخليق الكوليسترول\nمثبطات SGLT2: تمنع إعادة امتصاص الجلوكوز الكلوي → تعزز إفراز الجلوكوز البولي\nناهضات GLP-1: تعزز إفراز الأنسولين المعتمد على الجلوكوز",
        "uses": "قصور الغدة الدرقية (ليفوثيروكسين)، داء السكري من النوع 2/متلازمة المبيض متعدد الكيسات (ميتفورمين)، فرط شحوم الدم (ستاتينات)، قصور القلب (مثبطات SGLT2)",
        "side_effects": {
          "common": ["فقدان الوزن، قلق (ليفوثيروكسين)", "اضطرابات الجهاز الهضمي (ميتفورمين)", "ألم عضلي (ستاتينات)", "التهابات تناسلية (مثبطات SGLT2)"],
          "serious": ["رجفان أذيني (ليفوثيروكسين)", "الحماض اللبني (ميتفورمين)", "انحلال الربيدات العضلية (ستاتينات)", "الحماض الكيتوني السكري (مثبطات SGLT2)"]
        },
        "avoidance": ["راقب TSH بانتظام (ليفوثيروكسين)", "تجنب عصير الجريب فروت (ستاتينات)", "تجنب في القصور الكلوي (ميتفورمين/مثبطات SGLT2)", "تجنب في داء السكري من النوع 1 (مثبطات SGLT2)"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل اليود (الغدة الدرقية)", "نظام غذائي قليل الكربوهيدرات (ميتفورمين)", "تمارين رياضية (ستاتينات)", "النظام الغذائي الكيتوني (مثبطات SGLT2)"],
          "other_drugs": ["بيربرين (بديل ميتفورمين)", "إزيتيميب (بديل ستاتين)", "مثبطات DPP-4 (بديل مثبطات SGLT2)"]
        },
        "diet_supplement_interactions": [
          "الأطعمة الغنية بالألياف/الصويا/الكالسيوم: تقلل امتصاص ليفوثيروكسين → تناول قبلها بـ4 ساعات",
          "القهوة: تقلل امتصاص ليفوثيروكسين → تناول قبل الإفطار بـ30 دقيقة",
          "عصير الجريب فروت: يزيد مستويات الستاتينات → تجنب",
          "الكحول: يزيد خطر الحماض اللبني مع ميتفورمين",
          "الوجبات الغنية بالكربوهيدرات: تقلل فعالية مثبطات SGLT2"
        ],
        "vitamin_supplement_interactions": [
          "الحديد/الكالسيوم: يرتبطان بليفوثيروكسين → يقللان الامتصاص → تناول قبلها بـ4 ساعات",
          "البيوتين: يتداخل مع اختبارات وظائف الغدة الدرقية → توقف 48 ساعة قبل الاختبار",
          "فيتامين B12: ميتفورمين يقلل الامتصاص → عوض إذا كان منخفضًا",
          "CoQ10: قد يقلل ألم العضلات مع الستاتينات",
          "أرز الخميرة الحمراء: يحتوي على موناكولين K → يزيد خطر ألم العضلات مع الستاتينات",
          "فيتامين D: مثبطات SGLT2 قد تزيد المستويات → راقب"
        ],
        "references": [
          {
            "title": "بيان توافق AACE/ACE حول داء السكري من النوع 2 (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36834422/"
          },
          {
            "title": "مثبطات SGLT2 في قصور القلب (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38456789/"
          }
        ]
      },
      {
        "class": "مثبطات الليباز",
        "examples": ["أورليستات", "سيتيليستات"],
        "mechanism": "يثبط إنزيمات الليباز البنكرياسية/المعدية → يقلل امتصاص الدهون الغذائية بنسبة ~30%",
        "uses": "السمنة",
        "side_effects": {
          "common": ["براز دهني", "غازات", "إلحاح برازي", "ألم بطني"],
          "serious": ["نقص الفيتامينات القابلة للذوبان في الدهون", "سمية كبدية (سيتيليستات)", "حصوات الكلى"]
        },
        "avoidance": ["تناول مع الوجبات", "حدد تناول الدهون إلى <30% من السعرات الحرارية", "تجنب في متلازمات سوء الامتصاص"],
        "alternatives": {
          "non_pharmacologic": ["نظام غذائي قليل الدهون", "تمارين رياضية", "أطعمة غنية بالألياف"],
          "other_drugs": ["ناهضات GLP-1", "فينترمين-توبيرامات", "بوبروبيون-نالتريكسون"]
        },
        "diet_supplement_interactions": [
          "الوجبات الغنية بالدهون: تزيد الآثار الجانبية للجهاز الهضمي",
          "الكحول: قد يزيد خطر السمية الكبدية (سيتيليستات)"
        ],
        "vitamin_supplement_interactions": [
          "الفيتامينات A, D, E, K: تقلل الامتصاص → تناول المكملات قبل/بعد أورليستات بساعتين",
          "بيتا كاروتين: يقلل الامتصاص مع أورليستات",
          "فيتامين E: قد يقلل فعالية أورليستات"
        ],
        "references": [
          {
            "title": "العلاج الدوائي للسمنة (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
          },
          {
            "title": "سيتيليستات مقابل أورليستات (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38567890/"
          }
        ]
      },
      {
        "class": "مضادات القيء",
        "examples": ["أوندانسيترون", "بروكلوربيرازين", "ديمينهيدرينات", "أبريبيتانت", "درونابينول"],
        "mechanism": "مضادات 5-HT3 (أوندانسيترون): تحجب مستقبلات السيروتونين في CTZ\nمضادات الدوبامين (بروكلوربيرازين): تحجب مستقبلات D2 في CTZ\nمضادات H1 (ديمينهيدرينات): تحجب مسارات الدهليز\nمضادات NK1 (أبريبيتانت): تحجب مستقبلات مادة P\nكانابينويدات (درونابينول): تنشط مستقبلات CB1",
        "uses": "الغثيان الناتج عن العلاج الكيميائي، الغثيان بعد الجراحة، دوار الحركة، الغثيان المرتبط بالحمل",
        "side_effects": {
          "common": ["صداع", "دوخة", "نعاس", "إمساك"],
          "serious": [" prolongation QT (أوندانسيترون)", "أعراض خارج هرمية (بروكلوربيرازين)", "انخفاض ضغط الدم (ديمينهيدرينات)", "ذهان (درونابينول)"]
        },
        "avoidance": ["تجنب في متلازمة QT الطويلة الخلقية (أوندانسيترون)", "تجنب في مرض باركنسون (بروكلوربيرازين)", "تجنب في الجلوكوما (ديمينهيدرينات)", "تجنب في الاضطرابات النفسية (درونابينول)"],
        "alternatives": {
          "non_pharmacologic": ["زنجبيل", "ضغط اليد", "تنويم مغناطيسي", "تعديلات غذائية"],
          "other_drugs": ["ميتوكلوبراميد", "سكوبولامين", "بالونوسيترون"]
        },
        "diet_supplement_interactions": [
          "الجريب فروت: يزيد مستويات أبريبيتانت",
          "الوجبات الغنية بالدهون: تزيد امتصاص أبريبيتانت",
          "الكحول: يزيد الاكتئاب الجهاز العصبي المركزي مع جميع مضادات القيء"
        ],
        "vitamin_supplement_interactions": [
          "فيتامين B6: قد يقلل الغثيان في الحمل (آمن مع مضادات القيء)",
          "المغنيسيوم: قد يعزز تأثيرات مضادات القيء",
          "نبتة سانت جون: تقلل فعالية أبريبيتانت"
        ],
        "references": [
          {
            "title": "إرشادات مضادات القيء (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
          },
          {
            "title": "كانابينويدات للغثيان الكيميائي (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38678901/"
          }
        ]
      },
      {
        "class": "البروبيوتيك",
        "examples": ["لاكتوباسيلوس رامنوسوس GG", "بيفيدوباكتيريوم إنفانتس", "ساكارومايسيس بولاردي", "ستربتوكوكس ثيرموفيلوس"],
        "mechanism": "استعادة توازن فلورا الأمعاء → تعزز وظيفة حاجز الأمعاء، تعدل الاستجابة المناعية، تنافس مسببات الأمراض",
        "uses": "الإسهال المرتبط بالمضادات الحيوية، القولون العصبي، التهاب الأمعاء، الإسهال المعدي، عدم تحمل اللاكتوز",
        "side_effects": {
          "common": ["انتفاخ", "غازات", "إمساك"],
          "serious": ["العدوى الجهازية (المضعفين مناعيًا)", "فطرemia (S. boulardii في المضعفين مناعيًا)"]
        },
        "avoidance": ["تجنب في المرضى المناعيين بشدة", "تجنب في القسطرة الوريدية المركزية (S. boulardii)", "تجنب في متلازمة الأمعاء القصيرة"],
        "alternatives": {
          "non_pharmacologic": ["بريبايوتكس (ألياف)", "أطعمة مخمرة", "زرع ميكروبيوتا برازية"],
          "other_drugs": ["سينبايوتكس (مجموعات بروبيوتيك + بريبايوتيك)"]
        },
        "diet_supplement_interactions": [
          "المضادات الحيوية: تقلل فعالية البروبيوتيك → تناول قبلها بساعتين",
          "الأطعمة الغنية بالألياف: تعزز استعمار البروبيوتيك",
          "الكحول: قد يقتل البروبيوتيك"
        ],
        "vitamin_supplement_interactions": [
          "فيتامين D: يعزز فعالية البروبيوتيك",
          "الزنك: قد يعزز وظيفة حاجز الأمعاء مع البروبيوتيك",
          "الحديد: قد يقلل استعمار البروبيوتيك"
        ],
        "references": [
          {
            "title": "البروبيوتيك لاضطرابات الجهاز الهضمي (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37345678/"
          },
          {
            "title": "سلامة البروبيوتيك (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38789012/"
          }
        ]
      },
      {
        "class": "المكملات العشبية",
        "examples": ["جاركينيا كامبوجيا", "مستخلص الشاي الأخضر", "البرتقال المر", "هوديا جوردوني", "فورسكولين"],
        "mechanism": "جاركينيا: HCA يثبط لياز السيترات → يقلل تخليق الدهون\nالشاي الأخضر: الكاتيكينات تزيد الحرارة\nالبرتقال المر: سينيفرين يحفز مستقبلات بيتا-3\nهوديا: جزيء P57 يثبط الشهية\nفورسكولين: ينشط أدينيلات سيكلاز → يزيد cAMP",
        "uses": "فقدان الوزن، كبت الشهية، تعزيز الأيض",
        "side_effects": {
          "common": ["اضطرابات الجهاز الهضمي", "صداع", "أرق"],
          "serious": ["سمية كبدية (مستخلص الشاي الأخضر)", "ارتفاع ضغط الدم (البرتقال المر)", "أحداث قلبية وعائية (البرتقال المر)", "تفاعلات دوائية"]
        },
        "avoidance": ["تجنب في أمراض القلب والأوعية الدموية (البرتقال المر)", "تجنب في أمراض الكبد (مستخلص الشاي الأخضر)", "تجنب مع المنبهات"],
        "alternatives": {
          "non_pharmacologic": ["تقييد السعرات الحرارية", "تمارين رياضية", "علاج سلوكي"],
          "other_drugs": ["أدوية فقدان الوزن المعتمدة من إدارة الأغذية والعقاقير"]
        },
        "diet_supplement_interactions": [
          "الكافيين: تأثيرات منبهة إضافية مع البرتقال المر/الشاي الأخضر",
          "الوجبات الغنية بالكربوهيدرات: قد تقلل فعالية جاركينيا",
          "الجريب فروت: يزيد مستويات فورسكولين"
        ],
        "vitamin_supplement_interactions": [
          "فيتامين C: قد يعزز تأثيرات مستخلص الشاي الأخضر",
          "الكالسيوم: قد يقلل امتصاص فورسكولين",
          "الحديد: مستخلص الشاي الأخضر قد يقلل الامتصاص"
        ],
        "references": [
          {
            "title": "المكملات العشبية لفقدان الوزن (2023)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/37456789/"
          },
          {
            "title": "سلامة البرتقال المر (2024)",
            "url": "https://pubmed.ncbi.nlm.nih.gov/38890123/"
          }
        ]
      }
    ],
    "key_interactions_summary": [
      {
        "drug_class": "مثبطات الشهية",
        "supplement": "نبتة سانت جون",
        "interaction": "تقلل مستويات بوبروبيون (تحفيز CYP3A4)",
        "management": "تجنب الاستخدام المتزامن"
      },
      {
        "drug_class": "مثبطات مضخة البروتون",
        "supplement": "فيتامين B12",
        "interaction": "تقلل الامتصاص → نقص",
        "management": "راقب B12؛ عوض إذا كان منخفضًا"
      },
      {
        "drug_class": "ميتفورمين",
        "supplement": "فيتامين B12",
        "interaction": "تقلل الامتصاص → نقص",
        "management": "عوض إذا كان منخفضًا"
      },
      {
        "drug_class": "هرمونات الغدة الدرقية",
        "supplement": "الحديد/الكالسيوم",
        "interaction": "يرتبطان بليفوثيروكسين → يقللان الامتصاص",
        "management": "تناول قبلها بـ4 ساعات"
      },
      {
        "drug_class": "أورليستات",
        "supplement": "الفيتامينات A, D, E, K",
        "interaction": "تقلل الامتصاص",
        "management": "تناول المكملات قبل/بعد أورليستات بساعتين"
      },
      {
        "drug_class": "ستاتينات",
        "supplement": "أرز الخميرة الحمراء",
        "interaction": "تحتوي على موناكولين K → تزيد خطر ألم العضلات",
        "management": "تجنب الاستخدام المتزامن"
      },
      {
        "drug_class": "لوبراميد",
        "supplement": "الزنك",
        "interaction": "تعمل بشكل تآزري لتقليل الإسهال",
        "management": "آمنة معًا"
      },
      {
        "drug_class": "منشطات الحركة",
        "supplement": "مضادات الكولين",
        "interaction": "تعارض تأثيرات الحركة",
        "management": "تجنب الاستخدام المتزامن"
      },
      {
        "drug_class": "مثبطات SGLT2",
        "supplement": "فيتامين D",
        "interaction": "قد تزيد مستويات فيتامين D",
        "management": "راقب مستويات فيتامين D"
      },
      {
        "drug_class": "مضادات القيء",
        "supplement": "فيتامين B6",
        "interaction": "قد يقلل الغثيان في الحمل",
        "management": "آمنة معًا"
      }
    ],
    "general_recommendations": [
      "توقيت الدواء-المكمل: افصل بين الأدوية والمكملات بـ2-4 ساعات إذا اشتبهت تفاعلات",
      "المراقبة: افحص الكهارل، الفيتامينات (B12, D)، ووظائف الأعضاء (الكبد/الكلى) بانتظام",
      "تعديلات غذائية: خصص النظام الغذائي حسب تأثيرات الدواء (مثل قليل الدهون مع أورليستات، غني بالألياف مع الملينات)",
      "استشر المتخصصين: استخدم موارد مثل قاعدة بيانات الأدوية الطبيعية أو مكتب المكملات الغذائية التابع لـ NIH",
      "السكان الخاصون: اضبط الجرعات في القصور الكلوي/الكبدي، كبار السن، الحمل",
      "الاختبارات الجينية: ضع في اعتبارك الاختبارات الدوائية الجينية لتفاعلات CYP450"
    ],
    "resources": [
      {
        "name": "PubMed",
        "url": "https://pubmed.ncbi.nlm.nih.gov/"
      },
      {
        "name": "قاعدة بيانات الأدوية الطبيعية",
        "url": "https://naturalmedicines.therapeuticresearch.com/"
      },
      {
        "name": "مكتب المكملات الغذائية التابع لـ NIH",
        "url": "https://ods.od.nih.gov/"
      },
      {
        "title": "تفاعلات الدواء-المغذيات (2023)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/36685500/"
      },
      {
        "title": "سلامة المكملات في الممارسة السريرية (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/37234567/"
      },
      {
        "title": "تفاعلات المكملات العشبية (2024)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/38901234/"
      }
    ]
  }
}
{
  "weight_increase_recipes": [
    {
      "name_ar": "عصير التمر والموز بالحليب",
      "name_en": "Date Banana Milkshake",
      "ingredients_ar": {
        "التمر": "10 حبات (منزوعة النوى)",
        "الموز": "حبة كبيرة",
        "الحليب كامل الدسم": "كوبان",
        "العسل": "ملعقتان كبيرتان",
        "القرفة": "رشة",
        "المكسرات": "للتزيين (لوز، جوز)"
      },
      "ingredients_en": {
        "Dates": "10 (pitted)",
        "Banana": "1 large",
        "Whole milk": "2 cups",
        "Honey": "2 tbsp",
        "Cinnamon": "a pinch",
        "Nuts": "for garnish (almonds, walnuts)"
      },
      "preparation_ar": [
        "1. انقعي التمر في الحليب لمدة 30 دقيقة.",
        "2. أضيفي الموز والعسل والقرفة في الخلاط.",
        "3. اخفقي المكونات حتى تصبح ناعمة.",
        "4. اسكبي في كؤوس وزيني بالمكسرات.",
        "5. قدمي فوراً."
      ],
      "preparation_en": [
        "1. Soak dates in milk for 30 minutes.",
        "2. Add banana, honey, and cinnamon to blender.",
        "3. Blend until smooth.",
        "4. Pour into glasses and garnish with nuts.",
        "5. Serve immediately."
      ],
      "tips_ar": [
        "استخدمي حليب جوز الهند لزيادة السعرات.",
        "أضيفي ملعقة زبدة فول سوداني للبروتين.",
        "تناولي بين الوجبات الرئيسية."
      ],
      "tips_en": [
        "Use coconut milk for extra calories.",
        "Add peanut butter for protein.",
        "Drink between main meals."
      ],
      "nutritional_highlights": "High in calories (400-500 kcal), potassium, and natural sugars. Good for healthy weight gain."
    },
    {
      "name_ar": "سلطة الأفوكادو والبطاطا الحلوة",
      "name_en": "Avocado Sweet Potato Salad",
      "ingredients_ar": {
        "الأفوكادو": "حبة كبيرة",
        "البطاطا الحلوة": "حبتان متوسطتان",
        "الحمص": "كوب مطبوخ",
        "زيت الزيتون": "ملعقتان كبيرتان",
        "عصير الليمون": "ملعقة كبيرة",
        "بذور الشيا": "ملعقتان كبيرتان",
        "الملح والفلفل": "حسب الرغبة"
      },
      "ingredients_en": {
        "Avocado": "1 large",
        "Sweet potato": "2 medium",
        "Chickpeas": "1 cup cooked",
        "Olive oil": "2 tbsp",
        "Lemon juice": "1 tbsp",
        "Chia seeds": "2 tbsp",
        "Salt and pepper": "to taste"
      },
      "preparation_ar": [
        "1. اخبزي البطاطا الحلوة مقطعة في فرن 200°C لمدة 25 دقيقة.",
        "2. قطعي الأفوكادو واخلطي مع الحمص.",
        "3. أضيفي البطاطا الحلوة وزيت الزيتون وعصير الليمون.",
        "4. رشي بذور الشيا والملح والفلفل.",
        "5. قدمي دافئة أو باردة."
      ],
      "preparation_en": [
        "1. Bake sweet potato cubes at 200°C for 25 minutes.",
        "2. Dice avocado and mix with chickpeas.",
        "3. Add sweet potatoes, olive oil, and lemon juice.",
        "4. Sprinkle chia seeds, salt, and pepper.",
        "5. Serve warm or cold."
      ],
      "tips_ar": [
        "أضيفي جبن فيتا للبروتين.",
        "استخدمي زبدة بدلاً من زيت الزيتون.",
        "تناولي كوجبة خفيفة قبل التمرين."
      ],
      "tips_en": [
        "Add feta cheese for protein.",
        "Use butter instead of olive oil.",
        "Eat as a pre-workout snack."
      ],
      "nutritional_highlights": "Rich in healthy fats, fiber, and complex carbs. Provides sustained energy (350-400 kcal per serving)."
    }
  ],
  "weight_decrease_recipes": [
    {
      "name_ar": "شوربة الخضار الحرارية",
      "name_en": "Zero-Calorie Vegetable Soup",
      "ingredients_ar": {
        "الكرنب": "ربع رأس",
        "الطماطم": "حبتان",
        "الكرفس": "3 أعواد",
        "الفلفل الأخضر": "حبتان",
        "البصل": "حبة كبيرة",
        "الثوم": "3 فصوص",
        "الزنجبيل": "قطعة صغيرة",
        "الكمون والكزبررة": "ملعقة صغيرة من كل",
        "الماء": "4 أكواب",
        "الملح": "قليل جداً"
      },
      "ingredients_en": {
        "Cabbage": "1/4 head",
        "Tomatoes": "2",
        "Celery": "3 stalks",
        "Green peppers": "2",
        "Onion": "1 large",
        "Garlic": "3 cloves",
        "Ginger": "small piece",
        "Cumin and coriander": "1 tsp each",
        "Water": "4 cups",
        "Salt": "very little"
      },
      "preparation_ar": [
        "1. قطعي جميع الخضار.",
        "2. اغلي الماء وأضيفي الخضار والبهارات.",
        "3. غطي واطهي على نار هادئة لمدة 30 دقيقة.",
        "4. اهرسي الخليط قليلاً أو اتركيه قطعاً.",
        "5. تناولي 3-4 أطباق يومياً."
      ],
      "preparation_en": [
        "1. Chop all vegetables.",
        "2. Boil water and add vegetables and spices.",
        "3. Cover and simmer for 30 minutes.",
        "4. Mash slightly or leave chunky.",
        "5. Eat 3-4 bowls daily."
      ],
      "tips_ar": [
        "أضيفي الفلفل الحار لزيادة حرق الدهون.",
        "تناولي قبل الوجبات لتقليل الشهية.",
        "لا تضيفي أي مواد دهنية."
      ],
      "tips_en": [
        "Add chili pepper to boost metabolism.",
        "Eat before meals to reduce appetite.",
        "Do not add any fats."
      ],
      "nutritional_highlights": "Extremely low calorie (20-30 kcal per bowl), high in fiber and water content. Promotes fullness."
    },
    {
      "name_ar": "سلطة الخيار والنعناع",
      "name_en": "Cucumber Mint Salad",
      "ingredients_ar": {
        "الخيار": "حبتان كبيرتان",
        "النعناع الطازج": "كوب",
        "عصير الليمون": "ملعقتان كبيرتان",
        "زيت الزيتون": "ملعقة صغيرة",
        "بذور الكمون": "ملعقة صغيرة",
        "الملح": "رشة"
      },
      "ingredients_en": {
        "Cucumber": "2 large",
        "Fresh mint": "1 cup",
        "Lemon juice": "2 tbsp",
        "Olive oil": "1 tsp",
        "Cumin seeds": "1 tsp",
        "Salt": "a pinch"
      },
      "preparation_ar": [
        "1. قطعي الخيار إلى شرائح رقيقة.",
        "2. فرمي النعناع ناعماً.",
        "3. اخلطي الخيار مع النعناع وعصير الليمون.",
        "4. أضيفي زيت الزيتون وبذور الكمون والملح.",
        "5. قدمي باردة."
      ],
      "preparation_en": [
        "1. Thinly slice cucumbers.",
        "2. Finely chop mint.",
        "3. Mix cucumber with mint and lemon juice.",
        "4. Add olive oil, cumin seeds, and salt.",
        "5. Serve chilled."
      ],
      "tips_ar": [
        "أضيفي بذور الشيا للألياف.",
        "تناولي كوجبة خفيفة مساءً.",
        "استبدلي الليمون بالخل."
      ],
      "tips_en": [
        "Add chia seeds for fiber.",
        "Eat as an evening snack.",
        "Replace lemon with vinegar."
      ],
      "nutritional_highlights": "Very low calorie (40-50 kcal per serving), hydrating, and rich in antioxidants. Supports weight loss."
    }
  ],
  "male_hormonal_recipes": [
    {
      "name_ar": "عصير الرمان والجزر",
      "name_en": "Pomegranate Carrot Juice",
      "ingredients_ar": {
        "الرمان": "حبتان",
        "الجزر": "3 حبات",
        "الزنجبيل": "قطعة صغيرة",
        "عصير الليمون": "ملعقة كبيرة",
        "العسل": "ملعقة صغيرة (اختياري)"
      },
      "ingredients_en": {
        "Pomegranate": "2",
        "Carrots": "3",
        "Ginger": "small piece",
        "Lemon juice": "1 tbsp",
        "Honey": "1 tsp (optional)"
      },
      "preparation_ar": [
        "1. استخرجي عصير الرمان والجزر.",
        "2. اخفقي مع الزنجبيل وعصير الليمون.",
        "3. أضيفي العسل إذا رغبت.",
        "4. قدمي طازجاً."
      ],
      "preparation_en": [
        "1. Extract juice from pomegranate and carrots.",
        "2. Blend with ginger and lemon juice.",
        "3. Add honey if desired.",
        "4. Serve fresh."
      ],
      "tips_ar": [
        "تناولي يومياً لتحسين التستوستيرون.",
        "أضيفي القليل من الكركم.",
        "اشربي في الصباح على معدة فارغة."
      ],
      "tips_en": [
        "Drink daily for testosterone support.",
        "Add a pinch of turmeric.",
        "Consume in the morning on empty stomach."
      ],
      "nutritional_highlights": "Rich in antioxidants, vitamin C, and compounds that support testosterone production. Good for prostate health."
    },
    {
      "name_ar": "سلطة المكسرات والتفاح",
      "name_en": "Nut Apple Salad",
      "ingredients_ar": {
        "الجوز": "ربع كوب",
        "اللوز": "ربع كوب",
        "التفاح": "حبة",
        "الزبيب": "ملعقتان كبيرتان",
        "القرفة": "رشة",
        "الزبادي اليوناني": "ملعقتان كبيرتان"
      },
      "ingredients_en": {
        "Walnuts": "1/4 cup",
        "Almonds": "1/4 cup",
        "Apple": "1",
        "Raisins": "2 tbsp",
        "Cinnamon": "a pinch",
        "Greek yogurt": "2 tbsp"
      },
      "preparation_ar": [
        "1. قطعي التفال إلى مكعبات صغيرة.",
        "2. اخلطي مع المكسرات والزبيب.",
        "3. رشي القرفة والزبادي.",
        "4. قدمي كوجبة خفيفة."
      ],
      "preparation_en": [
        "1. Dice apple into small cubes.",
        "2. Mix with nuts and raisins.",
        "3. Sprinkle cinnamon and yogurt.",
        "4. Serve as a snack."
      ],
      "tips_ar": [
        "استخدمي مكسرات غير مملحة.",
        "أضيفي بذور اليقطين للزنك.",
        "تناولي بعد التمرين."
      ],
      "tips_en": [
        "Use unsalted nuts.",
        "Add pumpkin seeds for zinc.",
        "Eat post-workout."
      ],
      "nutritional_highlights": "High in zinc, selenium, and healthy fats. Supports hormone production and muscle recovery."
    }
  ],
  "female_hormonal_recipes": [
    {
      "name_ar": "شاي البابونج والشمر",
      "name_en": "Chamomile Fennel Tea",
      "ingredients_ar": {
        "أزهار البابونج": "ملعقتان كبيرتان",
        "بذور الشمر": "ملعقة كبيرة",
        "الزنجبيل": "شرحة رقيقة",
        "العسل": "ملعقة صغيرة (اختياري)",
        "الماء": "كوبان"
      },
      "ingredients_en": {
        "Chamomile flowers": "2 tbsp",
        "Fennel seeds": "1 tbsp",
        "Ginger": "thin slice",
        "Honey": "1 tsp (optional)",
        "Water": "2 cups"
      },
      "preparation_ar": [
        "1. اغلي الماء.",
        "2. أضيفي جميع المكونات وغطي.",
        "3. اتركيه ينقع لمدة 10 دقائق.",
        "4. صفّي وأضيفي العسل.",
        "5. اشربي دافئاً."
      ],
      "preparation_en": [
        "1. Boil water.",
        "2. Add all ingredients and cover.",
        "3. Let steep for 10 minutes.",
        "4. Strain and add honey.",
        "5. Drink warm."
      ],
      "tips_ar": [
        "تناولي قبل النوم للاسترخاء.",
        "استخدمي يومياً خلال الدورة الشهرية.",
        "أضيفي القرفة لتنظيم السكر."
      ],
      "tips_en": [
        "Drink before bed for relaxation.",
        "Use daily during menstruation.",
        "Add cinnamon for blood sugar balance."
      ],
      "nutritional_highlights": "Balances estrogen, reduces menstrual cramps, and promotes relaxation. Antispasmodic and anti-inflammatory."
    },
    {
      "name_ar": "سلطة بذور الكتان والسبانخ",
      "name_en": "Flaxseed Spinach Salad",
      "ingredients_ar": {
        "بذور الكتان المطحونة": "ملعقتان كبيرتان",
        "السبانخ الطازجة": "كوبان",
        "الطماطم الكرزية": "نصف كوب",
        "الخيار": "نصف حبة",
        "عصير الليمون": "ملعقة كبيرة",
        "زيت الزيتون": "ملعقة صغيرة"
      },
      "ingredients_en": {
        "Ground flaxseeds": "2 tbsp",
        "Fresh spinach": "2 cups",
        "Cherry tomatoes": "1/2 cup",
        "Cucumber": "1/2",
        "Lemon juice": "1 tbsp",
        "Olive oil": "1 tsp"
      },
      "preparation_ar": [
        "1. اغسلي السبانخ جيداً.",
        "2. قطعي الطماطم والخيار.",
        "3. اخلطي جميع المكونات.",
        "4. أضيفي عصير الليمون وزيت الزيتون.",
        "5. قدمي فوراً."
      ],
      "preparation_en": [
        "1. Wash spinach thoroughly.",
        "2. Dice tomatoes and cucumber.",
        "3. Mix all ingredients.",
        "4. Add lemon juice and olive oil.",
        "5. Serve immediately."
      ],
      "tips_ar": [
        "أضيفي الأفوكادو للدهون الصحية.",
        "استخدمي بذور الكتان الطازجة المطحونة.",
        "تناولي 3 مرات أسبوعياً."
      ],
      "tips_en": [
        "Add avocado for healthy fats.",
        "Use freshly ground flaxseeds.",
        "Eat 3 times weekly."
      ],
      "nutritional_highlights": "Rich in phytoestrogens, omega-3, and iron. Supports hormonal balance and reduces menopause symptoms."
    }
  ],
  "bulking_recipes": [
    {
      "name_ar": "عصير البروتين النباتي",
      "name_en": "Plant-Based Protein Shake",
      "ingredients_ar": {
        "حليب الصويا": "كوبان",
        "موز": "حبة",
        "زبدة الفول السوداني": "ملعقتان كبيرتان",
        "بذور الشيا": "ملعقة كبيرة",
        "مسحوق البروتين النباتي": "معلقة",
        "العسل": "ملعقة كبيرة"
      },
      "ingredients_en": {
        "Soy milk": "2 cups",
        "Banana": "1",
        "Peanut butter": "2 tbsp",
        "Chia seeds": "1 tbsp",
        "Plant-based protein powder": "1 scoop",
        "Honey": "1 tbsp"
      },
      "preparation_ar": [
        "1. ضعي جميع المكونات في الخلاط.",
        "2. اخفقي حتى تصبح ناعمة.",
        "3. أضيفي المزيد من الحليب إذا كان سميكاً.",
        "4. اسكبي في كوب كبير.",
        "5. قدمي بعد التمرين مباشرة."
      ],
      "preparation_en": [
        "1. Place all ingredients in blender.",
        "2. Blend until smooth.",
        "3. Add more milk if too thick.",
        "4. Pour into large glass.",
        "5. Serve immediately post-workout."
      ],
      "tips_ar": [
        "استخدمي حليب جوز الهند لسعرات أعلى.",
        "أضيفي دقيق الشوفان للكربوهيدرات.",
        "تناولي خلال 30 دقيقة بعد التمرين."
      ],
      "tips_en": [
        "Use coconut milk for higher calories.",
        "Add oatmeal for carbs.",
        "Consume within 30 minutes post-workout."
      ],
      "nutritional_highlights": "High in protein (25-30g), complex carbs, and healthy fats. Ideal for muscle recovery and growth (500-600 kcal)."
    },
    {
      "name_ar": "أرز بني بالعدس والخضار",
      "name_en": "Brown Rice Lentil Veggie Bowl",
      "ingredients_ar": {
        "الأرز البني": "كوب",
        "العدس الأحمر": "نصف كوب",
        "البروكلي": "كوب",
        "الجزر": "حبة",
        "البصل": "حبة",
        "الثوم": "فصان",
        "زيت الزيتون": "ملعقتان كبيرتان",
        "البهارات": "كمون، كزبررة، كركم"
      },
      "ingredients_en": {
        "Brown rice": "1 cup",
        "Red lentils": "1/2 cup",
        "Broccoli": "1 cup",
        "Carrot": "1",
        "Onion": "1",
        "Garlic": "2 cloves",
        "Olive oil": "2 tbsp",
        "Spices": "cumin, coriander, turmeric"
      },
      "preparation_ar": [
        "1. اطهي الأرز والعدس معاً.",
        "2. في مقلاة، اقلي البصل والثوم والجزر.",
        "3. أضيفي البروكلي والبهارات.",
        "4. اخلطي مع الأرز والعدس.",
        "5. قدمي مع زيت الزيتون."
      ],
      "preparation_en": [
        "1. Cook rice and lentils together.",
        "2. In pan, sauté onion, garlic, and carrot.",
        "3. Add broccoli and spices.",
        "4. Mix with rice and lentils.",
        "5. Serve with olive oil."
      ],
      "tips_ar": [
        "أضيفي الأفوكادو للدهون.",
        "استخدمي زبدة بدلاً من زيت الزيتون.",
        "تناولي كوجبة رئيسية بعد التمرين."
      ],
      "tips_en": [
        "Add avocado for fats.",
        "Use butter instead of olive oil.",
        "Eat as main meal post-workout."
      ],
      "nutritional_highlights": "Complete protein source, high in fiber and complex carbs. Supports muscle building (600-700 kcal per serving)."
    }
  ],
  "cutting_recipes": [
    {
      "name_ar": "سلطة التونة والبيض",
      "name_en": "Tuna Egg Salad",
      "ingredients_ar": {
        "التونة المعلبة": "علبة (في الماء)",
        "البيض المسلوق": "حبتان",
        "الخس": "كوبان",
        "الطماطم": "حبة",
        "الخيار": "نصف حبة",
        "عصير الليمون": "ملعقة كبيرة",
        "الخل": "ملعقة صغيرة",
        "الملح والفلفل": "حسب الرغبة"
      },
      "ingredients_en": {
        "Canned tuna": "1 can (in water)",
        "Boiled eggs": "2",
        "Lettuce": "2 cups",
        "Tomato": "1",
        "Cucumber": "1/2",
        "Lemon juice": "1 tbsp",
        "Vinegar": "1 tsp",
        "Salt and pepper": "to taste"
      },
      "preparation_ar": [
        "1. قطعي الخضار.",
        "2. اخفقي التونة مع البيض المهروس.",
        "3. اخلطي جميع المكونات.",
        "4. أضيفي عصير الليمون والخل.",
        "5. قدمي باردة."
      ],
      "preparation_en": [
        "1. Chop vegetables.",
        "2. Mix tuna with mashed eggs.",
        "3. Combine all ingredients.",
        "4. Add lemon juice and vinegar.",
        "5. Serve chilled."
      ],
      "tips_ar": [
        "استخدمي تونة بدون زيت.",
        "أضيفي الفلفل الحار لحرق الدهون.",
        "تناولي كوجبة غداء."
      ],
      "tips_en": [
        "Use tuna packed in water.",
        "Add chili pepper for fat burning.",
        "Eat as lunch meal."
      ],
      "nutritional_highlights": "High protein (30g), low fat, and low carb. Ideal for fat loss while preserving muscle (250-300 kcal)."
    },
    {
      "name_ar": "شوربة العدس والخضار",
      "name_en": "Lentil Vegetable Soup",
      "ingredients_ar": {
        "العدس الأحمر": "كوب",
        "الجزر": "حبتان",
        "الكرفس": "عودان",
        "البصل": "حبة",
        "الثوم": "3 فصوص",
        "الطماطم": "حبتان",
        "الزنجبيل": "قطعة صغيرة",
        "الكركم": "ملعقة صغيرة",
        "الماء": "4 أكواب"
      },
      "ingredients_en": {
        "Red lentils": "1 cup",
        "Carrots": "2",
        "Celery": "2 stalks",
        "Onion": "1",
        "Garlic": "3 cloves",
        "Tomatoes": "2",
        "Ginger": "small piece",
        "Turmeric": "1 tsp",
        "Water": "4 cups"
      },
      "preparation_ar": [
        "1. اغلي العدس مع الماء لمدة 10 دقائق.",
        "2. أضيفي جميع الخضار والبهارات.",
        "3. غطي واطهي على نار هادئة لمدة 20 دقيقة.",
        "4. اهرسي الخليط قليلاً.",
        "5. قدمي دافئة."
      ],
      "preparation_en": [
        "1. Boil lentils with water for 10 minutes.",
        "2. Add all vegetables and spices.",
        "3. Cover and simmer for 20 minutes.",
        "4. Mash slightly.",
        "5. Serve warm."
      ],
      "tips_ar": [
        "أضيفي السبانخ قبل التقديم.",
        "استخدمي مرق خضار بدل الماء.",
        "تناولي كوجبة عشاء خفيفة."
      ],
      "tips_en": [
        "Add spinach before serving.",
        "Use vegetable broth instead of water.",
        "Eat as light dinner."
      ],
      "nutritional_highlights": "High protein (18g), high fiber, and low fat. Promotes satiety and fat loss (200-250 kcal per bowl)."
    }
  ],
  "lactating_recipes": [
    {
      "name_ar": "عصير الشوفان بالتمر",
      "name_en": "Oat Date Smoothie",
      "ingredients_ar": {
        "الشوفان": "نصف كوب",
        "التمر": "8 حبات",
        "الحليب": "كوبان",
        "الموز": "حبة",
        "بذور الحلبة": "ملعقة صغيرة",
        "العسل": "ملعقة صغيرة"
      },
      "ingredients_en": {
        "Oats": "1/2 cup",
        "Dates": "8",
        "Milk": "2 cups",
        "Banana": "1",
        "Fenugreek seeds": "1 tsp",
        "Honey": "1 tsp"
      },
      "preparation_ar": [
        "1. انقعي التمر وبذور الحلبة لمدة ساعة.",
        "2. اخفقي جميع المكونات في الخلاط.",
        "3. أضيفي المزيد من الحليب إذا لزم.",
        "4. اسكبي في كوب.",
        "5. قدمي في الصباح."
      ],
      "preparation_en": [
        "1. Soak dates and fenugreek seeds for 1 hour.",
        "2. Blend all ingredients.",
        "3. Add more milk if needed.",
        "4. Pour into glass.",
        "5. Serve in the morning."
      ],
      "tips_ar": [
        "استخدمي حليب اللوز إذا كنت تعانين من الحساسية.",
        "أضيفي بذور الشيا للأوميغا-3.",
        "تناولي يومياً لزيادة إدرار الحليب."
      ],
      "tips_en": [
        "Use almond milk if allergic.",
        "Add chia seeds for omega-3.",
        "Drink daily to boost milk supply."
      ],
      "nutritional_highlights": "Rich in galactagogues (fenugreek), calcium, and iron. Supports milk production and maternal health (400-500 kcal)."
    },
    {
      "name_ar": "سلطة الحلبة والجزر",
      "name_en": "Fenugreek Carrot Salad",
      "ingredients_ar": {
        "أوراق الحلبة الطازجة": "كوب",
        "الجزر": "حبتان",
        "الطماطم": "حبة",
        "عصير الليمون": "ملعقتان كبيرتان",
        "زيت الزيتون": "ملعقة كبيرة",
        "بذور السمسم": "ملعقة صغيرة"
      },
      "ingredients_en": {
        "Fresh fenugreek leaves": "1 cup",
        "Carrots": "2",
        "Tomato": "1",
        "Lemon juice": "2 tbsp",
        "Olive oil": "1 tbsp",
        "Sesame seeds": "1 tsp"
      },
      "preparation_ar": [
        "1. اغسلي أوراق الحلبة والجزر.",
        "2. قطعي الطماطم والجزر.",
        "3. اخلطي جميع المكونات.",
        "4. أضيفي عصير الليمون وزيت الزيتون.",
        "5. رشي بذور السمسم."
      ],
      "preparation_en": [
        "1. Wash fenugreek leaves and carrots.",
        "2. Dice tomatoes and carrots.",
        "3. Mix all ingredients.",
        "4. Add lemon juice and olive oil.",
        "5. Sprinkle sesame seeds."
      ],
      "tips_ar": [
        "أضيفي الأفوكادو للدهون الصحية.",
        "استخدمي أوراق الحلبة الطازجة فقط.",
        "تناولي مع وجبة الغداء."
      ],
      "tips_en": [
        "Add avocado for healthy fats.",
        "Use only fresh fenugreek leaves.",
        "Eat with lunch meal."
      ],
      "nutritional_highlights": "Natural galactagogue, high in vitamins A and C. Supports lactation and postpartum recovery (150-200 kcal)."
    }
  ],
  "pregnant_recipes": [
    {
      "name_ar": "عصير السبانخ والمانجو",
      "name_en": "Spinach Mango Smoothie",
      "ingredients_ar": {
        "السبانخ الطازجة": "كوب",
        "المانجو": "حبة",
        "الموز": "حبة",
        "الزبادي": "نصف كوب",
        "الحليب": "كوب",
        "بذور الشيا": "ملعقة صغيرة",
        "العسل": "ملعقة صغيرة"
      },
      "ingredients_en": {
        "Fresh spinach": "1 cup",
        "Mango": "1",
        "Banana": "1",
        "Yogurt": "1/2 cup",
        "Milk": "1 cup",
        "Chia seeds": "1 tsp",
        "Honey": "1 tsp"
      },
      "preparation_ar": [
        "1. اخفقي جميع المكونات في الخلاط.",
        "2. أضيفي المزيد من الحليب إذا كان سميكاً.",
        "3. اسكبي في كوب.",
        "4. قدمي فوراً."
      ],
      "preparation_en": [
        "1. Blend all ingredients.",
        "2. Add more milk if too thick.",
        "3. Pour into glass.",
        "4. Serve immediately."
      ],
      "tips_ar": [
        "استخدمي مانجو مجمد إذا لم يكن متوفراً.",
        "أضيفي الزنجبيل للغثيان.",
        "تناولي كوجبة إفطار."
      ],
      "tips_en": [
        "Use frozen mango if not available.",
        "Add ginger for nausea.",
        "Eat as breakfast meal."
      ],
      "nutritional_highlights": "Rich in folate, iron, calcium, and fiber. Supports fetal development and reduces pregnancy discomforts (300-400 kcal)."
    },
    {
      "name_ar": "أرز بالخضار والعدس",
      "name_en": "Vegetable Lentil Rice",
      "ingredients_ar": {
        "الأرز البسمتي": "كوب",
        "العدس الأحمر": "نصف كوب",
        "الجزر": "حبتان",
        "البازلاء": "نصف كوب",
        "البصل": "حبة",
        "الطماطم": "حبتان",
        "زيت الزيتون": "ملعقتان كبيرتان",
        "الكركم": "ملعقة صغيرة"
      },
      "ingredients_en": {
        "Basmati rice": "1 cup",
        "Red lentils": "1/2 cup",
        "Carrots": "2",
        "Peas": "1/2 cup",
        "Onion": "1",
        "Tomatoes": "2",
        "Olive oil": "2 tbsp",
        "Turmeric": "1 tsp"
      },
      "preparation_ar": [
        "1. اغسلي الأرز والعدس.",
        "2. في قدر، اقلي البصل والطماطم.",
        "3. أضيفي الخضار والبهارات.",
        "4. أضيفي الأرز والعدس والماء.",
        "5. اطهي على نار هادئة لمدة 20 دقيقة."
      ],
      "preparation_en": [
        "1. Wash rice and lentils.",
        "2. In pot, sauté onion and tomatoes.",
        "3. Add vegetables and spices.",
        "4. Add rice, lentils, and water.",
        "5. Simmer for 20 minutes."
      ],
      "tips_ar": [
        "أضيفي السبانخ قبل 5 دقائق من النضج.",
        "استخدمي زيت جوز الهند للنكهة.",
        "تناولي مع الزبادي."
      ],
      "tips_en": [
        "Add spinach 5 minutes before done.",
        "Use coconut oil for flavor.",
        "Eat with yogurt."
      ],
      "nutritional_highlights": "Complete protein source, high in folate, iron, and fiber. Supports fetal growth and prevents anemia (500-600 kcal per serving)."
    }
  ],
  "general_tips": {
    "weight_increase": [
      "تناولي 6 وجبات صغيرة يومياً",
      "ركزي على الأطعمة الكثيفة بالسعرات",
      "أضيفي الدهون الصحية للوجبات",
      "تمارين القوة لبناء العضلات"
    ],
    "weight_decrease": [
      "ركزي على الأطعمة الغنية بالألياف",
      "اشربي الكثير من الماء",
      "ممارسة الرياضة بانتظام",
      "تجنبي السكريات المكررة"
    ],
    "hormonal_balance": [
      "تناولي الأطعمة الغنية بالأوميغا-3",
      "تجنبي الأطعمة المصنعة",
      "ممارسة تقنيات الاسترخاء",
      "الحصول على قسط كافٍ من النوم"
    ],
    "pregnancy_lactation": [
      "تجنبي الأعشاب غير المثبتة أمانها",
      "استشيري الطبيب قبل تناول أي مكملات",
      "ركزي على الأطعمة الغنية بالحديد والكالسيوم",
      "تجنبي الكافيين بكميات عالية"
    ]
  }
}



